Triazole modulators of DCN-1 and methods of use thereof

Compounds modulating DCN-1 induce fetal hemoglobin production, addressing the need for effective treatments for sickle cell disorders and thalassemia by enhancing hemoglobin function.

WO2026236355A1PCT designated stage Publication Date: 2026-11-12CELLARITY INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/026890
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-07
Filing Date
2026-05-06
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

There is a need for therapeutic agents and therapies to treat hemoglobin-related disorders such as sickle cell disorders and thalassemia, as existing treatments are inadequate in addressing the underlying causes of these conditions.

Method used

Compounds and compositions that modulate DCN-1, inducing fetal hemoglobin production, are developed to treat hemoglobin-related disorders including sickle cell disorders and thalassemia.

Benefits of technology

The compounds effectively modulate DCN-1, inducing fetal hemoglobin production, thereby providing a therapeutic approach to manage sickle cell disorders and thalassemia.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026026890_12112026_PF_FP_ABST
    Figure US2026026890_12112026_PF_FP_ABST
Patent Text Reader

Abstract

The present disclosure provides DCN-1 modulating compounds, pharmaceutically acceptable salts thereof, pharmaceutical compositions, and their use for treating sickle cell disorders, diseases, and conditions. Such compounds are of Formula Ia: or a pharmaceutically acceptable salt thereof.
Need to check novelty before this filing date? Find Prior Art

Description

TRIAZOLE MODULATORS OF DCN-1 AND METHODS OF USE THEREOFCROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit under 35 U. S. C. §119(e) of U. S. Provisional Application No. 63 / 801,474 filed on May 7, 2025, the entirety of which is incorporated herein by referenceTECHNICAL FIELD OF THE INVENTION

[0002] The present disclosure relates generally to various compounds and compositions useful in the treatment of hemoglobin-related disorders including sickle cell disorders, diseases, and conditions, and thalassemia.BACKGROUND OF THE INVENTION

[0003] Hemoglobinopathies are diseases that affect hemoglobin that include sickle cell disease and thalassemia. Sickle cell disease or disorder is a group of inherited red blood cell disorders that affect hemoglobin and can block blood flow to the body. Specifically, a defective beta hemoglobin chain in sickle cell patients twists and changes the shape of each red blood cell from a doughnutlike shape into a “sickled” or croissant shape that can clog small blood vessels and prevent the delivery of oxygen around the body. Sickle-cell disease is characterized by various acute and chronic complications, which are associated with significant morbidity and mortality in an afflicted subject. Thalassemia is also an inherited red blood cell disorder that is caused by a defect in the beta-globin gene, controlling the production of the beta-globin chains of hemoglobin. Accordingly, a patient suffering from thalassemia can’t make enough normal hemoglobin and thus has relatively fewer red blood cells and lower blood oxygen levels than people who do not suffer from the disease. Thalassemia patients may not make enough of either or both of the alpha or beta proteins in hemoglobin.

[0004] The cullin family of ubiquitination E3s are the most well-characterized substrates of neddylation. Upon neddylation, the cullins constellate the cullin-RING E3 UB ligase family (CRLs), which has approximately 300 members. The CRLs regulate diverse biological processes including cell cycle, signal transduction, DNA replication, and viral modulation. CRL dysfunction is implicated in a number of human diseases, including cancer. Drug discovery efforts targeting1335850176 CENC-014 / 01WO 360899-2049the CRLs and the associated proteasomal protein degradation machinery have been extensive and continue to grow. The neddylation pathway has been successfully targeted by MLN4924 (Pevonedistat), an inhibitor of NEDD8’s El enzyme, that completely blocks NEDD8 ligation to substrates. MLN4924 is currently being tested in oncology clinical trials. An inhibitor of the COP9 signalosome, responsible for de-neddylation of the CRLs, has been reported and also displays antitumor activity. Defective in cullin neddylation 1 (DCN-1) is a protein that interacts with cullins and is required for neddylation. DCN-1 is also known as DCUN1D1, DCNL1 or Squamous Cell Carcinoma-related Oncogene (SCCRO). DCN-1 is the most well characterized isoform due to its common amplification as part of a large 3q26.3 amplicon in squamous cell carcinomas (SCC) and other tumors. DCN-1 amplification in SCC negatively correlates with cause-specific survival, suggesting that targeting DCN-1 may be of clinical utility in cancers. Its role in other diseases remains under-explored.

[0005] There remains a need to find therapeutic agents, methods, and therapies for the treatment of hemoglobin-related disorders including sickle cell disorders, diseases and conditions and thalassemia. The present invention fulfils this need and provides other related advantages.DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS1. General Description of Certain Embodiments of the Invention; Definitions

[0006] It has now been found that the compounds and compositions of the disclosure can modulate DCN-1, induce fetal hemoglobin production, and are useful in treating hemoglobin-related disorders including sickle cell disorders, diseases and conditions, and thalassemia.

[0007] In one aspect, the present disclosure provides a compound of Formula la:la2335850176 CENC-014 / 01WO 360899-2049or a pharmaceutically acceptable salt thereof, wherein:Ring A is phenyl, 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, a 4-10 membered saturated or partially unsaturated bicyclic carbocyclic ring, an 8-10 membered bicyclic aromatic carbocyclic ring, a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-10 membered bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur;Ring B is phenyl or a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;Ring C is phenyl or a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;each occurrence of R1is independently an optionally substituted Ci-6 aliphatic, halogen, -CN, - C(O)R, -C(O)OR, -OC(O)R, -C(O)N(R)2, -N(R)C(O)R, -N(R)C(O)N(R)2, -OC(O)N(R)2, - N(R)C(O)OR, -OR, -N(R)2, -NO2, -SR, -S(O)R, -S(O)2R, -S(O)2N(R)2, or -NRS(O)2R; or two instances of R1together form a 4-6 membered optionally substituted heterocyclic ring having 1-4 heteroatoms selected from nitrogen, oxygen, and sulfur, or two instances of R1together form a 4-6 membered optionally substituted carbocyclic ring;R2is an optionally substituted group selected from Ci-6 aliphatic and a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring;each occurrence of R3is independently an optionally substituted Ci-6 aliphatic, C3-6 cycloalkyl, halogen, -CN, -C(O)R, -C(O)OR, -OC(O)R, -C(O)N(R)2, -N(R)C(O)R, -N(R)C(O)N(R)2, - OC(O)N(R)2, -N(R)C(O)OR, -OR, -N(R)2, -NO2, -SR, -S(O)R, -S(O)2R, -S(O)2N(R)2, or - NRS(O)2R;R4is a substituent comprising a warhead group;each occurrence of R5is independently, halogen, -CN, -C(O)R, -C(O)OR, -OC(O)R, -C(O)N(R)2, -N(R)C(O)R, -N(R)C(O)N(R)2, -OC(O)N(R)2, -N(R)C(O)OR, -OR, -N(R)2, -NO2, -SR, - S(O)R, -S(O)2R, -S(O)2N(R)2, -NRS(O)2R, or an optionally substituted group selected from3335850176 CENC-014 / 01WO 360899-2049Ci-6 aliphatic, phenyl, or a 5-6 membered heteroaromatic ring having 1-3 heteroatoms selected from nitrogen, sulfur, and oxygen;R6is hydrogen or an optionally substituted Ci-6 aliphatic group;each occurrence of R is independently hydrogen or an optionally substituted group selected from Ci-6 aliphatic, a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic aromatic carbocyclic ring, a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur;m is 0, 1, 2, 3, 4, or 5;n is 0, 1, 2, 3, 4, or 5; andp is 0, 1, 2, 3, 4, or 5.

[0008] As defined generally above, Ring A is selected from phenyl, 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, a 4-10 membered saturated or partially unsaturated bicyclic carbocyclic ring, an 8-10 membered bicyclic aromatic carbocyclic ring, a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-10 membered bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0009] In some embodiments, Ring A is phenyl. In some embodiments, Ring A is a 3-8 membered saturated monocyclic carbocyclic ring. In some embodiments, Ring A is a 3-8 membered partially unsaturated monocyclic carbocyclic ring. In some embodiments, Ring A is a 4-10 membered saturated bicyclic carbocyclic ring. In some embodiments, Ring A is a 4-10 membered partially unsaturated bicyclic carbocyclic ring. In some embodiments, Ring A is an 8-10 membered bicyclic aromatic carbocyclic ring. In some embodiments, Ring A is a 3-8 membered saturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring A is a 3-8 membered partially4335850176 CENC-014 / 01WO 360899-2049unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring A is a 5-10 membered bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring A is a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring A is an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0010] In some embodiments, Ring A is phenyl.

[0011] In some embodiments, Ring A is selected from those depicted in Table 1, below.

[0012] As defined generally above, Ring B is selected from phenyl and a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0013] In some embodiments, Ring B is phenyl. In some embodiments, Ring B is a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0014] In some embodiments, Ring B, taken together with (R3)n, is selected from

[0015] In some embodiments, Ring B is a thiazole, pyridyl, or pyrimidinyl ring.

[0016] In some embodiments, Ring B, taken together with R3, is selected from335850176 CENC-014 / 01WO 360899-2049

[0017] In some embodiments, Ring B, taken together with R3, is. In someembodiments, Ring B, taken together with R3, is

[0018] In some embodiments, Ring B is selected from those depicted in Table 1, below.

[0019] As defined generally above, Ring C is selected from phenyl and a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0020] In some embodiments, Ring C is phenyl. In some embodiments, Ring C is a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0021] In some embodiments, Ring C is phenyl.

[0022] In some embodiments, Ring C is selected from those depicted in Table 1, below.

[0023] As defined generally above, each occurrence of R1is independently an optionally substituted Ci-6 aliphatic, halogen, -CN, -C(O)R, -C(O)OR, -OC(O)R, -C(O)N(R)2, -N(R)C(O)R, -N(R)C(O)N(R)2, -OC(O)N(R)2, -N(R)C(O)OR, -OR, -N(R)2, -NO2, -SR, -S(O)R, -S(O)2R, -S(O)2N(R)2, or -NRS(O)2R; ortwo instances of R1together form a 4-6 membered optionally substituted heterocyclic ring having 1-4 heteroatoms selected from nitrogen, oxygen, and sulfur, or two instances of R1together form a 4-6 membered optionally substituted carbocyclic ring.

[0024] In some embodiments, each occurrence of R1is independently optionally substituted Ci-6 aliphatic, halogen, -CN, -C(O)R, -C(O)OR, -OC(O)R, -C(O)N(R)2, -N(R)C(O)R, -N(R)C(O)N(R)2, -OC(O)N(R)2, -N(R)C(O)OR, -OR, -N(R)2, -NO2, -SR, -S(O)R, -S(O)2R, -S(O)2N(R)2, or -NRS(O)2R.

[0025] In some embodiments, R1is a Ci-6 aliphatic group. In some embodiments, R1is a substituted Ci-6 aliphatic group. In some embodiments, R1is halogen. In some embodiments, R1is -CN. In some embodiments, R1is -C(O)R. In some embodiments, R1is -C(O)OR. In some embodiments, R1is -OC(O)R. In some embodiments, R1is -C(O)N(R)2. In some embodiments, R1is -N(R)C(O)R. In some embodiments, R1is -N(R)C(O)N(R)2. In some embodiments, R1is -OC(O)N(R)2. In some embodiments, R1is -N(R)C(O)OR. In some embodiments, R1is -OR. In6335850176 CENC-014 / 01WO 360899-2049some embodiments, R1is -N(R)2. In some embodiments, R1is -NO2. In some embodiments, R1is -SR. In some embodiments, R1is -S(O)R. In some embodiments, R1is -S(O)2R. In some embodiments, R1is -S(O)2N(R)2. In some embodiments, R1is -NRS(O)2R.

[0026] In some embodiments, R1is selected from those depicted in Table 1, below.

[0027] As defined generally above, R2is an optionally substituted group selected from Ci-6 aliphatic and a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring.

[0028] In some embodiments, R2is a Ci-6 aliphatic group. In some embodiments, R2is a substituted Ci-6 aliphatic group. In some embodiments, R2is a 3-8 membered saturated monocyclic carbocyclic ring. In some embodiments, R2is a 3-8 membered partially unsaturated monocyclic carbocyclic ring. In some embodiments, R2is a substituted 3-8 membered saturated monocyclic carbocyclic ring. In some embodiments, R2is a substituted 3-8 membered partially unsaturated monocyclic carbocyclic ring.

[0029] In some embodiments, R2is selected from

[0031] In some embodiments, R2is selected from Ci-6 alkyl optionally substituted with 1, 2, 3, 4, 5, or 6 halogen or deuterium atoms.7335850176 CENC-014 / 01WO 360899-2049

[0032] In some embodiments, R2is selected from methyl, -CD3, -CF3, ethyl, -CH2CF3, n-propyl, isopropyl, n-butyl, and s-butyl.

[0033] In some embodiments, R2is ethyl.

[0034] In some embodiments, R2is selected from those depicted in Table 1, below.

[0035] As defined generally above, each occurrence of R3is independently an optionally substituted C1-6 aliphatic, C3-6 cycloalkyl, halogen, -CN, -C(O)R, -C(O)OR, -OC(O)R, -C(O)N(R)2, -N(R)C(O)R, -N(R)C(O)N(R)2, -OC(O)N(R)2, -N(R)C(O)OR, -OR, -N(R)2, -NO2, -SR, -S(O)R, -S(O)2R, -S(O)2N(R)2, or -NRS(O)2R.

[0036] In some embodiments, each occurrence of R3is independently optionally substituted C1-6 aliphatic, halogen, -CN, -C(O)R, -C(O)OR, -OC(O)R, -C(O)N(R)2, -N(R)C(O)R, -N(R)C(O)N(R)2, -OC(O)N(R)2, -N(R)C(O)OR, -OR, -N(R)2, -NO2, -SR, -S(O)R, -S(O)2R, -S(O)2N(R)2, or -NRS(O)2R.

[0037] In some embodiments, R3is a C1-6 aliphatic group. In some embodiments, R3is a substituted C1-6 aliphatic group. In some embodiments, R3is halogen. In some embodiments, R3is -CN. In some embodiments, R3is -C(O)R. In some embodiments, R3is -C(O)OR. In some embodiments, R3is -OC(O)R. In some embodiments, R3is -C(O)N(R)2. In some embodiments, R3is -N(R)C(O)R. In some embodiments, R3is -N(R)C(O)N(R)2. In some embodiments, R3is -OC(O)N(R)2. In some embodiments, R3is -N(R)C(O)OR. In some embodiments, R3is -OR. In some embodiments, R3is -N(R)2. In some embodiments, R3is -NO2. In some embodiments, R3is -SR. In some embodiments, R3is -S(O)R. In some embodiments, R3is -S(O)2R. In some embodiments, R3is -S(O)2N(R)2. In some embodiments, R3is -NRS(O)2R.

[0038] In some embodiments, R3is a C1-6 aliphatic group substituted with 1, 2, or 3 halogen atoms. In some embodiments, R3is a C1-6 alkyl group substituted with 1, 2, or 3 halogen atoms.

[0039] In some embodiments, R3is a C1-6 alkyl group optionally substituted with 1, 2, or 3 halogen atoms, -C1-6 alkylene, -OR, -C2-4 alkenyl, -C2-4 alkynyl, halogen, -OR, -C(O)R, -CN, -C(O)NR2, -NHMe, -NMe2, or -NH2.

[0040] In some embodiments, R3is -CF3.

[0041] In some embodiments, R3is selected from those depicted in Table 1, below.

[0042] As defined generally above, R4is a substituent comprising a warhead group.

[0043] In some embodiments, the warhead group comprises an electrophilic group capable of reacting with a nucleophile under biological conditions to form a covalent bond to the nucleophile.8335850176 CENC-014 / 01WO 360899-2049In some embodiments, the warhead group comprises an electrophilic group capable of reacting with the thiol group of a cysteine under biological conditions to form a covalent bond to the cysteine. In some embodiments, the warhead group comprises an epoxide, a Michael acceptor (e.g., substituted or unsubstituted acrylamide, substituted or unsubstituted acrylate, substituted or unsubstituted alpha halo acetamide), an alkyl chloride, alkyl bromide, alkyl iodide, a sulfonyl halide, an alpha-halo ketone, an alpha-halo amide, an aldehyde, an aminonitrile, an N-cyanamide, a nitrile, a vinyl sulfone, a vinyl sulfonamide, or an anhydride. In some embodiments, the warhead groups comprise those described in Table 1c.

[0044] In some embodiments, the warhead group is -L2-Y, wherein:L2is a covalent bond or a bivalent Ci-8 saturated or unsaturated, straight or branched, hydrocarbon chain, wherein one, two, or three methylene units of L2are optionally and independently replaced by cyclopropylene, — NR —, — N(R)C(O) —, — C(O)N(R) —, — N(R)SO2—, — SO2N(R)—, — O—, — C(O)—, — OC(O)—, — C(O)O—, — S—, —SO—, — SO2—, -O- P(O)(OR)O-, — C(=S)—, — C(=NR)—, — N=N—, or — C(=N2)—;Y is hydrogen, C1-6 aliphatic optionally substituted with oxo, halogen, NO2, or CN, or a 3-10 membered monocyclic or bicyclic, saturated, partially unsaturated, or aryl ring having 0- 3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and wherein said ring is substituted with 1-4 Regroups; andeach Reis independently selected from -Q-Z, oxo, NO2, halogen, CN, a suitable leaving group, or a C1-6 aliphatic optionally substituted with oxo, halogen, NO2, or CN, wherein:Q is a covalent bond or a bivalent C1-6 saturated or unsaturated, straight or branched, hydrocarbon chain, wherein one or two methylene units of Q are optionally and independently replaced by — N(R)—, — S—, — O—, — C(O)—, — OC(O)—, — C(O)O—, —SO—, or — SO2—, — N(R)C(O)—, — C(O)N(R)—, — N(R)SO2—, or — SO2N(R)—; andZ is hydrogen or C1-6 aliphatic optionally substituted with oxo, halogen, NO2, or CN.

[0045] In certain embodiments, L2is a covalent bond. In certain embodiments, L2is a bivalent C1-8 saturated or unsaturated, straight or branched, hydrocarbon chain. In certain embodiments, L2is — CH2—.

[0046] In certain embodiments, L2is a covalent bond, — CH2—, — NH —, — CH2NH —, — NHCH2—, — NHC(O)—, — NHC(O)CH2OC(O)—, — CH2NHC(O)—, — NHSO2—, — NHSO2CH2—, — NHC(O)CH2OC(O)—, or— SO2NH—.9335850176 CENC-014 / 01WO 360899-2049

[0047] In some embodiments, L2is a bivalent C2-8 straight or branched, hydrocarbon chain wherein L2has at least one double bond and one or two additional methylene units of L2are optionally and independently replaced by — NRC(O) —, — C(O)NR —, — N(R)SO2 —, — SO2N(R)—, — S—, — S(O)—, — SO2—, — OC(O)—, — C(O)O—, cyclopropylene, — O—, — N(R)—, -O-P(O)(OR)O-, or — C(O)—.

[0048] In certain embodiments, L2is a bivalent C2-8 straight or branched, hydrocarbon chain wherein L2has at least one double bond and at least one methylene unit of L2is replaced by — C(O)—, — NRC(O)—, — C(O)NR—, — N(R)SO2— — SO2N(R)—, — S—, — S(O)—, — SO2—, — OC(O) —, or — C(O)O —, and one or two additional methylene units of L2are optionally and independently replaced by cyclopropylene, — O —, — N(R) —, or — C(O) —.

[0049] In some embodiments, L2is a bivalent C2-8 straight or branched, hydrocarbon chain wherein L2has at least one double bond and at least one methylene unit of L2is replaced by — C(O) —, and one or two additional methylene units of L2are optionally and independently replaced by cyclopropylene, — O —, — N(R) —, -O-P(O)(OR)O-, or — C(O) —. In some embodiments, L2is a bivalent C2-8 straight or branched, hydrocarbon chain wherein L2has at least one double bond and at least one methylene unit of L2is replaced by — C(O) —, and one or two additional methylene units of L2are optionally and independently replaced by cyclopropylene, — O —, — N(R) —, -O-P(O)(OR)O-, or — C(O) —, wherein at least one double bond is located in an alpha-beta position relative to a — C(O) —.

[0050] As described above, in certain embodiments, L2is a bivalent C2-8 straight or branched, hydrocarbon chain wherein L2has at least one double bond. One of ordinary skill in the art will recognize that such a double bond may exist within the hydrocarbon chain backbone or may be “exo” to the backbone chain and thus forming an alkylidene group. By way of example, such an L2group having an alkylidene branched chain includes — CH2C(=CH2)CH2 —. Thus, in some embodiments, L2is a bivalent C2-8 straight or branched, hydrocarbon chain wherein L2has at least one alkylidenyl double bond. In some embodiments, L2is a bivalent C2-8 straight or branched, hydrocarbon chain wherein L2has at least one alkylidenyl double bond located in an alpha-beta position relative to a — C(O) —. Exemplary L2groups include — NHC(O)C(=CH2)CH2 —.

[0051] In certain embodiments, L2is a bivalent C2-8 straight or branched, hydrocarbon chain wherein L2has at least one double bond and at least one methylene unit of L2is replaced by — C(O)—. In certain embodiments, L2is — C(O)CH=CH(CH3)—, — C(O)CH=CHCH2NH(CH3)—10335850176 CENC-014 / 01WO 360899-2049— C(O)CH=CH(CH3)— — C(O)CH=CH— — CH2C(O)CH=CH— — CH2C(O)CH=CH(CH3)—, — CH2CH2C(O)CH=CH—, — CH2CH2C(O)CH=CHCH2—, — CH2CH2C(O)CH=CHCH2NH(CH3)— — CH2CH2C(O)CH=CH(CH3)—, or — CH(CH3)OC(O)CH=CH—.

[0052] In certain embodiments, L2is a bivalent C2-s straight or branched, hydrocarbon chain wherein L2has at least one double bond and at least one methylene unit of L2is replaced by — OC(O)—.

[0053] In some embodiments, L2is a bivalent C2-s straight or branched, hydrocarbon chain wherein L2has at least one double bond and at least one methylene unit of L2is replaced by — NRC(O), — C(O)NR—, N(R)SO2—, SO2N(R), — S—, — S(O) —, SO2—, OC(O) —, or — C(O)O —, and one or two additional methylene units of L2are optionally and independently replaced by cyclopropylene, — O —, — N(R) —, or — C(O) —. In some embodiments, L2is — CH2OC(O)CH=CHCH2—, — CH2— OC(O)CH=CH—, or — CH(CH=CH2)OC(O)CH=CH—.

[0054] In certain embodiments, L2is — NRC(O)CH=CH —, — NRC(O)CH=CHCH2N(CH3)—, — NRC(O)CH=CHCH2O—, — CH2NRC(O)CH=CH—, — NRSO2CH=CH—, — NRSO2CH=CHCH2—, — NRC(O)(C=N2)C(O)—, — NRC(O)CH=CHCH2N(CH3)—, — NRSO2CH=CH—, — NRSO2CH=CHCH2—, — NRC(O)CH=CHCH2O—, — NRC(O)C(=CH2)CH2—, — CH2NRC(O)—, — CH2NRC(O)CH=CH— — CH2CH2NRC(O)—, or — CH2NRC(O)cyclopropylene-, wherein each R is independently hydrogen or optionally substituted Ci-6 aliphatic.

[0055] In certain embodiments, L2is — NHC(O)CH=CH —, — NHC(O)CH=CHCH2N(CH3)—, — NHC(O)CH=CHCH2O—, — CH2NHC(O)CH=CH—, — NHSO2CH=CH—, — NHSO2CH=CHCH2—, — NHC(O)(C=N2)C(O)—, — NHC(O)CH=CHCH2N(CH3)—, — NHSO2CH=CH—, — NHSO2CH=CHCH2—, — NHC(O)CH=CHCH2O—, — NHC(O)C(=CH2)CH2—, — CH2NHC(O)—, — CH2NHC(O)CH=CH—, — CH2CH2NHC(O)—, or— CH2NHC(O)cyclopropylene-.

[0056] In some embodiments, L2is a bivalent C2-s straight or branched, hydrocarbon chain wherein L2has at least one triple bond. In certain embodiments, L2is a bivalent C2-s straight or branched, hydrocarbon chain wherein L2has at least one triple bond and one or two additional methylene units of L2are optionally and independently replaced by — NRC(O) —, — C(O)NR —,11335850176 CENC-014 / 01WO 360899-2049— S—, — S(O)—, — SO2—, — C(=S)—, — C(=NR)—, — O—, — N(R)—, or — C(O)—. In some embodiments, L2has at least one triple bond and at least one methylene unit of L2is replaced by — N(R)—, — N(R)C(O)—, — C(O)—, — C(O)O—, or — OC(O)—, or — O—. In some embodiments, L2has at least one triple bond and at least one methylene unit of L2is replaced by — N(R) —, — N(R)C(O) —, — C(O) —, — C(O)O —, or — OC(O) —, or — O —, wherein at least one triple bond is located in an alpha-beta position relative to a — C(O) —.

[0057] Exemplary L2groups include — C=C —, — C=CCH2N(isopropyl)-, — NHC(O)C=CCH2CH2—, — CH2— OCNCH2—, — OCCH2O—, — CH2C(O)C=C—, — C(O)C=C—, or — CH2OC(=O)C=C—.

[0058] In certain embodiments, L2is a bivalent C2-8 straight or branched, hydrocarbon chain wherein one methylene unit of L2is replaced by cyclopropylene and one or two additional methylene units of L2are independently replaced by — C(O) —, — NRC(O) —, — C(O)NR —, — N(R)SO2 —, or — SC>2N(R) —. Exemplary L2groups include — NHC(O)-cyclopropylene-SC>2 — and — NHC(O)-cyclopropylene-.

[0059] In certain embodiments, L2is a bivalent C2-8 straight or branched, hydrocarbon chain wherein one methylene unit of L2is replaced by -O-P(O)(OR)O-.

[0060] As defined generally above, Y is hydrogen, C1-6 aliphatic optionally substituted with oxo, halogen, NO2, or CN, or a 3-10 membered monocyclic or bicyclic, saturated, partially unsaturated, or aryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and wherein said ring is substituted with at 1 -4 Regroups, each Reis independently selected from -Q-Z, oxo, NO2, halogen, CN, a suitable leaving group, or C1-6 aliphatic, wherein Q is a covalent bond or a bivalent C1-6 saturated or unsaturated, straight or branched, hydrocarbon chain, wherein one or two methylene units of Q are optionally and independently replaced by — N(R) —, — S—, — O—, — C(O)—, — OC(O)—, — C(O)O—, —SO—, or — SO2—, — N(R)C(O)—, — C(O)N(R) —, — N(R)SO2 —, or — SO2N(R) —; and, Z is hydrogen or C1-6 aliphatic optionally substituted with oxo, halogen, NO2, or CN.

[0061] In certain embodiments, Y is hydrogen. In some embodiments, when L is a covalent bond, Y is other than hydrogen.

[0062] In certain embodiments, Y is C1-6 aliphatic optionally substituted with oxo, halogen, NO2, or CN. In some embodiments, Y is C2-ealkenyl optionally substituted with oxo, halogen, NO2, or CN. In other embodiments, Y is C2-ealkynyl optionally substituted with oxo, halogen,12335850176 CENC-014 / 01WO 360899-2049NO2, or CN. In some embodiments, Y is C2-6alkenyl. In other embodiments, Y is C2-4alkynyl.

[0063] In other embodiments, Y is C1-6 alkyl substituted with oxo, halogen, NO2, or CN. Such Y groups include — CH2F, — CH2CI, — CH2CN, and — CH2NO2.

[0064] In certain embodiments, Y is a saturated 3-6 membered monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein Y is substituted with 1-4 Regroups, wherein each Reis as defined above in warhead group -L2-Y.

[0065] In some embodiments, Y is a saturated 3-4 membered heterocyclic ring having 1 heteroatom selected from oxygen or nitrogen wherein said ring is substituted with 1-2 Regroups, wherein each Reis as defined above in warhead group is -L2-Y. Exemplary such rings are epoxide and oxetane rings, wherein each ring is substituted with 1-2 Regroups, wherein each Reis as defined above in warhead group is -L2-Y.

[0066] In other embodiments, Y is a saturated 5-6 membered heterocyclic ring having 1-2 heteroatom selected from oxygen or nitrogen wherein said ring is substituted with 1-4 Regroups, wherein each Reis as defined above in warhead group -L2-Y. Such rings include piperidine and pyrrolidine, wherein each ring is substituted with 1-4 Regroups, wherein each Reis as defined above in warhead group is -L2-Y. In certain embodiments, Y iswherein each R, Q, Z, and Reis as defined above in warhead group -L2-Y.

[0067] In some embodiments, Y is a saturated 3-6 membered carbocyclic ring, wherein said ring is substituted with 1-4 Regroups, wherein each Reis as defined above in warhead group -L2-Y. In certain embodiments, Y is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, wherein each ring is substituted with 1-4 Regroups, wherein each Reis as defined above in warhead group -L2-Y. In certain embodiments,wherein Reis as defined above in warhead group -L2-Y.

[0068] In certain embodiments, Y is cyclopropyl optionally substituted with halogen, CN or NO2.

[0069] In certain embodiments, Y is a partially unsaturated 3-6 membered monocyclic ring335850176 CENC-014 / 01WO 360899-2049having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 Regroups, wherein each Reis as defined above in warhead group -L2-Y.

[0070] In some embodiments, Y is a partially unsaturated 3-6 membered carbocyclic ring, wherein said ring is substituted with 1-4 Regroups, wherein each Reis as defined above in warhead group - L2-Y. In some embodiments, Y is cyclopropenyl, cyclobutenyl, cyclopentenyl, or cyclohexenyl wherein each ring is substituted with 1-4 Regroups, wherein each Reis as definedwherein each Reis as defined above in warhead group -L2-Y.

[0071] In certain embodiments, Y is a partially unsaturated 4-6 membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 Regroups, wherein each Reis as defined above in warhead group -L2-Y. In certain embodiments, Y is selected from:

[0072] wherein each R is as defined above and described herein and Reis as defined above in warhead group -L2-Y.

[0073] In certain embodiments, Y is a 6-membered aromatic ring having 0-2 nitrogens wherein said ring is substituted with 1-4 Regroups, wherein each Regroup is as defined above in warhead group — L2-Y. In certain embodiments, Y is phenyl, pyridyl, or pyrimidinyl, wherein each ring is substituted with 1-4 Regroups, wherein each Reis as defined above in warhead group -L2-Y.

[0074] In some embodiments, Y is selected from:wherein each Reis as defined above in warhead group -L2-Y.

[0075] In other embodiments, Y is a 5-membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-314335850176 CENC-014 / 01WO 360899-2049Regroups, wherein each Regroup is as defined above in warhead group -L2-Y. In some embodiments, Y is a 5 membered partially unsaturated or aryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said ring is substituted with 1-4 Regroups, wherein each Regroup is as defined above in warhead group -L2-Y. Exemplary such rings are isoxazolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, pyrrolyl, furanyl, thienyl, triazole, thiadiazole, and oxadiazole, wherein each ring is substituted with 1-3 Regroups, wherein each Regroup is as defined above in warhead group -L2-Y. In certain embodiments, Y is selected from:wherein each R is as defined above and described herein and Reis as defined above in warhead group — L2-Y.

[0076] In certain embodiments, Y is an 8-10 membered bicyclic, saturated, partially unsaturated, or aryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 Regroups, wherein Reis as defined above in warhead group -L2-Y. According to another aspect, Y is a 9-10 membered bicyclic, partially unsaturated, or aryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 Regroups, wherein Reis as defined above in warhead group -L2-Y. Exemplary such bicyclic rings include 2,3-dihydrobenzo[d]isothiazole, wherein said ring is substituted with 1-4 Regroups, wherein Reis as defined above in warhead group - L2-Y.

[0077] As defined generally above, each Regroup is independently selected from -Q-Z, oxo,15335850176 CENC-014 / 01WO 360899-2049NCh, halogen, CN, a suitable leaving group, or Ci-6 aliphatic optionally substituted with oxo, halogen, NCh, or CN, wherein Q is a covalent bond or a bivalent Ci-6 saturated or unsaturated, straight or branched, hydrocarbon chain, wherein one or two methylene units of Q are optionally and independently replaced by — N(R) —, — S —, — O —, — C(O) —, — OC(O) —, — C(O)O —, — SO—, or — SO2—, — N(R)C(O)—, — C(O)N(R)—, — N(R)SO2—, or — SO2N(R)—; and Z is hydrogen or C1-6 aliphatic optionally substituted with oxo, halogen, NO2, or CN.

[0078] In certain embodiments, Reis C1-6 aliphatic optionally substituted with oxo, halogen, NO2, or CN. In other embodiments, Reis oxo, NO2, halogen, or CN.

[0079] In some embodiments, Reis -Q-Z, wherein Q is a covalent bond and Z is hydrogen (i.e., Reis hydrogen). In other embodiments, Reis -Q-Z, wherein Q is a bivalent C1-6 saturated or unsaturated, straight or branched, hydrocarbon chain, wherein one or two methylene units of Q are optionally and independently replaced by — NR —, — NRC(O) —, — C(O)NR —, — S —, — O —, — C(O) —, — SO —, or — SO2—. In other embodiments, Q is a bivalent C2-6 straight or branched, hydrocarbon chain having at least one double bond, wherein one or two methylene units of Q are optionally and independently replaced by — NR —, — NRC(O) —, — C(O)NR —, — S —, — O —, — C(O) —, — SO —, or — SO2—. In certain embodiments, the Z moiety of the Regroup is hydrogen. In some embodiments, -Q-Z is — NHC(O)CH=CH2or — C(O)CH=CH2.

[0080] In certain embodiments, each Reis independently selected from oxo, NO2, CN, fluoro, chloro, — NHC(O)CH=CH2, — C(O)CH=CH2, — CH2CH=CH2, — C =CH, — C(O)OCH2C1, — C(O)OCH2F, — C(O)OCH2CN, — C(O)CH2C1, — C(O)CH2F, — C(O)CH2CN, or — CH2C(O)CH3.

[0081] In certain embodiments, Reis a suitable leaving group, i.e., a group that is subject to nucleophilic displacement. A “suitable leaving” is a chemical group that is readily displaced by a desired incoming chemical moiety such as the thiol moiety of a cysteine of interest. In some embodiments, the warhead group modifies a cysteine of DCN-1. In some embodiments, the cysteine of DCN-1 is Cysll5. Suitable leaving groups are well known in the art, e.g., see, “Advanced Organic Chemistry,” Jerry March, 5thEd., pp. 351-357, John Wiley and Sons, N. Y. Such leaving groups include, but are not limited to, halogen, alkoxy, sulfonyloxy, optionally substituted alkylsulfonyloxy, optionally substituted alkenylsulfonyloxy, optionally substituted arylsulfonyloxy, acyl, and diazonium moieties. Examples of suitable leaving groups include16335850176 CENC-014 / 01WO 360899-2049chloro, iodo, bromo, fluoro, acetoxy, methanesulfonyloxy (mesyloxy), tosyloxy, triflyloxy, nitrophenyl sulfonyloxy (nosyloxy), and bromo-phenylsulfonyloxy (brosyloxy).

[0082] In certain embodiments, the following embodiments, and combinations of -L2-Y apply:(a) L2is a bivalent C2-8 straight or branched, hydrocarbon chain wherein L2has at least one double bond and one or two additional methylene units of L2are optionally and independently replaced by — NRC(O) —, — C(O)NR —, — N(R)SCh —, — SO2N(R) —, — S —, — S(O)—, — SO2—, — OC(O)—, — C(O)O—, cyclopropylene, — O—, — N(R)—, -O- P(O)(OR)O-, or — C(O) —; and Y is hydrogen, or C1-6 aliphatic optionally substituted with oxo, halogen, NO2, or CN; wherein -L2-Y comprises an alpha, beta-unsaturated carbonyl moiety; or(b) L2is a bivalent C2-8 straight or branched, hydrocarbon chain wherein L2has at least one double bond and at least one methylene unit of L2is replaced by — C(O) —, — NRC(O) —, — C(O)NR— — N(R)SO2—, — SO2N(R)—, — S— — S(O)—, — SO2—, — OC(O)—, or — C(O)O —, and one or two additional methylene units of L2are optionally and independently replaced by cyclopropylene, — O —, — N(R) —, or — C(O) —; and Y is hydrogen, halogen or C1-6 aliphatic optionally substituted with oxo, halogen, NO2, or CN; wherein -L2-Y comprises an alpha, beta-unsaturated carbonyl moiety; or(c) L2is a bivalent C2-8 straight or branched, hydrocarbon chain wherein L2has at least one double bond and at least one methylene unit of L2is replaced by — C(O) —, and one or two additional methylene units of L2are optionally and independently replaced by cyclopropylene, — O —, — N(R) —, or — C(O) —; and Y is hydrogen, or C1-6 aliphatic optionally substituted with oxo, halogen, NO2, or CN; wherein -L2-Y comprises an alpha, betaunsaturated carbonyl moiety; or(d) L2is a bivalent C2-8 straight or branched, hydrocarbon chain wherein L2has at least one double bond and at least one methylene unit of L2is replaced by — C(O) —; and Y is hydrogen, or C1-6 aliphatic optionally substituted with oxo, halogen, NO2, or CN; wherein -L2- Y comprises an alpha, beta-unsaturated carbonyl moiety; or(e) L2is a bivalent C2-8 straight or branched, hydrocarbon chain wherein L2has at least one double bond and at least one methylene unit of L2is replaced by — OC(O) —; and Y is hydrogen, or C1-6 aliphatic optionally substituted with oxo, halogen, NO2, or CN; wherein -L2- Y comprises an alpha, beta-unsaturated carbonyl moiety; or17335850176 CENC-014 / 01WO 360899-2049(f) L2is — NRC(O)CH=CH—, — NRC(O)CH=CHCH2N(CH3)—, — NRC(O)CH=CHCH2O—, — CH2NRC(O)CH=CH—, — NRSO2CH=CH— — NRSChCH=CHCH2—, — NRC(O)(C=N2)—, — NRC(O)(C=N2)C(O)—, — NRC(O)CH=CHCH2N(CH3)—, — NRSChCH=CH—, — NRSO2CH=CHCH2—, — NRC(O)CH=CHCH2O—, — NRC(O)C(=CH2)CH2— — CH2NRC(O)—, — CH2NRC(O)CH=CH —, — CH2CH2NRC(O) —, or — CH2NRC(O)cyclopropylene-; wherein R is H or optionally substituted Ci-6 aliphatic; and Y is hydrogen, or Ci-6 aliphatic optionally substituted with oxo, halogen, NCh, or CN; wherein -L2-Y comprises an alpha, betaunsaturated carbonyl moiety; or(g) L2is NHC(O)CH=CH — NHC(O)CH=CHCH2N(CH3) — NHC(O)CH=CHCH2O—, — CH2NHC(O)CH=CH—, — NHSChCH=CH—, — NHSO2CH=CHCH2—, — NHC(O)(C=N2)—, — NHC(O)(C=N2)C(O)—, — NHC(O)CH=CHCH2N(CH3)—, — NHSO2CH=CH— — NHSO2CH=CHCH2—, — NHC(O)CH=CHCH2O—, — NHC(O)C(=CH2)CH2—, — CH2NHC(O)—, — CH2NHC(O)CH=CH—, — CH2CH2NHC(O)—, or — CH2NHC(O)cyclopropylene-; and Y is hydrogen, or Ci-6 aliphatic optionally substituted with oxo, halogen, NCh, or CN; wherein - L2-Y comprises an alpha, beta-unsaturated carbonyl moiety; or(h) L2is a bivalent C2-s straight or branched, hydrocarbon chain wherein L2has at least one alkylidenyl double bond and at least one methylene unit of L2is replaced by — C(O) —, — NRC(O)—, — C(O)NR— — N(R)SCh—, — SChN(R)—, — S—, — S(O)—, — SC —, — OC(O) —, or — C(O)O —, and one or two additional methylene units of L2are optionally and independently replaced by cyclopropylene, — O —, — N(R) —, or — C(O) —; and Y is hydrogen, or Ci-6 aliphatic optionally substituted with oxo, halogen, NCh, or CN; wherein -L2- Y comprises an alpha, beta-unsaturated carbonyl moiety; or(i) L2is a bivalent C2-s straight or branched, hydrocarbon chain wherein L2has at least one triple bond and one or two additional methylene units of L2are optionally and independently replaced by — NRC(O) —, — C(O)NR —, — N(R)SCh —, — SO2N(R) —, — S —, — S(O) —, — SCh —, — OC(O) —, or — C(O)O —, and Y is hydrogen, or Ci-6 aliphatic optionally substituted with oxo, halogen, NCh, or CN; wherein -L2-Y comprises an alpha, betaunsaturated carbonyl moiety; or(j) L2is — C=C—, — C=CCH2N(isopropyl)-, — NHC(O)C=CCH2CH2—, — CH2—18335850176 CENC-014 / 01WO 360899-2049C=C=CH2— — C=CCH2O—, — CH2C(O)C=C— — C(O)C=C— or — CH2C(=O)C=C—; and Y is hydrogen, or Ci-6 aliphatic optionally substituted with oxo, halogen, NO2, or CN; wherein -L2-Y comprises an alpha, beta-unsaturated carbonyl moiety; or(k) L2is a bivalent C2-s straight or branched, hydrocarbon chain wherein one methylene unit of L2is replaced by cyclopropylene and one or two additional methylene units of L2are independently replaced by — NRC(O) —, — C(O)NR —, — N(R)SO2—, — SO2N(R) —, — S —, — S(O) —, — SO2—, — OC(O) —, or — C(O)O —; and Y is hydrogen, or Ci-6 aliphatic optionally substituted with oxo, halogen, NO2, or CN; wherein -L2-Y comprises an alpha, betaunsaturated carbonyl moiety; or(l) L2is a covalent bond and Y is selected from:(i) Ci-6 alkyl substituted with oxo, halogen, NO2, or CN;(ii) C2-ealkenyl optionally substituted with oxo, halogen, NO2, or CN; or (iii) C2-ealkynyl optionally substituted with oxo, halogen, NO2, or CN; or (iv) a saturated 3-4 membered heterocyclic ring having 1 heteroatom selected from oxygen or nitrogen wherein said ring is substituted with 1-2 Regroups, wherein each Reis as defined above in warhead group -L2-Y; or(v) a saturated 5-6 membered heterocyclic ring having 1-2 heteroatom selected from oxygen or nitrogen wherein said ring is substituted with 1-4 Regroups, wherein each Reis as defined above in warhead group -L2-Y; orReis as defined above in warhead group -L2-Y; or(vii) a saturated 3-6 membered carbocyclic ring, wherein said ring is substituted with 1-4 Regroups, wherein each Reis as defined above in warhead group -L2-Y; or (viii) a partially unsaturated 3-6 membered monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 Regroups, wherein each Reis as defined above in warhead group -L2-Y; or(ix) a partially unsaturated 3-6 membered carbocyclic ring, wherein said ring is substituted with 1-4 Regroups, wherein each Reis as defined above in warhead group 19335850176 CENC-014 / 01WO 360899-2049(x) ’ wherein each Reis as defined above in warhead group -L2- Y; or(xi) a partially unsaturated 4-6 membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 Regroups, wherein each Reis as defined above in warhead groupwherein each R is as defined above and described herein and Reis as defined above in warhead group -L2-Y; or(xiii) a 6-membered aromatic ring having 0-2 nitrogens wherein said ring is substituted with 1-4 Rcgroups, wherein each Rcgroup is as defined above in warhead group - L2-Y; or(xiv)each Reis as defined above in warhead group -L2-Y; or(xv) a 5-membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-3 Regroups, wherein each Regroup is as defined above in warhead group -L2-Y; or(xvi)335850176 CENC-014 / 01WO 360899-2049wherein each R is as defined above and described herein and Reis as defined above in warhead group -L2-Y; or(xvii) an 8-10 membered bicyclic, saturated, partially unsaturated, or aryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 Regroups, wherein Reis as defined above in warhead group -L2-Y;(m) L2is — C(O) — and Y is selected from:(i) Ci-6 alkyl substituted with oxo, halogen, NO2, or CN; or(ii) C2-6alkenyl optionally substituted with oxo, halogen, NO2, or CN; or(iii) C2-ealkynyl optionally substituted with oxo, halogen, NO2, or CN; or(iv) a saturated 3-4 membered heterocyclic ring having 1 heteroatom selected from oxygen or nitrogen wherein said ring is substituted with 1-2 Regroups, wherein each Reis as defined above in warhead group -L2-Y; or(v) a saturated 5-6 membered heterocyclic ring having 1-2 heteroatom selected from oxygen or nitrogen wherein said ring is substituted with 1-4 Regroups, wherein each Reis as defined above in warhead group -L2-Y; ordefined above in warhead group -L2-Y; or21335850176 CENC-014 / 01WO 360899-2049(vii) a saturated 3-6 membered carbocyclic ring, wherein said ring is substituted with 1-4 Regroups, wherein each Reis as defined above in warhead group -L2-Y; or (viii) a partially unsaturated 3-6 membered monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 Regroups, wherein each Reis as defined above in warhead group -L2-Y; or(ix) a partially unsaturated 3-6 membered carbocyclic ring, wherein said ring is substituted with 1-4 Regroups, wherein each Reis as defined above in warhead group -L2-Y; or(x)wherein each Reis as defined above in warhead group -L2-Y; or (xi) a partially unsaturated 4-6 membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 Regroups, wherein each Reis as defined above in warhead groupwherein each R is as defined above and described herein and Reis as defined above in warhead group -L2-Y; or(xiii) a 6-membered aromatic ring having 0-2 nitrogens wherein said ring is substituted with 1-4 Regroups, wherein each Regroup is as defined above in warhead group -L2- Y; orwherein each Reis as defined above in warhead group -L2-Y; or(xv) a 5-membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-3 Regroups, wherein each Regroup is as defined above in warhead group -L2-Y; or22335850176 CENC-014 / 01WO 360899-2049(xvi)wherein each R is as defined above and described herein and Reis as defined above in warhead group -L2-Y; or(xvii) an 8-10 membered bicyclic, saturated, partially unsaturated, or aryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 Regroups, wherein Reis as defined above in warhead group - L2-Y;(n) L2is — N(R)C(O) — and Y is selected from:(i) Ci-6 alkyl substituted with oxo, halogen, NO2, or CN; or(ii) C2-6alkenyl optionally substituted with oxo, halogen, NO2, or CN; or(iii) C2-salkynyl optionally substituted with oxo, halogen, NO2, or CN; or(iv) a saturated 3-4 membered heterocyclic ring having 1 heteroatom selected from oxygen or nitrogen wherein said ring is substituted with 1-2 Regroups, wherein each Reis as defined above in warhead group -L2-Y; or(v) a saturated 5-6 membered heterocyclic ring having 1-2 heteroatom selected from oxygen or nitrogen wherein said ring is substituted with 1-4 Regroups, wherein each Reis as defined above in warhead group -L2-Y; or23335850176 CENC-014 / 01WO 360899-2049defined above in warhead group -L2-Y; or(vii) a saturated 3-6 membered carbocyclic ring, wherein said ring is substituted with 1-4 Regroups, wherein each Reis as defined above in warhead group -L2-Y; or (viii) a partially unsaturated 3-6 membered monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 Regroups, wherein each Reis as defined above in warhead group -L2-Y; or(ix) a partially unsaturated 3-6 membered carbocyclic ring, wherein said ring is substituted with 1-4 Regroups, wherein each Reis as defined above in warhead group -L2-Y; orwherein each Reis as defined above in warhead group -L2-Y; or (xi) a partially unsaturated 4-6 membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 Rcgroups, wherein each Reis as defined above in warhead group -L2-Y; orand Reis as defined above in warhead group -L2-Y; or(xiii) a 6-membered aromatic ring having 0-2 nitrogens wherein said ring is substituted with 1-4 Regroups, wherein each Regroup is as defined above in warhead group -L2- Y; orwherein each Reis as defined above in warhead group -L2-Y; or335850176 CENC-014 / 01WO 360899-2049(xv) a 5-membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-3 Regroups, wherein each Regroup is as defined above in warhead group -L2-Y; or(xvi)wherein each R is as defined above and described herein and Reis as defined above in warhead group -L2-Y; or(xvii) an 8-10 membered bicyclic, saturated, partially unsaturated, or aryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 Regroups, wherein Reis as defined above in warhead group - L2-Y;(o) L2is a bivalent Ci-8 saturated or unsaturated, straight or branched, hydrocarbon chain; and Y is selected from:(i) Ci-6 alkyl substituted with oxo, halogen, NO2, or CN;(ii) C2-6alkenyl optionally substituted with oxo, halogen, NO2, or CN; or(iii) C2-6alkynyl optionally substituted with oxo, halogen, NO2, or CN; or(iv) a saturated 3-4 membered heterocyclic ring having 1 heteroatom selected from oxygen or nitrogen wherein said ring is substituted with 1-2 Regroups, wherein each Reis as defined above in warhead group -L2-Y; or(v) a saturated 5-6 membered heterocyclic ring having 1-2 heteroatom selected from oxygen or nitrogen wherein said ring is substituted with 1-4 Regroups, wherein each Reis as defined above in warhead group -L2-Y; or25335850176 CENC-014 / 01WO 360899-2049defined above in warhead group -L2-Y; or(vii) a saturated 3-6 membered carbocyclic ring, wherein said ring is substituted with 1-4 Regroups, wherein each Reis as defined above in warhead group -L2-Y; or (viii) a partially unsaturated 3-6 membered monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 Regroups, wherein each Reis as defined above in warhead group -L2-Y; or(ix) a partially unsaturated 3-6 membered carbocyclic ring, wherein said ring is substituted with 1-4 Regroups, wherein each Reis as defined above in warhead group -L2-Y; or(x), wherein each Reis as defined above in warhead group -L2-Y; or (xi) a partially unsaturated 4-6 membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 Regroups, wherein each Reis as defined above in warhead group -L2-Y; oreach R is as defined above and described herein and Reis as defined above in warhead group -L2-Y; or(xiii) a 6-membered aromatic ring having 0-2 nitrogens wherein said ring is substituted with 1-4 Regroups, wherein each Regroup is as defined above in warhead group -L2- Y; or26335850176 CENC-014 / 01WO 360899-2049wherein each Reis as defined above in warhead group -L2-Y; or(xv) a 5-membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-3 Regroups, wherein each Regroup is as defined above in warhead group -L2-Y; or(xvi)wherein each R is as defined above and described herein and Reis as defined above in warhead group -L2-Y; or(xvii) an 8-10 membered bicyclic, saturated, partially unsaturated, or aryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 Regroups, wherein Reis as defined above in warhead group - L2-Y;(p) L2is a covalent bond, — CH2—, — NH—, — C(O)—, — CH2NH—, — NHCH2—, — NHC(O)—, — NHC(O)CH2OC(O)—, — CH2NHC(O)—, — NHSO2—, — NHSO2CH2—, — NHC(O)CH2OC(O) —, or — SO2NH —; and Y is selected from:(i) C1-6 alkyl substituted with oxo, halogen, NO2, or CN; or(ii) C2-6alkenyl optionally substituted with oxo, halogen, NO2, or CN; or(iii) C2-salkynyl optionally substituted with oxo, halogen, NO2, or CN; or27335850176 CENC-014 / 01WO 360899-2049(iv) a saturated 3-4 membered heterocyclic ring having 1 heteroatom selected from oxygen or nitrogen wherein said ring is substituted with 1-2 Regroups, wherein each Reis as defined above in warhead group -L2-Y; or(v) a saturated 5-6 membered heterocyclic ring having 1-2 heteroatom selected from oxygen or nitrogen wherein said ring is substituted with 1-4 Regroups, wherein each Reis as defined above in warhead group, wherein each R, Q, Z, and Reis as defined above in warhead group -L2-Y; or(vii) a saturated 3-6 membered carbocyclic ring, wherein said ring is substituted with 1-4 Regroups, wherein each Reis as defined above in warhead group -L2-Y; or (viii) a partially unsaturated 3-6 membered monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 Regroups, wherein each Reis as defined above in warhead group(ix) a partially unsaturated 3-6 membered carbocyclic ring, wherein said ring is substituted with 1-4 Regroups, wherein each Reis as defined above in warhead groupwherein each Reis as defined above in warhead group -L2-Y; or (xi) a partially unsaturated 4-6 membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 Regroups, wherein each Reis as defined above in warhead group28335850176 CENC-014 / 01WO 360899-2049R and Reis as defined above in warhead group -L2-Y; or(xiii) a 6-membered aromatic ring having 0-2 nitrogens wherein said ring is substituted with 1-4 Regroups, wherein each Regroup is as defined above in warhead group -L2- Y; orwherein each Reis as defined above in warhead group -L2-Y; or(xv) a 5-membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-3 Regroups, wherein each Regroup is as defined above in warhead group L2-Y; or(xvi)wherein each R is as defined above and described herein and Reis as defined above in warhead group -L2-Y; or(xvii) an 8-10 membered bicyclic, saturated, partially unsaturated, or aryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 Regroups, wherein Reis as defined above in warhead group -L2-Y;29335850176 CENC-014 / 01WO 360899-2049(q) L2is a bivalent Ci-8 saturated or unsaturated, straight or branched, hydrocarbon chain, wherein one, two, or three methylene units of L2are optionally and independently replaced by cyclopropylene, —NR—, — N(R)C(O)—, — C(O)N(R)—, — N(R)SO2—, — SO2N(R)—, — O—, — C(O)—, — OC(O)—, — C(O)O—, — S—, —SO—, — SO2—, -O-P(O)(OR)O-, — C(=S) —, — C(=NR) —, — N=N —, or — C(=N2) —; and Y is hydrogen or Ci-6 aliphatic optionally substituted with oxo, halogen, NO2, or CN, wherein -L2-Y comprises an alpha, beta-unsaturated carbonyl moiety;(r) L2is a bivalent Ci-s saturated or unsaturated, straight or branched, hydrocarbon chain, wherein one, two, or three methylene units of L2are optionally and independently replaced by cyclopropylene, —NR—, — N(R)C(O)—, — C(O)N(R)—, — N(R)SO2—, — SO2N(R)—, O—, — C(O)—, — OC(O)—, — C(O)O—, — S—, —SO—, — SO2—, -O-P(O)(OR)O-, — C(=S)—, — C(=NR) —, — N=N —, or — C(=N2) —; and Y is hydrogen or Ci-6 aliphatic optionally substituted with oxo, halogen, NO2, or CN, wherein -L2-Y comprises an alpha halo carbonyl moiety.

[0083] In certain embodiments, a Y group is selected from those set forth in Table la, below.

[0084] In certain embodiments, R4is L2-Y. In certain embodiments, the following embodiments, and combinations of -L2-Y apply:L2is a covalent bond or a bivalent C2-s straight or branched, hydrocarbon chain wherein one or two methylene units of L2are optionally and independently replaced by — NRC(O) —, — C(O)NR—, — N(R)SO2—, — SO2N(R)—, — S—, -O-, -NR-, — S(O)—, — SO2—, -C(O)-, — OC(O) —, or — C(O)O —; and additionally one methylene unit of L2is optionally replaced by an optionally substituted ring selected from a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, a 4-10 membered bicyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic aromatic carbocyclic ring, a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-10 membered bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur; andY is hydrogen, halogen, -COOR, -CN, -CON(R)2, -NRCN, NO2, -N(R)2, optionally substituted Ci- s aliphatic, or an optionally substituted ring selected from a 3-8 membered saturated or partially30335850176 CENC-014 / 01WO 360899-2049unsaturated monocyclic carbocyclic ring, a 4-10 membered bicyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic aromatic carbocyclic ring, a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-10 membered bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein -L2-Y comprises an alpha, beta-unsaturated carbonyl moiety, amide, cyano group, halogen, carbonyl, alkynyl group, sulfonyl group, or epoxide.

[0085] In certain embodiments, R4is L2-Y. In certain embodiments, the following embodiments, and combinations of -L2-Y apply:L2is a covalent bond or a bivalent C2-8 straight or branched, hydrocarbon chain wherein one or two methylene units of L2are optionally and independently replaced by — NRC(O) —, — C(O)NR—, — N(R)SO2—, — SO2N(R)—, — S—, -O-, -NR-, — S(O)—, — SO2—, -C(O)-, — OC(O) —, or — C(O)O —; and additionally one methylene unit of L2is optionally replaced by an optionally substituted ring selected from a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, or a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; andY is hydrogen, halogen, -COOR1, -CN, -CONRf2, -NRfCN, NO2, -NRf2, Ci-s aliphatic optionally substituted with halogen, NO2, or CN, or an optionally substituted ring selected from a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-10 membered bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein -L2-Y comprises an alpha, beta-unsaturated carbonyl moiety, amide, cyano group, halogen, carbonyl, alkynyl group, sulfonyl group, or epoxide; and wherein each occurrence of Rfis independently H, or straight or branched C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl group optionally substituted with 1, 2 or 3 halogen atoms.

[0086] In certain embodiments, R4is L2-Y. In certain embodiments, the following31335850176 CENC-014 / 01WO 360899-2049embodiments, and combinations of -L2-Y apply:L2is a covalent bond or a bivalent C2-8 straight or branched, hydrocarbon chain wherein one or two methylene units of L2are optionally and independently replaced by — NRC(O) —, — C(O)NR—, — N(R)SO2—, — SO2N(R)—, — S—, — S(O)—, — SO2—, -C(O)-, — OC(O)— or — C(O)O —; and additionally one methylene unit of L2is optionally replaced by a ring-Nl CN, NO2, -NRf2, epoxide, C1-8 aliphatic optionally substituted with halogen, NO2, or CN,; wherein -L2-Y comprises an alpha, beta-unsaturated carbonyl moiety, amide, cyano group, halogen, carbonyl, C2-6 alkynyl group, sulfonyl group, or epoxide; wherein each occurrence of R1is independently H, or straight or branched C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl group optionally substituted with 1, 2 or 3 halogen atoms; and wherein each occurrence of Rgand Rhis independently H, halogen, or OH, or straight or branched C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl group optionally substituted with 1, 2 or 3 halogen atoms.32335850176 CENC-014 / 01WO 360899-2049

[0087] In certain embodiments, a L2-Y group is selected from those set forth in Table 1c, Table Id and Table le below. In certain embodiments, a warhead group is selected from those set forth in Table 1c, Table Id and Table le below.Table la. Exemplary ¥ groups335850176 CENC-014 / 01WO 360899-204935335850176 CENC-014 / 01WO 360899-2049wherein each Reis independently a suitable leaving group, NO2, CN or oxo.

[0088] In certain embodiments, a warhead group is — C=CH, — C=CCH2NH(isopropyl), — NHC(O)C=CCH2CH3, — CH2— OOCt, — OCCH2OH, — CH2C(O)C=CH, — C(O)C=CH, or — CH2C(=0)C=CH. In some embodiments, a warhead group is selected from — NHC(O)CH=CH2, — NHC(O)CH=CHCH2N(CH3)2, or — CH2NHC(O)CH=CH2.

[0089] In certain embodiments, a warhead group is selected from those set forth in Table lb, below, wherein each wavy line indicates the point of attachment to the rest of the molecule. In certain embodiments, R4is selected from those set forth in Table lb.Table lb. Exemplary Warhead Groups335850176 CENC-014 / 01WO 360899-2049335850176 CENC-014 / 01WO 360899-2049335850176 CENC-014 / 01WO 360899-204939335850176 CENC-014 / 01WO 360899-2049wherein each Reis independently a suitable leaving group, NO2, CN, or oxo.

[0090] In some embodiments, Y of a warhead group is an isoxazoline compound or derivative capable of covalently binding to serine. In some embodiments, Y of a warhead group is an isoxazoline compound or derivative described in WO 2010135360, the entire content of which is incorporated herein by reference. As understood by one skilled in the art, an isoxazoline compound or derivative described in WO 2010135360, as Y of a warhead group, can covalently connect to L2of the warhead group at any reasonable position of the isoxazoline compound or derivative. Insome embodiments, Y of a warhead group is: Rawherein G, Ra, and Rcare:335850176 CENC-014 / 01WO 360899-2049335850176 CENC-014 / 01WO 360899-2049335850176 CENC-014 / 01WO 360899-2049335850176 CENC-014 / 01WO 360899-2049335850176 CENC-014 / 01WO 360899-2049

[0091] In some embodiments, a warhead group is selected from those set forth in Table 1c, below, wherein each wavy line indicates the point of attachment to the rest of the molecule. In some embodiments, R4is selected from those set forth in Table 1c.45335850176 CENC-014 / 01WO 360899-2049Table 1c. Exemplary Warhead Groups335850176 CENC-014 / 01WO 360899-2049335850176 CENC-014 / 01WO 360899-2049335850176 CENC-014 / 01WO 360899-2049

[0092] In some embodiments, a warhead group is selected from those set forth in Table Id, below, wherein each wavy line indicates the point of attachment to the rest of the molecule. In some embodiments, R4is selected from those set forth in Table Id.Table Id. Exemplary Warhead Groups335850176 CENC-014 / 01WO 360899-2049335850176 CENC-014 / 01WO 360899-2049

[0093] In some embodiments, R4is selected from those set forth in Table Id.

[0094] In some embodiments, a warhead group is selected from those set forth in Table le, below, wherein each wavy line indicates the point of attachment to the rest of the molecule. In some embodiments, R4is selected from those set forth in Table le.Table le. Exemplary Warhead Groups

[0095] In some embodiments, R4is selected from those set forth in Table le.335850176 CENC-014 / 01WO 360899-2049

[0097] In some embodiments, R4is selected from those depicted in Table 1, below.

[0098] As defined generally above, each occurrence of R5is independently halogen, -CN, - C(O)R, -C(O)OR, -OC(O)R, -C(O)N(R)2, -N(R)C(O)R, -N(R)C(O)N(R)2, -OC(O)N(R)2, - N(R)C(O)OR, -OR, -N(R)2, -NO2, -SR, -S(O)R, -S(O)2R, -S(O)2N(R)2, -NRS(O)2R, or an optionally substituted group selected from Ci-6 aliphatic, phenyl, or a 5-6 membered heteroaromatic ring having 1-3 heteroatoms selected from nitrogen, sulfur, and oxygen.

[0099] In some embodiments, R5is Ci-6 aliphatic group. In some embodiments, R5is substituted Ci-6 aliphatic group. In some embodiments, R5is halogen. In some embodiments, R3is -CN. In some embodiments, R5is -C(O)R. In some embodiments, R5is -C(O)OR. In some embodiments, R5is -OC(O)R. In some embodiments, R5is -C(O)N(R)2. In some embodiments, R3is -N(R)C(O)R. In some embodiments, R5is -N(R)C(O)N(R)2. In some embodiments, R3is -OC(O)N(R)2. In some embodiments, R5is -N(R)C(O)OR. In some embodiments, R5is -OR. In some embodiments, R5is -N(R)2. In some embodiments, R5is -NO2. In some embodiments, R5is61335850176 CENC-014 / 01WO 360899-2049-SR. In some embodiments, R5is -S(O)R. In some embodiments, R5is -S(O)2R. In some embodiments, R5is -S(O)2N(R)2. In some embodiments, R5is -NRS(O)2R. In some embodiments, R5is phenyl. In some embodiments, R5is a 5-6 membered heteroaromatic ring having 1-3 heteroatoms selected from nitrogen, sulfur, and oxygen.

[0100] In some embodiments, R5is Ci-6 aliphatic optionally substituted with 1, 2, or 3 halogen atoms, halogen, -CN, -C(O)R, -C(O)OR, -OC(O)R, -C(O)N(R)2, -N(R)C(O)R, -OR, -N(R)2, -SR, -S(O)R, -S(O)2R, or -S(O)2N(R)2.

[0101] In some embodiments, R5is halogen. In some embodiments, R5is selected from F, Cl or Br. In some embodiments, R5is F.

[0102] In some embodiments, R5is selected from those depicted in Table 1, below.

[0103] As defined generally above, R6is hydrogen or an optionally substituted Ci-6 aliphatic group.

[0104] In some embodiments, R6is hydrogen. In some embodiments, R6is an optionally substituted Ci-6 aliphatic group. In some embodiments, R6is an optionally substituted Ci-6 aliphatic group.embodiments, R6is selected from hydrogen,pharmaceutically acceptable salt thereof.O=P-OHi

[0106] In some embodiments, R6is selected from hydrogen and OH or a pharmaceutically acceptable salt thereof.

[0107] In some embodiments, R6is selected from those depicted in Table 1, below.335850176 CENC-014 / 01WO 360899-2049

[0108] As defined generally above, each occurrence of R is independently hydrogen or an optionally substituted group selected from Ci-6 aliphatic, a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic aromatic carbocyclic ring, a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0109] In some embodiments, R is hydrogen. In some embodiments, R is a Ci-6 aliphatic group. In some embodiments, R is a substituted Ci-6 aliphatic group. In some embodiments, R is a 3-8 membered saturated monocyclic carbocyclic ring. In some embodiments, R is a 3-8 membered partially unsaturated monocyclic carbocyclic ring. In some embodiments, R is a substituted 3-8 membered saturated monocyclic carbocyclic ring. In some embodiments, R is a substituted 3-8 membered partially unsaturated monocyclic carbocyclic ring. In some embodiments, R is phenyl. In some embodiments, R is a substituted phenyl. In some embodiments, R is an 8-10 membered bicyclic aromatic carbocyclic ring. In some embodiments, R is a substituted 8-10 membered bicyclic aromatic carbocyclic ring. In some embodiments, R is a 4-8 membered saturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is a 4-8 membered partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is a substituted 4-8 membered saturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is a substituted 4-8 membered partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is a substituted 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is a substituted 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur.63335850176 CENC-014 / 01WO 360899-2049

[0110] In some embodiments, R is selected from those depicted in Table 1, below.

[0111] As defined generally above, m is 0, 1, 2, 3, 4 or 5. In some embodiments, m is 0. In some embodiments, m is 1. In some embodiments, m is 2. In some embodiments, m is 3. In some embodiments, m is 4. In some embodiments, m is 5.

[0112] In some embodiments, m is selected from those depicted in Table 1, below.

[0113] As defined generally above, n is 0, 1, 2, 3, 4 or 5. In some embodiments, n is 0. In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 3. In some embodiments, n is 4. In some embodiments, n is 5.

[0114] In some embodiments, n is selected from those depicted in Table 1, below.

[0115] As defined generally above, p is 0, 1, 2, 3, 4 or 5. In some embodiments, p is 0. In some embodiments, p is 1. In some embodiments, p is 2. In some embodiments, p is 3. In some embodiments, p is 4. In some embodiments, p is 5.

[0116] In some embodiments, p is selected from those depicted in Table 1, below.

[0117] In some embodiments, the present disclosure provides a compound of Formula II:or a pharmaceutically acceptable salt thereof, wherein:each of R1, R2, R3, R4, R3, R6, m, n, and p are as defined above and described in embodiments herein, both singly and in combination.

[0118] In some embodiments, the present disclosure provides a compound of Formula 111:335850176 CENC-014 / 01WO 360899-2049or a pharmaceutically acceptable salt thereof, wherein:each of R1, R2, R3, R4, R3, R6, m, n, and p are as defined above and described in embodiments herein, both singly and in combination.

[0119] In some embodiments, the present disclosure provides compounds of Formula IVa, Formula IVb, Formula IVc or Formula IVd:or a pharmaceutically acceptable salt thereof, wherein:each of R2, R3, R4, R5, R6, n, and p are as defined above and described in embodiments herein, both singly and in combination.65335850176 CENC-014 / 01WO 360899-2049

[0120] In some embodiments, the present disclosure provides compounds of Formula Va,or a pharmaceutically acceptable salt thereof, wherein:each of R3, R4, R5, R6, n, and p are as defined above and described in embodiments herein, both singly and in combination.

[0121] In some embodiments, the present disclosure provides compounds of Formula Va-i, Formula Vb-i, Formula Vc-i or Formula Vd-i:335850176 CENC-014 / 01WO 360899-2049Vc-i Vd-ior a pharmaceutically acceptable salt thereof, wherein:each of R3, R4, R5, R6, and p are as defined above and described in embodiments herein, both singly and in combination.

[0122] In some embodiments, the present disclosure provides compounds of Formula Via,or a pharmaceutically acceptable salt thereof, wherein:each of R4, R5, R6, and p are as defined above and described in embodiments herein, both singly and in combination.335850176 CENC-014 / 01WO 360899-2049

[0123] In some embodiments, the present disclosure provides compounds of Formula Vila, Formula Vllb, Formula Vile or Formula Vlld:Vile VITdor a pharmaceutically acceptable salt thereof, wherein:each of R4, R5, and p are as defined above and described in embodiments herein, both singly and in combination.

[0124] In some embodiments, the present disclosure provides compounds of Formula Villa, Formula VUIb, Formula VIIIc or Formula VUId:Villa VUIb68335850176 CENC-014 / 01WO 360899-2049VIIIc VUIdor a pharmaceutically acceptable salt thereof, wherein:R4is as defined above and described in embodiments herein, both singly and in combination.

[0125] In some embodiments, the present disclosure provides compounds of Formula IXa,or a pharmaceutically acceptable salt thereof, wherein R4is as defined above and described in embodiments herein.

[0126] In some embodiments, the present disclosure provides compounds of Formula Xa, Formula Xb, Formula Xc or Formula Xd:69335850176 CENC-014 / 01WO 360899-2049Xc Xdor a pharmaceutically acceptable salt thereof, wherein R4is as defined above and described in embodiments herein.

[0127] In some embodiments, the present disclosure provides compounds of Formula Xia, Formula Xlb, Formula XIc or Formula Xld:Xia Xlb70335850176 CENC-014 / 01WO 360899-2049XIc Xldor a pharmaceutically acceptable salt thereof, wherein R4is as defined above and described in embodiments herein.

[0128] In some embodiments, the present disclosure provides compounds of Formula Xlla, Formula Xllb, Formula XIIc or Formula Xlld:XIIc Xlldor a pharmaceutically acceptable salt thereof, wherein R4is as defined above and described in embodiments herein.

[0129] In some embodiments, the present disclosure provides compounds of Formula XHIa, Formula XHIb, Formula XIIIc or Formula XHId:335850176 CENC-014 / 01WO 360899-2049or a pharmaceutically acceptable salt thereof, wherein R4is as defined above and described in embodiments herein.

[0130] In some embodiments of Formula IXa, Formula IXb, Formula IXc, Formula IXd, Formula Xa, Formula Xb, Formula Xc, Formula Xd, Formula Xia, Formula Xlb, Formula XIc, Formula Xld, Formula Xlla, Formula Xllb, Formula XIIc, Formula Xlld, Formula Xllla, Formula Xlllb, Formula XIIIc or Formula Xllld, R4is L2-Y, whereinL2is a covalent bond, bivalent C2-8 straight or branched, hydrocarbon chain wherein one or two methylene units of L2are optionally independently replaced by — NRC(O) —, — C(O)NR —, — N(R)SO2—, — SO2N(R)—, — S—, — S(O)—, — SO2—, -C(O)-, — OC(O)—, or — C(O)O —; and additionally one methylene unit of L2is optionally replaced by an optionally substituted 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic aromatic carbocyclic ring, a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-10 membered bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen,72335850176 CENC-014 / 01WO 360899-2049oxygen, and sulfur, or an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur; andY is hydrogen, halogen, -COORf, -CN, -CONRf2, -NRfCN, NO2, -NRf2, epoxide, or a ring selected from an optionally substituted 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic aromatic carbocyclic ring, a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-10 membered bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or C1-8 aliphatic optionally substituted with halogen, NO2, or CN; wherein -L2-Y comprises an alpha, beta-unsaturated carbonyl moiety, amide, cyano group, halogen, carbonyl, alkynyl group, sulfonyl group, or epoxide; and wherein each occurrence of Rf, Rgand Rhis independently H, halogen, OH, or straight or branched C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl group optionally substituted with 1, 2 or 3 halogen atoms.

[0131] In some embodiments of Formula IXa, Formula IXb, Formula IXc, Formula IXd, Formula Xa, Formula Xb, Formula Xc, Formula Xd, Formula Xia, Formula Xlb, Formula XIc, Formula Xld, Formula Xlla, Formula Xllb, Formula XIIc, and Formula Xlld, R4is L2-Y, wherein L2is a covalent bond, bivalent C2-8 straight or branched, hydrocarbon chain wherein one or two methylene units of L2are optionally independently replaced by — NRC(O) —, — C(O)NR —, — N(R)SO2—, — SO2N(R)—, — S—, — S(O)—, — SO2—, -C(O)-, — OC(O)—, or — C(O)O —; and additionally one methylene unit of L2is optionally replaced by an optionally substituted 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, or a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; andY is hydrogen, halogen, -COORf, -CN, -CONRf2, -NRfCN, NO2, -NRf2, epoxide, or a ring selected from an optionally substituted 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-10 membered bicyclic heterocyclic ring having 1-4 heteroatoms independently73335850176 CENC-014 / 01WO 360899-2049selected from nitrogen, oxygen, and sulfur, or C1-8 aliphatic optionally substituted with halogen, NO2, or CN; wherein -L2-Y comprises an alpha, beta-unsaturated carbonyl moiety, amide, cyano group, halogen, carbonyl, alkynyl group, sulfonyl group, or epoxide; and wherein each occurrence of Rf, Rgand Rhis independently H, halogen, OH, or straight or branched C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl group optionally substituted with 1, 2 or 3 halogen atoms.

[0132] In some embodiments of Formula IXa, Formula IXb, Formula IXc, Formula IXd, Formula Xa, Formula Xb, Formula Xc, Formula Xd, Formula Xia, Formula Xlb, Formula XIc, Formula Xld, Formula Xlla, Formula Xllb, Formula XIIc, and Formula Xlld, R4is L2-Y, wherein L2is a covalent bond, bivalent C2-8 straight or branched, hydrocarbon chain wherein one or two methylene units of L2are optionally independently replaced by — NRC(O) —, — C(O)NR —, — N(R)SO2—, — SO2N(R)—, — S—, — S(O)—, — SO2—, -C(O)-, — OC(O)—, or — C(O)O —; and additionally one methylene unit of L2is optionally replaced by a ring selectedsubstituted with halogen, NO2, or CN; wherein -L2-Y comprises an alpha, beta-unsaturated335850176 CENC-014 / 01WO 360899-2049carbonyl moiety, amide, cyano group, halogen, carbonyl, alkynyl group, sulfonyl group, or epoxide; and wherein each occurrence of Rf, Rgand Rhis independently H, halogen, OH, or Ci- 6 straight or branched alkyl, C2-6 alkenyl, or C2-6 alkynyl group optionally substituted with 1, 2 or 3 halogen atoms.

[0133] In some embodiments, the present disclosure provides a compound selected from one of the following:335850176 CENC-014 / 01WO 360899-204913 14335850176 CENC-014 / 01WO 360899-2049or a pharmaceutically acceptable salt thereof.

[0134] Further exemplary compounds of the disclosure are set forth in Table 1, below.

[0135] In some embodiments, the present disclosure provides a compound shown in Table 1, below, or a pharmaceutically acceptable salt thereof.335850176 CENC-014 / 01WO 360899-2049335850176 CENC-014 / 01WO 360899-2049I-20a2. Compounds and Related Definitions

[0136] As described generally above, the present invention provides a compound of Formula la:335850176 CENC-014 / 01WO 360899-2049laor a pharmaceutically acceptable salt thereof, wherein the variables are as described above.Definitions

[0137] Compounds of the present invention include those described generally herein, and are further illustrated by the classes, subclasses, and species disclosed herein. As used herein, the following definitions shall apply unless otherwise indicated. For purposes of this invention, the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75thEd. Additionally, general principles of organic chemistry are described in Organic Chemistry, Thomas Sorrell, University Science Books, Sausalito: 1999, and March’s Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, M. B. Smith and J. March, 7thEdition, John Wiley & Sons: 2013; the entire contents of each of which are hereby incorporated by reference.

[0138] The term “aliphatic” or “aliphatic group,” as used herein, means a straight-chain (i.e., unbranched) or branched, substituted or unsubstituted hydrocarbon chain that is completely saturated or that contains one or more units of unsaturation, or a monocyclic hydrocarbon or bicyclic hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic (also referred to herein as “carbocycle,” “cycloaliphatic” or “cycloalkyl”), that has a single point of attachment to the rest of the molecule. Unless otherwise specified, aliphatic groups contain 1-6 aliphatic carbon atoms. In some embodiments, aliphatic groups contain 1-5 aliphatic carbon atoms. In other embodiments, aliphatic groups contain 1-4 aliphatic carbon atoms. In still other embodiments, aliphatic groups contain 1-3 aliphatic carbon atoms, and in yet other embodiments, aliphatic groups contain 1-2 aliphatic carbon atoms. In some embodiments, “cycloaliphatic” (or “carbocycle” or “cycloalkyl”) refers to a monocyclic C3-C6 hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but 83335850176 CENC-014 / 01WO 360899-2049which is not aromatic, that has a single point of attachment to the rest of the molecule. Suitable aliphatic groups include, but are not limited to, linear or branched, substituted or unsubstituted alkyl, alkenyl, alkynyl groups and hybrids thereof such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl or (cycloalkyl)alkenyl.

[0139] As used herein, the term “bicyclic ring” or “bicyclic ring system” refers to any bicyclic ring system, i.e. carbocyclic or heterocyclic, saturated, or having one or more units of unsaturation, having one or more atoms in common between the two rings of the ring system. Thus, the term includes any permissible ring fusion, such as / 7 / w-fused or spirocyclic. As used herein, the term “spirocyclic” refers to organic compounds that contain at least two rings with one common atom, generally a quaternary carbon. Generally, the number of carbon atoms linked to the spiro atom in each ring is indicated in ascending order in brackets placed between the spiro prefix and thehydrocarbon name. For example,can be represented as spiro[4.5]decane.[00140J As used herein, the term “heterobicyclic” is a subset of “bicyclic” that requires that one or more heteroatoms are present in one or both rings of the bicycle. Such heteroatoms may be present at ring junctions and are optionally substituted, and may be selected from nitrogen (including N-oxides), oxygen, sulfur (including oxidized forms such as sulfones and sulfonates), phosphorus (including oxidized forms such as phosphates), boron, etc. In some embodiments, a bicyclic group has 7-12 ring members and 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. As used herein, the term “bridged bicyclic” refers to any bicyclic ring system, i.e. carbocyclic or heterocyclic, saturated, or partially unsaturated, having at least one bridge. As defined by IUPAC, a “bridge” is an unbranched chain of atoms or an atom or a valence bond connecting two bridgeheads, where a “bridgehead” is any skeletal atom of the ring system which is bonded to three or more skeletal atoms (excluding hydrogen). In some embodiments, a bridged bicyclic group has 7-12 ring members and 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. Such bridged bicyclic groups are well known in the art and include those groups set forth below where each group is attached to the rest of the molecule at any substitutable carbon or nitrogen atom. Unless otherwise specified, a bridged bicyclic group is optionally substituted with one or more substituents as set forth for aliphatic groups. Additionally, or alternatively, any substitutable nitrogen of a bridged bicyclic group is optionally substituted. Exemplary bicyclic rings include:335850176 CENC-014 / 01WO 360899-2049

[0141] Exemplary bridged bicyclics include:

[0142] The term “lower alkyl” refers to a Ci-4 straight or branched alkyl group. Exemplary lower alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, and tert-butyl.

[0143] The term “lower haloalkyl” refers to a C1-4 straight or branched alkyl group that is substituted with one or more halogen atoms.

[0144] The term “heteroatom” means one or more of oxygen, sulfur, nitrogen, phosphorus, or silicon (including, any oxidized form of nitrogen, sulfur, phosphorus, or silicon; the quaternized form of any basic nitrogen or; a substitutable nitrogen of a heterocyclic ring, for example N (as in 3,4-dihydro-2 / f-pyrrolyl), NH (as in pyrrolidinyl) or NR. (as in N-substituted pyrrolidinyl)).

[0145] The term “unsaturated,” as used herein, means that a moiety has one or more units of unsaturation.335850176 CENC-014 / 01WO 360899-2049

[0146] As used herein, the term “bivalent Ci-8 (or Cue) saturated or unsaturated, straight or branched, hydrocarbon chain,” refers to bivalent alkylene, alkenylene, and alkynylene chains that are straight or branched as defined herein.

[0147] The term “alkylene” refers to a bivalent alkyl group. An “alkylene chain” is a polymethylene group, i.e., -(CH2)n-, wherein n is a positive integer, preferably from 1 to 6, from 1 to 4, from 1 to 3, from 1 to 2, or from 2 to 3. A substituted alkylene chain is a polymethylene group in which one or more methylene hydrogen atoms are replaced with a substituent. Suitable substituents include those described below for a substituted aliphatic group.

[0148] The term “alkenylene” refers to a bivalent alkenyl group. A substituted alkenylene chain is a polymethylene group containing at least one double bond in which one or more hydrogen atoms are replaced with a substituent. Suitable substituents include those described below for a substituted aliphatic group.

[0149] The term “halogen” means F, Cl, Br, or I.

[0150] The term “aryl” used alone or as part of a larger moiety as in “aralkyl,” “aralkoxy,” or “aryloxyalkyl,” refers to monocyclic or bicyclic ring systems having a total of five to fourteen ring members, wherein at least one ring in the system is aromatic and wherein each ring in the system contains 3 to 7 ring members. The term “aryl” may be used interchangeably with the term “aryl ring.” In certain embodiments of the present invention, “aryl” refers to an aromatic ring system which includes, but not limited to, phenyl, biphenyl, naphthyl, anthracyl and the like, which may bear one or more substituents. Also included within the scope of the term “aryl,” as it is used herein, is a group in which an aromatic ring is fused to one or more non-aromatic rings, such as indanyl, phthalimidyl, naphthimidyl, phenanthridinyl, or tetrahydronaphthyl, and the like. The term “phenylene” refers to a multivalent phenyl group having the appropriate number of open valences to account for groups attached to it. For example, “phenylene” is a bivalent phenyl grouparyl group.

[0151] The terms “heteroaryl” and “heteroar-,” used alone or as part of a larger moiety, e.g., “heteroaralkyl,” or “heteroaralkoxy,” refer to groups having 5 to 10 ring atoms, preferably 5, 6, or 86335850176 CENC-014 / 01WO 360899-20499 ring atoms; having 6, 10, or 14 K electrons shared in a cyclic array; and having, in addition to carbon atoms, from one to five heteroatoms. The term “heteroatom” refers to nitrogen, oxygen, or sulfur, and includes any oxidized form of nitrogen or sulfur, and any quaternized form of a basic nitrogen. Heteroaryl groups include, without limitation, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, purinyl, naphthyridinyl, and pteridinyl. The terms “heteroaryl” and “heteroar- ” as used herein, also include groups in which a heteroaromatic ring is fused to one or more aryl, cycloaliphatic, or heterocyclyl rings, where the radical or point of attachment is on the heteroaromatic ring. Nonlimiting examples include indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzthiazolyl, quinolyl, isoquinolyl, cinnolinyl, phthal azinyl, quinazolinyl, quinoxalinyl, 4F / -quinolizinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and pyrido[2,3- / >]-l,4-oxazin-3(4 / / )-one. A heteroaryl group may be mono- or bicyclic. The term “heteroaryl” may be used interchangeably with the terms “heteroaryl ring,” “heteroaryl group,” or “heteroaromatic,” any of which terms include rings that are optionally substituted. The term “heteroaralkyl” refers to an alkyl group substituted with a heteroaryl, wherein the alkyl and heteroaryl portions independently are optionally substituted.

[0152] The term “heteroarylene” refers to a multivalent heteroaryl group having the appropriate number of open valences to account for groups attached to it. For example, “heteroarylene” is a bivalent heteroaryl group when it has two groups attached to it; “heteroarylene” is a trivalent heteroaryl group when it has three groups attached to it. The term “pyridinylene” refers to a multivalent pyridine radical having the appropriate number of open valences to account for groups attached to it. For example, “pyridinylene” is a bivalent pyridineradical when it has two groups attached to it (e.g.,“pyridinylene” is a trivalentpyridine radical when it has three groups attached t

[0153] As used herein, the terms “heterocycle,” “heterocyclyl,” “heterocyclic radical,” and “heterocyclic ring” are used interchangeably and refer to a stable 5- to 7-membered monocyclic or 7-10-membered bicyclic heterocyclic moiety that is either saturated or partially unsaturated,335850176 CENC-014 / 01WO 360899-2049and having, in addition to carbon atoms, one or more, preferably one to four, heteroatoms, as defined above. When used in reference to a ring atom of a heterocycle, the term “nitrogen” includes a substituted nitrogen. As an example, in a saturated or partially unsaturated ring having 0-3 heteroatoms selected from oxygen, sulfur or nitrogen, the nitrogen may be N (as in 3,4-di hydro-2 / / pyrrol yl), NH (as in pyrrolidinyl), or+NR (as in A substituted pyrrolidinyl).

[0154] A heterocyclic ring can be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure and any of the ring atoms can be optionally substituted. Examples of such saturated or partially unsaturated heterocyclic radicals include, without limitation, tetrahydrofuranyl, tetrahydrothiophenyl pyrrolidinyl, piperidinyl, pyrrolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl, oxazepinyl, thiazepinyl, morpholinyl, 2-oxa-6-azaspiro[3.3]heptane, and quinuclidinyl. The terms “heterocycle,” “heterocyclyl,” “heterocyclyl ring,” “heterocyclic group,” “heterocyclic moiety,” and “heterocyclic radical,” are used interchangeably herein, and also include groups in which a heterocyclyl ring is fused to one or more aryl, heteroaryl, or cycloaliphatic rings, such as indolinyl, 3 / -indolyl, chromanyl, phenanthridinyl, or tetrahydroquinolinyl. A heterocyclyl group may be mono- or bicyclic. The term “heterocyclylalkyl” refers to an alkyl group substituted by a heterocyclyl, wherein the alkyl and heterocyclyl portions independently are optionally substituted. The term “oxo-heterocyclyl” refers to a heterocyclyl substituted by an oxo group. The term “heterocyclylene” refers to a multivalent heterocyclyl group having the appropriate number of open valences to account for groups attached to it. For example, “heterocyclylene” is a bivalent heterocyclyl group when it has two groups attached to it; “heterocyclylene” is a trivalent heterocyclyl group when it has three groups attached to it.

[0155] As used herein, the term “partially unsaturated” refers to a ring moiety that includes at least one double or triple bond. The term “partially unsaturated” is intended to encompass rings having multiple sites of unsaturation but is not intended to include aryl or heteroaryl moieties, as herein defined.

[0156] As described herein, compounds of the invention may contain “optionally substituted” moieties. In general, the term “substituted,” whether preceded by the term “optionally” or not, means that one or more hydrogens of the designated moiety are replaced with a suitable substituent. Unless otherwise indicated, an “optionally substituted” group may have a suitable substituent88335850176 CENC-014 / 01WO 360899-2049(“optional substituent”) at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position. Combinations of substituents envisioned by this invention are preferably those that result in the formation of stable or chemically feasible compounds. The term “stable,” as used herein, refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and, in certain embodiments, their recovery, purification, and use for one or more of the purposes disclosed herein.

[0157] Suitable monovalent substituents on a substitutable carbon atom of an “optionally substituted” group are independently halogen; -(CH2)o 4R0; -(CH2)o 4OR0; -0(CH2)o-4R°, -O-(CH2)O4C(0)0RO; -(CH2)O-4CH(OR0)2; -(CH2)O-4SR°; -(CH2)o-Ph, which may be substituted with R°; -(CH2)o 40(CH2)o iPh which may be substituted with R°; -CH=CHPh, which may be substituted with R°; -(CH2)o-40(CH2)o i-pyridyl which may be substituted with R°; -NO2; -CN; -N3; -(CH2)O-4N(R°)2; -(CH2)O ^N(R°)C(O)R°; -N(R°)C(S)R°; -(CH2)O- 4N(RO)C(O)NR°2; -N(RO)C(S)NR°2; -(CH2)O-IN(R0)C(0)OR°;N(R°)N(R°)C(O)R°; -N(R°)N(R°)C(O)NR°2; -N(R°)N(R°)C(O)OR°; -(CH2)o^C(0)R°; -C(S)R°; -(CH2)o4C(O)ORO; -(CH2)O4C(O)SRO; -(CH2)O 4C(O)OSiR°3; -(CH2)o^OC(0)R°; -OC(0)(CH2)O -4SR-, SC(S)SR°; -(CH2)o^SC(0)R°; -(CH2)o 4C(O)NR°2; -C(S)NR°2; -C(S)SR°; -SC(S)SR°, -(CH2)O4OC(O)NR°2; -C(O)N(OR°)R°; -C(O)C(O)R°; -C(O)CH2C(O)RO; -C(NOR°)R°; -(CH2)o 4SSR0; -(CH2)o4S(O)2RO; (CH2)o 4S(O)2OR°; (CH2)o^OS(0)2R0; S(O)2NR°2; - CH2)O 4S(O)RC; -N(RO)S(O)2NR°2; -N(RO)S(O)2R°; -N(OR°)R°; -C(NH)NRO2; -P(O)2R°; -P(O)RO2; -OP(O)RO2; -OP(O)(ORO)2; SiR°3; -(C1-4 straight or branched alkylene)O-N(R°)2; or — (C1-4 straight or branched alkylene)C(O)O-N(R°)2, wherein each R° may be substituted as defined below and is independently hydrogen, C1-6 aliphatic, -CH2PI1, 0(CH2)o iPh, -CH2-(5-6 membered heteroaryl ring), or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or, notwithstanding the definition above, two independent occurrences of R°, taken together with their intervening atom(s), form a 3-12-membered saturated, partially unsaturated, or aryl mono- or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, which may be substituted as defined below.89335850176 CENC-014 / 01WO 360899-2049

[0158] Suitable monovalent substituents on R° (or the ring formed by taking two independent occurrences of R° together with their intervening atoms), are independently halogen, -(CH2)o 2R*, -(haloR*), -(CH2)o 2OH, -(CH2)O2OR*, -(CH2)O2CH(OR*)2; -O(haloR*), -CN, -N3, -(CH2)o2C(O)R*, -(CH2)O2C(O)OH, -(CH2)O2C(O)OR*, -(CH2)O -2SR*, -(CH2)O -2SH, -(CH2)o 2NH2, -(CH2)o2NHR*, -(CH2)O-2NR*2, -NO2, -SiR*3, -OSiR*3, -C(O)SR* -(Ci-i straight or branched alkylene)C(O)OR*, or -SSR* wherein each R* is unsubstituted or where preceded by “halo” is substituted only with one or more halogens, and is independently selected from C 1 4 aliphatic, -CH2PI1, -0(CH2)o-iPh, or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. Suitable divalent substituents on a saturated carbon atom of R° include =0 and =S.

[0159] Suitable divalent substituents on a saturated carbon atom of an “optionally substituted” group include the following: =0, =S, =NNR*2, =NNHC(O)R*, =NNHC(O)OR*, =NNHS(O)2R*, =NR*, =NOR*, — O(C(R2))23O—, or -S(C(R*2))2-3S- wherein each independent occurrence of R* is selected from hydrogen, C1-6 aliphatic which may be substituted as defined below, or an unsubstituted 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. Suitable divalent substituents that are bound to vicinal substitutable carbons of an “optionally substituted” group include: -O(CR*2)23O-, wherein each independent occurrence of R* is selected from hydrogen, C1-6 aliphatic which may be substituted as defined below, or an unsubstituted 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0160] Suitable substituents on the aliphatic group of R include halogen, -R*, -(haloR*), -OH, -OR*, -O(haloR*), -CN, -C(O)OH, -C(O)OR*, -NH2, -NHR*, -NR*2, or -NO2, wherein each R* is unsubstituted or where preceded by “halo” is substituted only with one or more halogens, and is independently C1-4 aliphatic, -CH2PI1, 0(CH2)o iPh, or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0161] Suitable substituents on a substitutable nitrogen of an “optionally substituted” group includef, C(O)CH2; wherein each R:is independently hydrogen, C1-6 aliphatic which may be substituted as defined below,90335850176 CENC-014 / 01WO 360899-2049unsubstituted -OPh, or an unsubstituted 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or, notwithstanding the definition above, two independent occurrences of R1', taken together with their intervening atom(s) form an unsubstituted 3-12-membered saturated, partially unsaturated, or aryl mono- or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0162] Suitable substituents on the aliphatic group of R1' are independently halogen, -R*, -(haloR*), -OH, -OR*, -O(haloR*), -CN, -C(O)OH, -C(O)OR*, -NH2, -NHR*, -NR*2, or -NO2, wherein each R* is unsubstituted or where preceded by “halo” is substituted only with one or more halogens, and is independently Ci 4 aliphatic, -CH2PI1, -0(CH2)o-iPh, or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0163] As used herein, the term “pharmaceutically acceptable salt” refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, and are commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge et al., describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, incorporated herein by reference. Pharmaceutically acceptable salts of the compounds of this invention include those derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecyl sulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2- naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate,91335850176 CENC-014 / 01WO 360899-20493-phenylpropionate, phosphate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like.

[0164] Further, acids which are generally considered suitable for the formation of pharmaceutically useful salts from basic pharmaceutical compounds are discussed, for example, by P. Stahl et al., Camille G. (eds.) Handbook of Pharmaceutical Salts. Properties, Selection and Use. (2002) Zurich: Wiley-VCH; S. Berge et al., Journal of Pharmaceutical Sciences (1977) 66(1) 1-19; P. Gould, International J. of Pharmaceutics (1986) 33 201-217; Anderson et al, The Practice of Medicinal Chemistry (1996), Academic Press, New York; and in The Orange Book (Food & Drug Administration, Washington, D. C. on their website). These disclosures are incorporated herein by reference.

[0165] Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium, and N+(Ci-4alkyl)4 salts. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, loweralkyl sulfonate and aryl sulfonate.

[0166] Unless otherwise stated, structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure; for example, the R and S configurations for each asymmetric center, Z and E double bond isomers, and Z and E conformational isomers. Therefore, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the present compounds are within the scope of the invention. Unless otherwise stated, all tautomeric forms of the compounds of the invention are within the scope of the invention. Additionally, unless otherwise stated, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures including the replacement of hydrogen by deuterium or tritium, or the replacement of a carbon by a13C- or14C-enriched carbon are within the scope of this invention. Such compounds are useful, for example, as analytical tools, as probes in biological assays, or as therapeutic agents in accordance with the present invention.

[0167] Compounds containing one or more stereocenters are a mixture of stereoisomers, unless otherwise stated or described (for example, with use of dashed or wedged bonds denoting92335850176 CENC-014 / 01WO 360899-2049stereochemistry). Generally, enhanced stereochemical representation introduces three types of identifiers that can be attached to a stereogenic center. A stereochemical group label is composed from an identifier and a group number. Each stereogenic center marked with wedge bonds belongs to one (and only one) stereochemical group. Grouping allows to specify relative relationships among stereogenic centers.

[0168] ABS denotes a stereogenic center where the absolute configuration is known. As used herein, “or” denotes a stereogenic center where the relative configuration is known, but the absolute configuration is not known. The structure represents one stereoisomer that is either the structure as drawn (R, S) or the epimer in which the stereogenic centers have the opposite configuration (S, R). One of skill in the art would understand that if a single stereogenic center is present, the designation “or” represents a single isomer for which the absolute configuration is not known. As used herein, “orl”, “or2” denote stereogenic centers where the relative configuration is known, but the absolute configuration is not known when applied to a multi-center stereogroup. The designations “and” and “&” are used interchangeably and denote a mixture of stereoisomers. It can be a pair of enantiomers or all the diastereomers.

[0169] Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods known to those skilled in the art, such as, for example, by chromatography and / or fractional crystallization. Enantiomers can be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., chiral auxiliary such as a chiral alcohol or Mosher’s acid chloride), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereomers to the corresponding pure enantiomers. Alternatively, a particular enantiomer of a compound of the present invention may be prepared by asymmetric synthesis. Still further, where the molecule contains a basic functional group (such as amino) or an acidic functional group (such as carboxylic acid) diastereomeric salts are formed with an appropriate optically-active acid or base, followed by resolution of the diastereomers thus formed by fractional crystallization or chromatographic means known in the art, and subsequent recovery of the pure enantiomers.

[0170] Individual stereoisomers of the compounds of the invention may, for example, be substantially free of other isomers, or may be admixed, for example, as racemates or with all other, or other selected, stereoisomers. Chiral center(s) in a compound of the present invention can have the S or R configuration as defined by the IUPAC 1974 Recommendations. Further, to the extent93335850176 CENC-014 / 01WO 360899-2049a compound described herein may exist as an atropisomer (e.g., substituted biaryls), all forms of such atropisomers are considered part of this invention.

[0171] Chemical names, common names, and chemical structures may be used interchangeably to describe the same structure. If a chemical compound is referred to using both a chemical structure and a chemical name, and an ambiguity exists between the structure and the name, the structure predominates. It should also be noted that any carbon as well as heteroatom with unsatisfied valences in the text, schemes, examples, and tables herein is assumed to have the sufficient number of hydrogen atom(s) to satisfy the valences.

[0172] The terms “a” and “an” as used herein mean “one or more” and include the plural unless the context is inappropriate.

[0173] The term “alkyl” refers to a saturated straight or branched hydrocarbon, such as a straight or branched group of 1-12, 1-10, or 1-6 carbon atoms, referred to herein as C1-C12 alkyl, C1-C10 alkyl, and Ci-Ce alkyl, respectively. Exemplary alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, 2-methyl-l -propyl, 2-methyl-2-propyl, 2-methyl-l -butyl, 3-methyl-1 -butyl, 2-methyl-3 -butyl, 2,2-dimethyl-l -propyl, 2-methyl-l -pentyl, 3 -methyl -1 -pentyl, 4-methyl-l -pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2-dimethyl-l-butyl, 3,3-dimethyl-l -butyl, 2-ethyl-l -butyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, heptyl, octyl, etc.

[0174] The term “cycloalkyl” refers to a monovalent saturated cyclic, bicyclic, or bridged cyclic (e.g., adamantyl) hydrocarbon group of 3-12, 3-8, 4-8, or 4-6 carbons, referred to herein, e.g., as “C3-C6 cycloalkyl,” derived from a cycloalkane. Exemplary cycloalkyl groups include cyclohexyl, cyclopentyl, cyclobutyl, and cyclopropyl. The term “cycloalkylene” refers to a bivalent cycloalkyl group.

[0175] The term “haloalkyl” refers to an alkyl group that is substituted with at least one halogen. Exemplary haloalkyl groups include -CH2F, -CHF2, -CF3, -CH2CF3, -CF2CF3, and the like. The term “haloalkylene” refers to a bivalent haloalkyl group.

[0176] The term “hydroxyalkyl” refers to an alkyl group that is substituted with at least one hydroxyl. Exemplary hydroxyalkyl groups include -CH2CH2OH, -C(H)(OH)CH3, -CH2C(H)(OH)CH2CH2OH, and the like.94335850176 CENC-014 / 01WO 360899-2049

[0177] The terms “alkenyl” and “alkynyl” are art-recognized and refer to unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but that contain at least one double or triple bond, respectively.

[0178] The term “carbocyclylene” refers to a multivalent carbocyclyl group having the appropriate number of open valences to account for groups attached to it. For example, “carbocyclylene” is a bivalent carbocyclyl group when it has two groups attached to it; “carbocyclylene” is a trivalent carbocyclyl group when it has three groups attached to it.

[0179] The terms “alkoxy!” or “alkoxy” are art-recognized and refer to an alkyl group, as defined above, having an oxygen radical attached thereto. Representative alkoxyl groups include methoxy, ethoxy, propyloxy, / c / V-butoxy and the like. The term “haloalkoxyl” refers to an alkoxyl group that is substituted with at least one halogen. Exemplary haloalkoxyl groups include -OCH2F, -OCHF2, -OCF3, -OCH2CF3, -OCF2CF3, and the like. The term “hydroxyalkoxyl” refers to an alkoxyl group that is substituted with at least one hydroxyl. Exemplary hydroxyalkoxyl groups include -OCH2CH2OH, -OCH2C(H)(OH)CH2CH2OH, and the like. The term “alkoxylene” refers to a bivalent alkoxyl group.

[0180] The term “oxo” is art-recognized and refers to a “=O” substituent. For example, a cyclopentane substituted with an oxo group is cyclopentanone.

[0181] The symbol “ T W” indicates a point of attachment. The point of attachment can bedrawn at the end of the bond in a chemical structure, for example,or at the center ofthe bond in a chemical structure, for example, 47 N

[0182] When a chemical structure containing a ring is depicted with a substituent having a bond that crosses a ring bond, the substituent may be attached at any available position on the ring.RXFor example, the chemical structure N encompasses N,, andIn the context of a polycyclic fused ring, when a chemical structure containing a polycyclic fused ring is depicted with one or more substituent(s) having a bond that crosses 95335850176 CENC-014 / 01WO 360899-2049multiple rings, the one or more substituent(s) may be independently attached to any of the ringscrossed by the bond. To illustrate, the chemical structureencompasses, forexample,

[0183] When any substituent or variable occurs more than one time in any constituent or the compound of the invention, its definition on each occurrence is independent of its definition at every other occurrence, unless otherwise indicated.

[0184] The term “warhead” or “warhead group” as used herein refers to a functional group present on a compound wherein that functional group is capable of reversibly or irreversibly participating in a reaction with a protein. Warheads may, for example, form covalent bonds with the protein. For example, the warhead moiety can be a functional group on an inhibitor that can participate in a bond-forming reaction, wherein a new covalent bond is formed between a portion of the warhead and a donor, for example an amino acid residue of a protein. In some embodiments, the warhead is an electrophile and the “donor” is a nucleophile such as the side chain of a cysteine residue.

[0185] One or more compounds of the invention may exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like, and it is intended that the invention embrace both solvated and unsolvated forms. “Solvate” means a physical association of a compound of this invention with one or more solvent molecules. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances, the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. “Solvate” encompasses both solution-phase and isolatable solvates. Non-limiting examples of suitable solvates include ethanolates, methanolates, and the like. “Hydrate” is a solvate wherein the solvent molecule is H2O.

[0186] As used herein, the terms “subject” and “patient” are used interchangeably and refer to organisms to be treated by the methods of the present invention. Such organisms preferably96335850176 CENC-014 / 01WO 360899-2049include, but are not limited to, mammals (e.g., murines, simians, equines, bovines, porcines, canines, felines, and the like), and, most preferably, includes humans.

[0187] The term “ICso” is art-recognized and refers to the concentration of a compound that is required to achieve 50% inhibition of the target. The potency of an inhibitor is usually defined by its ICso value. The lower the IC50 value the greater the potency of the antagonist and the lower the concentration that is required to inhibit the maximum biological response. In certain embodiments, an inhibitor has an IC50 and / or binding constant of less than about 100 pM, less than about 50 pM, less than about 1 pM, less than about 500 nM, less than about 100 nM, less than about 10 nM, or less than about 1 nM.

[0188] As used herein, the term “inhibitor” is defined as a compound that binds to and / or inhibits the target with measurable affinity. In some embodiments, inhibition in the presence of the inhibitor is observed in a dose-dependent manner. In some embodiments, the measured signal (e.g., signaling activity or biological activity) is at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% lower than the signal measured with a negative control under comparable conditions.

[0189] The terms “measurable affinity” and “measurably inhibit,” as used herein, means a measurable change or inhibition in target activity between a sample comprising a compound of the present invention, or composition thereof an equivalent sample comprising target, in the absence of said compound, or composition thereof.

[0190] As used herein, the term “effective amount” refers to the amount of a compound sufficient to effect beneficial or desired results (e.g, a therapeutic, ameliorative, inhibitory, or preventative result). An effective amount can be administered in one or more administrations, applications, or dosages and is not intended to be limited to a particular formulation or administration route.

[0191] As used herein, the term “treating” includes any effect, e.g., lessening, reducing, modulating, ameliorating, or eliminating, that results in the improvement of the condition, disease, disorder, and the like, or ameliorating a symptom thereof. In some embodiments, treatment can be97335850176 CENC-014 / 01WO 360899-2049administered after one or more symptoms have developed. In other embodiments, treatment can be administered in the absence of symptoms. For example, treatment can be administered to a susceptible individual prior to the onset of symptoms (e.g., in light of a history of symptoms and / or in light of genetic or other susceptibility factors). Treatment can also be continued after symptoms have resolved, for example, to prevent or delay their recurrence.

[0192] As used herein, the term “pharmaceutical composition” refers to the combination of an active agent with a carrier, inert or active, making the composition especially suitable for diagnostic or therapeutic use in vivo or ex vivo.

[0193] As used herein, the term “pharmaceutically acceptable carrier” refers to any of the standard pharmaceutical carriers, such as a phosphate buffered saline solution, water, emulsions e.g., such as an oil / water or water / oil emulsions), and various types of wetting agents. The compositions also can include stabilizers and preservatives. For examples of carriers, stabilizers, and adjuvants, see e.g., Martin, Remington’s Pharmaceutical Sciences, 15th Ed., Mack Publ. Co., Easton, PA

[1975] ,

[0194] For therapeutic use, salts of the compounds of the present invention are contemplated as being pharmaceutically acceptable. However, salts of acids and bases that are non-pharmaceutically acceptable may also find use, for example, in the preparation or purification of a pharmaceutically acceptable compound.

[0195] In addition, when a compound of the invention contains both a basic moiety (such as, but not limited to, a pyridine or imidazole) and an acidic moiety (such as, but not limited to, a carboxylic acid) zwitterions (“inner salts”) may be formed. Such acidic and basic salts used within the scope of the invention are pharmaceutically acceptable (i.e., non-toxic, physiologically acceptable) salts. Such salts of the compounds of the invention may be formed, for example, by reacting a compound of the invention with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in an aqueous medium followed by lyophilization.

[0196] Throughout the description, where compositions are described as having, including, or comprising specific components, or where processes and methods are described as having, including, or comprising specific steps, it is contemplated that, additionally, there are compositions of the present invention that consist essentially of, or consist of, the recited components, and that98335850176 CENC-014 / 01WO 360899-2049there are processes and methods according to the present invention that consist essentially of, or consist of, the recited processing steps.

[0197] As a general matter, compositions specifying a percentage are by weight unless otherwise specified.3. Methods of Use

[0198] It has now been found that the compounds and compositions of the disclosure can modulate DCN-1 (also referred to herein as DCN1) and are useful in treating disorders, diseases, and conditions associated with DCN-1. In some embodiments, modulating DCN-1 is inhibiting or reducing the activity of DCN-1. Without being limited to a specific mechanism, as shown herein, inhibiting or reducing the activity of DCN-1 results in reduced neddylation and other downstream effects. It has also been found that the compounds and compositions of the disclosure can modulate DCN-2 (also referred to herein as DCN2) and are useful in treating disorders, diseases, and conditions associated with DCN-2. In some embodiments, modulating DCN-2 is inhibiting or reducing the activity of DCN-2. Without being limited to a specific mechanism, as shown herein, inhibiting or reducing the activity of DCN-2 results in reduced neddylation and other downstream effects.

[0199] In one aspect, the present disclosure provides a method of modulating the activity of DCN-1 in vitro or in vivo, comprising contacting DCN-1 with a compound or composition thereof disclosed herein, or a pharmaceutically acceptable salt thereof. In one aspect, the present disclosure provides a method of modulating the activity of DCN-2 in vitro or in vivo, comprising contacting DCN-2 with a compound or composition thereof disclosed herein, or a pharmaceutically acceptable salt thereof.

[0200] In some embodiments, the present disclosure provides a method of modulating the activity of DCN-1 and / or DCN-2 in a subject, comprising administering to the subject a compound or composition thereof disclosed herein, or a pharmaceutically acceptable salt thereof.

[0201] In one aspect, the disease, disorder, or condition associated with DCN-1 or DCN-2 is a hemoglobinopathy such as sickle cell disorder or disease, or thalassemia disorder or disease.

[0202] In some embodiments, the disease, disorder, or condition associated with DCN-1 or DCN-2 is selected from one of those described in He et al. (Int Journal of Biological Macromolecules 227, 2024, 134541). In some embodiments, the disease, disorder, or condition associated with DCN-1 or DCN-2 is cancer (e.g., non-small cell lung cancer or gastric cancer), liver injury (e.g., non-alcoholic99335850176 CENC-014 / 01WO 360899-2049fatty liver disease), cardiac remodeling (e.g., atherosclerosis) or neurodegenerative disease (e.g., frontotemporal lobar degeneration). In some embodiments, the disease, disorder, or condition associated with DCN-1 or DCN-2 is characterized by overexpression of DCN-1 and / or DCN-2. In some embodiments, the disease, disorder, or condition associated with DCN-1 and / or DCN-2 overexpression is cancer (e.g., non-small cell lung cancer or gastric cancer).

[0203] In one aspect, the disclosure provides compounds and compositions for the treatment of of hemoglobinopathies such as sickle cell disorder or disease or thalassemia disorder or disease. In one aspect, the compounds and compositions described herein induce HbF (fetal hemoglobin; expressed by the gamma globin genes HBG1 and HBG2). It should be appreciated that induction of HbF allows for the treatment of hemoglobinopathies such as sickle cell disorder or disease or thalassemia disorder or disease. Thus, in one aspect, the disclosure provides compounds and compositions for the treatment of sickle cell disease.

[0204] In one aspect, the disclosure provides compounds and compositions for the treatment of of hemoglobinopathies such as sickle cell disorder or disease or thalassemia disorder or disease In one aspect, the compounds and compositions described herein induce HbF (fetal hemoglobin; expressed by the gamma globin genes HBG1 and HBG2) and reduce HbA (adult hemoglobin; expressed by the beta globin gene HBB), thus inducing production of fetal hemoglobin and reducing the expression of the hemoglobin beta gene. It should be appreciated that induction of HbF and reduction of HbA allows for the treatment of hemoglobinopathies such as sickle cell disorder or disease or thalassemia disorder or disease. Thus, in one aspect, the disclosure provides compounds and compositions for the treatment of sickle cell disease.

[0205] In some embodiments, a compound described herein is an irreversible covalent inhibitor of DCN-1 and / or DCN-2. In some embodiments, an irreversible covalent inhibitor of DCN-1 and / or DCN-2 provided herein can be used to treat diseases associated with DCN-1 and / or DCN-2. In some embodiments, an irreversible covalent inhibitor of DCN-1 and / or DCN-2 provided herein can be used to treat sickle cell disease. In some embodiments, a compound described herein is a reversible covalent inhibitor of DCN-1 and / or DCN-2. In some embodiments, a reversible covalent inhibitor of DCN-1 and / or DCN-2 provided herein can be used to treat diseases associated with DCN-1 and / or DCN-2. In some embodiments, a reversible covalent inhibitor of DCN-1 and / or DCN-2 provided herein can be used to treat sickle cell disease. In some embodiments, a compound described herein is a reversible inhibitor of DCN-1 and / or DCN-2. In some embodiments, a reversible inhibitor of100335850176 CENC-014 / 01WO 360899-2049DCN-1 and / or DCN-2 provided herein can be used to treat diseases associated with DCN-1 and / or DCN-2. In some embodiments, a reversible covalent of DCN-1 and / or DCN-2 provided herein can be used to treat sickle cell disease.

[0206] In one aspect, the disclosure provides irreversible covalent inhibitors of DCN-1 and / or DCN-2 for the treatment of a disease, disorder, or condition associated with DCN-1 and / or DCN-2. In some embodiments, the disclosure provides irreversible covalent inhibitors of DCN-1 and / or DCN-2 for the treatment of sickle cell disease. In some embodiments, the irreversible covalent inhibitors of DCN-1 and / or DCN-2 irreversibly covalently modify a cysteine of DCN-1 and / or DCN-2. In some embodiments, the irreversible covalent inhibitors of DCN-1 and / or DCN-2 irreversibly covalently modify Cysll5 of DCN-1 and / or DCN-2.

[0207] In one aspect, the disclosure provides reversible covalent inhibitors of DCN-1 and / or DCN-2 for the treatment of a disease, disorder, or condition associated with DCN-1 and / or DCN-2. In some embodiments, the disclosure provides reversible covalent inhibitors of DCN-1 and / or DCN-2 for the treatment of sickle cell disease. In some embodiments, the reversible covalent inhibitors of DCN-1 and / or DCN-2 reversibly covalently modify a cysteine of DCN-1 and / or DCN-2. In some embodiments, the reversible covalent inhibitors of DCN-1 and / or DCN-2 reversibly covalently modify Cysll5 of DCN-1 and / or DCN-2.

[0208] In one aspect, the disclosure provides reversible inhibitors of DCN-1 and / or DCN-2 for the treatment of a disease, disorder, or condition associated with DCN-1 or DCN-2. In one aspect, the disclosure provides reversible inhibitors of DCN-1 and / or DCN-2 for the treatment of sickle cell disease.

[0209] In some embodiments, the disclosure provides irreversible covalent inhibitors of DCN-1 and / or DCN-2, wherein the compound has a warhead that can irreversible covalently modify a cysteine of DCN-1 and / or DCN-2. In some embodiments, the cysteine is Cysl 15 of DCN-1 and / or DCN-2. In some embodiments, the disclosure provides reversible covalent inhibitors of DCN-1 and / or DCN-2, wherein the compound has a warhead that can reversible covalently modify a cysteine of DCN-1 and / or DCN-2. In some embodiments, the cysteine is Cysl 15 of DCN-1 and / or DCN-2.

[0210] In one aspect, the disclosure provides a DCN-1 that is covalently modified at Cysl 15. In some embodiments, the disclosure provides methods and compositions for covalently modifying DCN-1 in a subject. In some embodiments, the disclosure provides methods and101335850176 CENC-014 / 01WO 360899-2049compositions for covalently modifying DCN-1 Cys-115 in a subject. In some embodiments, the disclosure provides methods and compositions for covalently modifying DCN-1 Cys-115 in a subject for the treatment of sickle cell disease.

[0211] In one aspect, the disclosure provides a DCN-2 that is covalently modified at Cysl 15. In some embodiments, the disclosure provides methods and compositions for covalently modifying DCN-2 in a subject. In some embodiments, the disclosure provides methods and compositions for covalently modifying DCN-2 Cys-115 in a subject. In some embodiments, the disclosure provides methods and compositions for covalently modifying DCN-2 Cys-115 in a subject for the treatment of sickle cell disease.

[0212] In one aspect, the present disclosure provides a method of treating a hemoglobinopathy disorder or disease, comprising administering to a subject in need thereof a compound or composition thereof disclosed herein, or a pharmaceutically acceptable salt thereof. In another aspect, the present disclosure provides a method of inducing or increasing production of fetal hemoglobin. Such methods are useful, for example, in treating hemoglobin-related disorders including sickle cell disorders, diseases and conditions and thalassemia.

[0213] In some embodiments, the hemoglobinopathy is a sickle cell disorder or disease.

[0214] In some embodiments, the hemoglobinopathy is a thalassemia disorder or disease.

[0215] In one aspect, the present disclosure provides a method to increase red blood cell levels and / or hemoglobin levels in a subject in need thereof, treat or prevent an anemia in a subject in need thereof, treat sickle-cell disease in a subject in need thereof, or treat one or more complications of sickle-cell disease in a subject in need thereof, comprising administering to a subject in need thereof a compound disclosed herein, or a pharmaceutically acceptable salt thereof, in combination with hydroxyurea or a pharmaceutically acceptable salt thereof.

[0216] In one aspect, the present disclosure provides a method to increase fetal hemoglobin levels in a subject in need thereof, treat or prevent an anemia in a subject in need thereof, treat sickle-cell disease in a subject in need thereof, or treat one or more complications of sicklecell disease in a subject in need thereof, comprising administering to a subject in need thereof a compound disclosed herein, or a pharmaceutically acceptable salt thereof, in combination with hydroxyurea or a pharmaceutically acceptable salt thereof.

[0217] In some embodiments, the present disclosure provides a method for the treatment of a DCN-1 associated disease. In some embodiments, the present disclosure provides a method for102335850176 CENC-014 / 01WO 360899-2049the treatment of a DCN-2 associated disease. In some embodiments, the present disclosure provides a method for the treatment of cancers, premalignant conditions (e.g., hyperplasia, metaplasia, and dysplasia), benign tumors, hyperproliferative disorders, and benign dysproliferative disorders. Such methods comprise the step of administering to a subject in need thereof a compound disclosed herein, or a pharmaceutically acceptable salt thereof. In some embodiments, the cancer is characterized by overexpression ofDCN-1 and / or DCN-2.

[0218] In some embodiments, cancers and related disorders that can be treated or prevented by methods disclosed herein include, but are not limited, to the following: a squamous cell carcinoma, a metastatic squamous cell carcinoma, a non-small cell lung carcinoma, a uterine carcinosarcoma, an embryonal rhabdomyosarcoma, a glioblastoma, a medulloblastoma, an osteosarcoma, or an adrenocortical tumor. In some embodiments, the cancer and related disorders include a cancer of the lung, cervix, ovary, uterus, esophagus, prostate, or head and neck.

[0219] In some embodiments, the cancer of the lung includes a non-small cell lung cancer, including, but not limited to a squamous cell carcinoma, adenocarcinoma, or large cell-undifferentiated carcinoma.

[0220] In some embodiments, cancers and related disorders include a hematological malignancy such as a leukemia, a lymphoma, a myeloma, a multiple lymphoma, a B-cell nonHodgkin’s lymphoma, or an acute myeloid leukemia.

[0221] In some embodiments, the present disclosure provides a method for the treatment of a cancer, including, but not limited to, leukemia, acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemia, myeloblastic, promyelocytic, myelomonocytic, monocytic, erythroleukemia, chronic leukemia, chronic myelocytic (granulocytic) leukemia, chronic lymphocytic leukemia, polycythemia vera, Lymphoma, Hodgkin’s disease, non-Hodgkin’s disease, multiple myeloma, Waldenstrom’s macroglobulinemia, heavy chain disease, solid tumors, sarcomas and carcinomas, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing’s tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma,103335850176 CENC-014 / 01WO 360899-2049hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms’ tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, menangioma, melanoma, neuroblastoma, and retinoblastoma.

[0222] In some embodiments, the present disclosure provides a method for the treatment of leukemia, including, but not limited to, acute leukemia, acute lymphocytic leukemia; acute myelocytic leukemia, including, but not limited to, myeloblastic, promyelocytic, myelomonocytic, monocytic, erythroleukemia and myelodysplastic syndrome; chronic leukemia, including, but not limited to, chronic myelocytic (granulocytic) leukemia, chronic lymphocytic leukemia, hairy cell leukemia; polycythemia vera; lymphomas, including, but not limited to, Hodgkin's lymphoma, non-Hodgkin's lymphoma; myeloma, including, but not limited, to smoldering multiple myeloma, nonsecretory myeloma, osteosclerotic myeloma, plasma cell leukemia, solitary plasmacytoma and extramedullary plasmacytoma; Waldenstrom's macroglobulinemia; monoclonal gammopathy of undetermined significance; benign monoclonal gammopathy; heavy chain disease; bone and connective tissue sarcomas, including, but not limited to, bone sarcoma, osteosarcoma, chondrosarcoma, Ewing's sarcoma, malignant giant cell tumor, fibrosarcoma of bone, chordoma, periosteal sarcoma, soft-tissue sarcomas, angiosarcoma (hemangiosarcoma), fibrosarcoma, Kaposi's sarcoma, leiomyosarcoma, liposarcoma, lymphangiosarcoma, neurilemmoma, rhabdomyosarcoma, synovial sarcoma; brain tumor, including, but not limited to, glioma, astrocytoma, brain stem glioma, ependymoma, oligodendroglioma, nonglial tumor, acoustic neurinoma, craniopharyngioma, medulloblastoma, meningioma, pineocytoma, pineoblastoma, primary brain lymphoma; breast cancer, including, but not limited to, adenocarcinoma, lobular (small cell) carcinoma, intraductal carcinoma, medullary breast cancer, mucinous breast cancer, tubular breast cancer, papillary breast cancer, Paget's disease, and inflammatory breast cancer; adrenal cancer, including, but not limited to, pheochromocytom and adrenocortical carcinoma; thyroid cancer, including, but not limited to, papillary or follicular thyroid cancer, medullary thyroid cancer and anaplastic thyroid cancer; pancreatic cancer, including, but not limited to, insulinoma, gastrinoma, glucagonoma, vipoma, somatostatin-secreting tumor, and carcinoid or islet cell tumor; pituitary cancers, including, but not limited to, Cushing's disease, prolactinsecreting tumor, acromegaly, and diabetes insipius; eye cancer, including, but not limited to, ocular104335850176 CENC-014 / 01WO 360899-2049melanoma such as iris melanoma, choroidal melanoma, and cilliary body melanoma, and retinoblastoma; vaginal cancer, including, but not limited to, squamous cell carcinoma, adenocarcinoma, and melanoma; vulvar cancer, including, but not limited to, squamous cell carcinoma, melanoma, adenocarcinoma, basal cell carcinoma, sarcoma, and Paget's disease; cervical cancer, including, but not limited to, squamous cell carcinoma, and adenocarcinoma; uterine cancer, including, but not limited to, endometrial carcinoma and uterine sarcoma; ovarian cancers, including, but not limited to, ovarian epithelial carcinoma, borderline tumor, germ cell tumor, and stromal tumor; esophageal cancer, including, but not limited to, squamous cancer, adenocarcinoma, adenoid cyctic carcinoma, mucoepidermoid carcinoma, adenosquamous carcinoma, sarcoma, melanoma, plasmacytoma, verrucous carcinoma, and oat cell (small cell) carcinoma; stomach cancer, including, but not limited to, adenocarcinoma, fungating (polypoid), ulcerating, superficial spreading, diffusely spreading, malignant lymphom, liposarcoma, fibrosarcoma, and carcinosarcoma; colon cancer; rectal cancer; liver cancer, including, but not limited to, hepatocellular carcinoma and hepatoblastoma, gallbladder cancer, including, but not limited to, adenocarcinoma; cholangiocarcinoma, including, but not limited to, pappillary, nodular, and diffuse; lung cancer, including, but not limited to, non-small cell lung cancer, squamous cell carcinoma (epidermoid carcinoma), adenocarcinoma, large-cell carcinoma and small-cell lung cancer; testicular cancer, including, but not limited to, germinal tumor, seminoma, anaplastic, classic (typical), spermatocytic, nonseminoma, embryonal carcinoma, teratoma carcinoma, and choriocarcinoma (yolk-sac tumor); prostate cancer, including, but not limited to, adenocarcinoma, leiomyosarcoma, and rhabdomyosarcoma; penal cancers; oral cancer, including, but not limited to, squamous cell carcinoma; basal cancers; salivary gland cancer, including, but not limited to, adenocarcinoma, mucoepidermoid carcinoma, and adenoidcystic carcinoma; pharynx cancer, including, but not limited to, squamous cell cancer, and verrucous; skin cancer, including, but not limited to, basal cell carcinoma, squamous cell carcinoma and melanoma, superficial spreading melanoma, nodular melanoma, lentigo malignant melanoma, and acral lentiginous melanoma; kidney cancer, including, but not limited to, renal cell cancer, adenocarcinoma, hypernephroma, fibrosarcoma, and transitional cell cancer (renal pelvis and / or uterer); Wilms’ tumor; bladder cancer, including, but not limited to, transitional cell carcinoma, squamous cell cancer, adenocarcinoma, carcinosarcoma. In addition, cancer includes myxosarcoma, osteogenic sarcoma, endotheliosarcoma, lymphangioendotheliosarcoma, mesothelioma, synovioma,105335850176 CENC-014 / 01WO 360899-2049hemangioblastoma, epithelial carcinoma, cystadenocarcinoma, bronchogenic carcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma and papillary adenocarcinomas.

[0223] In some embodiments, the present disclosure provides a method for the treatment of liver injury. Without being limited to a specific mechanism, targeting neddylation provides a method for the treatment of liver fibrosis and liver injury. (See e.g., Zubiete-Franco et al. Hepatology 65 (2) 2017, 694-709). Thus, in some embodiments, the present disclosure provides a method for the treatment of hepatitis, Non-alcoholic fatty liver disease (NAFLD), alcoholic liver disease, cirrhosis, hemochromatosis, jaundice, autoimmune liver disorders, liver cancer, galactosemia, alpha-1 antitrypsin deficiency, Wilson disease, oxalosis, liver adenoma, Alagille syndrome, primary biliary cholangitis (PBC), and lysosomal acid lipase deficiency (LAL-D).

[0224] In some embodiments, the present disclosure provides a method for the treatment of heart disease. Without being limited to a specific mechanism, targeting neddylation, provides a method for the treatment of heart disease (See e.g., Kandala et al., Am. J. Cardiovasc. Dis 4, 2014, 140). Thus, in some embodiments, the present disclosure provides a method for the treatment of arrhythmia, heart failure, coronary artery disease, heart valve disease, congenital heart disease, angina, cardiomyopathy, pericarditis, peripheral artery disease, aortic aneurysm, aortic stenosis, deep vein thrombosis, Mlarfan syndrome and rheumatic heart disease.

[0225] In some embodiments, the present disclosure provides a method for the treatment of neurodegenerative diseases (See e.g., Villa et al., Eur J. Neurol. 16 (7) 2009, 870. Thus, in some embodiments, the present disclosure provides a method for the treatment of amyotrophic lateral sclerosis, multiple sclerosis, Parkinson’s disease, Alzheimer’s disease, Huntington’s disease, multiple system atrophy, tauopathies and prion diseases.

[0226] In some embodiments, the method optionally comprises co-administration of a second therapeutic agent. In some embodiments, the second therapeutic agent is hydroxyurea or a pharmaceutically acceptable salt thereof.

[0227] In one aspect, the present disclosure provides a method of treating a hemoglobinopathy disorder or disease, comprising administering to a subject in need thereof a compound disclosed herein, or a pharmaceutically acceptable salt thereof, in combination with a second agent such as hydroxyurea or a pharmaceutically acceptable salt thereof.

[0228] In some embodiments, the hemoglobinopathy is a sickle cell disorder or disease.

[0229] In some embodiments, the hemoglobinopathy is a thalassemia disorder or disease.106335850176 CENC-014 / 01WO 360899-2049

[0230] In some embodiments, the compound or pharmaceutically acceptable salt thereof and the hydroxyurea or a pharmaceutically acceptable salt thereof act synergistically.

[0231] In some embodiments, the compound or pharmaceutically acceptable salt thereof is selected from one of those shown in Table 1, or a pharmaceutically acceptable salt thereof.

[0232] In one aspect, the present disclosure provides a method of increasing efficacy and / or reducing toxicity of hydroxyurea treatment in a subject undergoing said treatment, comprising administering to the subject a compound disclosed herein, or a pharmaceutically acceptable salt thereof. In some embodiments, the hydroxyurea treatment is for a hemoglobinopathy. In some embodiments, the hydroxyurea treatment is for sickle cell disease. In some embodiments, the hydroxyurea treatment is for a thalassemia disorder.

[0233] In some embodiments, the method further comprises the step of decreasing an amount of hydroxyurea being administered to the subject.

[0234] In some embodiments, the amount of hydroxyurea being administered is decreased by 10-90%.

[0235] In one aspect, the present disclosure provides a method of decreasing the dose of hydroxyurea or a pharmaceutically acceptable salt thereof needed for effective treatment of a hemoglobinopathy disorder or disease, comprising administering to a subject in need thereof a compound disclosed herein, or a pharmaceutically acceptable salt thereof, in combination with hydroxyurea or a pharmaceutically acceptable salt thereof, wherein the dose of hydroxyurea or a pharmaceutically acceptable salt thereof needed for effective treatment of the hemoglobinopathy disorder or disease is less than the dose needed for treatment in the subject using hydroxyurea or a pharmaceutically acceptable salt thereof as a monotherapy.

[0236] In some embodiments, the dose of hydroxyurea or a pharmaceutically acceptable salt thereof co-administered with the compound or pharmaceutically acceptable salt thereof is reduced by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% relative to the dose needed for treatment in the subject using hydroxyurea or a pharmaceutically acceptable salt thereof as a monotherapy.

[0237] In some embodiments, the compound or pharmaceutically acceptable salt thereof is selected from one of those shown in Table 1, or a pharmaceutically acceptable salt thereof.

[0238] In some embodiments, the present disclosure provides a method to treat or prevent one or more complications of sickle cell disease including, for example, anemia, anemia crisis,107335850176 CENC-014 / 01WO 360899-2049splenomegaly, pain crisis, chest syndrome, acute chest syndrome, blood transfusion requirement, organ damage, pain medicine (management) requirement, splenic sequestration crises, hyperhemolytic crisis, vaso-occlusion, vaso-occlusion crisis, acute myocardial infarction, sicklecell chronic lung disease, thromboemboli, hepatic failure, hepatomegaly, hepatic sequestration, iron overload and complications of iron overload (e.g., congestive heart failure, cardiac arrhythmia, myocardial infarction, other forms of cardiac disease, diabetes mellitus, dyspnea, hepatic disease and adverse effects of iron chelation therapy), splenic infarction, acute and / or chronic D renal failure, pyelonephritis, aneurysm, ischemic stroke, intraparenchymal hemorrhage, subarachnoid hemorrhage, intraventricular hemorrhage, peripheral retinal ischemia, proliferative sickle retinopathy, vitreous hemorrhage, and / or priapism; comprising administering to a subject in need thereof a disclosed compound or pharmaceutically acceptable salt thereof, optionally in combination with a second therapeutic agent such as hydroxyurea or a pharmaceutically acceptable salt thereof.

[0239] In some embodiments, the compound or pharmaceutically acceptable salt thereof acts synergistically in combination with the second therapeutic agent, e.g., hydroxyurea or a pharmaceutically acceptable salt thereof.4. Combination Therapies

[0240] In one aspect, the compounds of the present disclosure are used advantageously in combination with a second therapeutic agent. Such a second therapeutic agent includes, in some embodiments, hydroxyurea or a pharmaceutically acceptable salt thereof.

[0241] In some embodiments, the disclosure provides methods for using a compound or combination therapy (for example, a disclosed compound or pharmaceutically acceptable salt thereof in combination with hydroxyurea or a pharmaceutically acceptable salt thereof) to treat or prevent vascular occlusion (vaso-occlusion) in a sickle-cell disease patient in need thereof as well as various complications associated with vaso-occlusion in a sickle-cell disease patient (e.g., vasoocclusion crisis, pain crisis, etc.). In some embodiments, the disclosure provides methods for using a disclosed compound or combination therapy to treat or prevent anemia in a sickle-cell disease patient in need thereof as well as various complications associated with anemia in a sickle-cell disease patient (e.g., aplastic crisis, hyperhemolytic crisis, etc.). In such methods, a disclosed compound or combination therapy can be used to increase red blood cell levels while reducing the need for red blood cell transfusions and / or iron chelation therapy, and thereby reduce morbidity108335850176 CENC-014 / 01WO 360899-2049and mortality associated with iron accumulation in vulnerable tissues / organs. In such methods, a disclosed compound or combination therapy can also be used to reduce the need for other supportive therapies for treating sickle-cell disease [e.g., treatment with hydroxyurea, treatment with an EPO or other EPO agonist, and / or pain management (e.g., treatment with one or more of opioid analgesic agents, non-steroidal anti-inflammatory drugs, and / or corticosteroids)]. In part, a disclosed compound or combination therapy can be used in combination with existing supportive therapies for sickle-cell disease including, for example, transfusion of red blood cells, iron chelation therapy, hydroxyurea therapy, EPO or EPO agonist therapy, and / or pain management therapy. Optionally, a disclosed compound or combination therapy can be used to reduce the amount, duration, etc. of an existing supportive therapy for sickle-cell disease. For example, while transfusion of red blood cells and iron chelation therapy may help treat certain complications of sickle-cell disease, they sometimes result in adverse side effects. Therefore, in certain aspects, a disclosed compound or combination therapy can be used to reduce the amount of a second supportive therapy, e.g., reduce blood cell transfusion burden or reduce the dosage of a chelation therapeutic. In certain aspects, the disclosure provides uses of a disclosed compound or combination therapy (optionally in combination with one or more supportive therapies for sicklecell disease) for making a medicament for the treatment or prevention of sickle-cell disease, particularly one or more complications of sickle-cell disease as disclosed herein.5. Compositions

[0242] The present disclosure also provides compositions that comprise or deliver a compound as provided herein. In some embodiments, the present disclosure provides compositions comprising a compound provided herein with one or more other components.

[0243] In some embodiments, provided compositions comprise and / or deliver a compound described herein. In some embodiments, a provided composition is a pharmaceutical composition that comprises and / or delivers a compound provided herein and further comprises a pharmaceutically acceptable carrier.

[0244] Pharmaceutical compositions typically contain an active agent (e.g., a compound described herein) in an amount effective to achieve a desired therapeutic effect while avoiding or minimizing adverse side effects. In some embodiments, provided pharmaceutical compositions comprise a compound described herein and one or more carriers or excipients (e.g., fillers, disintegrants, lubricants, glidants, anti-adherents, and / or anti-statics, etc.) Provided pharmaceutical109335850176 CENC-014 / 01WO 360899-2049compositions can be in a variety of forms including oral dosage forms, topical creams, topical patches, iontophoresis forms, suppository, nasal spray and / or inhaler, eye drops, intraocular injection forms, depot forms, as well as injectable and infusible solutions.

[0245] Provided pharmaceutical compositions can be prepared with any appropriate available technologies.

[0246] In some embodiments, provided compounds are formulated in a unit dosage form for ease of administration and uniformity of dosage. The expression “unit dosage form” as used herein refers to a physically discrete unit of an active agent (e.g., a compound described herein) for administration to a subject. Typically, each such unit contains a predetermined quantity of active agent. In some embodiments, a unit dosage form contains an entire single dose of the agent. In some embodiments, more than one unit dosage form is administered to achieve a total single dose. In some embodiments, administration of multiple unit dosage forms is required, or expected to be required, in order to achieve an intended effect. A unit dosage form may be, for example, a liquid pharmaceutical composition containing a predetermined quantity of one or more active agents, a solid pharmaceutical composition (e.g., a tablet, a capsule, or the like) containing a predetermined amount of one or more active agents, a sustained release formulation containing a predetermined quantity of one or more active agents, or a drug delivery device containing a predetermined amount of one or more active agents, etc.

[0247] Provided compositions may be administered in accordance with a dosing regimen (i.e., that includes a single dose or multiple doses separated from one another in time, administered via a particular route of administration) that is (e.g., has been demonstrated to be) effective for treating (e.g., delaying onset of and / or decreasing incidence and / or intensity of) a disease or disorder, for example as described herein.

[0248] The present disclosure also provides methods of preparing pharmaceutical compositions provided herein. In some embodiments, provided methods comprise (i) providing a provided compound or a pharmaceutically acceptable salt thereof; and (ii) formulating the compound with suitable excipients to give a pharmaceutical composition.6. General Methods of Providing the Present Compounds

[0249] The compounds of this invention may be prepared or isolated in general by synthetic and / or semi-synthetic methods known to those skilled in the art for analogous compounds and by methods described in detail in the Examples, herein.110335850176 CENC-014 / 01WO 360899-2049

[0250] In the schemes and chemical reactions depicted in the detailed description, Examples, where a particular protecting group (“PG”), leaving group (“LG”), or transformation condition is depicted, one of ordinary skill in the art will appreciate that other protecting groups, leaving groups, and transformation conditions are also suitable and are contemplated. Such groups and transformations are described in detail in March ’s Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, M. B. Smith and J. March, 7thEdition, John Wiley & Sons, 2013, Comprehensive Organic Transformations, R. C. Larock, 3rdEdition, John Wiley & Sons, 2018, and Protective Groups in Organic Synthesis, P. G. M. Wuts, 5thedition, John Wiley & Sons, 2014, the entirety of each of which is hereby incorporated herein by reference.

[0251] As used herein, the phrase “leaving group” (LG) includes, but is not limited to, halogens (e.g., fluoride, chloride, bromide, iodide), sulfonates (e.g., mesylate, tosylate, benzenesulfonate, brosylate, nosylate, triflate), diazonium, and the like.

[0252] As used herein, the phrase “oxygen protecting group” includes, for example, carbonyl protecting groups, hydroxyl protecting groups, etc. Hydroxyl protecting groups are well known in the art and include those described in detail in Protective Groups in Organic Synthesis, P. G. M. Wuts, 5thedition, John Wiley & Sons, 2014, and Philip Kocienski, in Protecting Groups, Georg Thieme Verlag Stuttgart, New York, 1994, the entireties of which are incorporated herein by reference. Examples of suitable hydroxyl protecting groups include, but are not limited to, esters, allyl ethers, ethers, silyl ethers, alkyl ethers, arylalkyl ethers, and alkoxyalkyl ethers. Examples of such esters include formates, acetates, carbonates, and sulfonates. Specific examples include formate, benzoyl formate, chloroacetate, trifluoroacetate, methoxyacetate, triphenylmethoxyacetate, p-chlorophenoxy acetate, 3 -phenylpropionate, 4-oxopentanoate, 4,4-(ethylenedithio)pentanoate, pivaloate (trimethyl acetyl), crotonate, 4-methoxy-crotonate, benzoate, p-benzylbenzoate, 2,4,6-trimethylbenzoate, carbonates such as methyl, 9-fluorenylmethyl, ethyl, 2,2,2-trichloroethyl, 2-(trimethylsilyl)ethyl, 2-(phenylsulfonyl)ethyl, vinyl, allyl, and p-nitrobenzyl. Examples of such silyl ethers include trimethylsilyl, triethylsilyl, t-butyldimethylsilyl, t-butyldiphenylsilyl, triisopropylsilyl, and other trialkylsilyl ethers. Alkyl ethers include methyl, benzyl, p-methoxybenzyl, 3,4-dimethoxybenzyl, trityl, t-butyl, allyl, and allyloxy carbonyl ethers or derivatives. Alkoxyalkyl ethers include acetals such as methoxymethyl, methylthiomethyl, (2-methoxyethoxy)methyl, benzyloxymethyl, beta- (trimethylsilyl)ethoxymethyl, and tetrahydropyranyl ethers. Examples of arylalkyl ethers include111335850176 CENC-014 / 01WO 360899-2049benzyl, p-methoxybenzyl (MPM), 3,4-dimethoxybenzyl, O-nitrobenzyl, p-nitrobenzyl, p-halobenzyl, 2,6-dichlorobenzyl, p-cyanobenzyl, and 2- and 4-picolyl.

[0253] Amino protecting groups are well known in the art and include those described in detail in Protective Groups in Organic Synthesis, P. G. M. Wuts, 5thedition, John Wiley & Sons, 2014, and Philip Kocienski, in Protecting Groups, Georg Thieme Verlag Stuttgart, New York, 1994, the entireties of which are incorporated herein by reference. Suitable amino protecting groups include, but are not limited to, aralkylamines, carbamates, cyclic imides, allyl amines, amides, and the like. Examples of such groups include t-butyloxycarbonyl (Boc), ethyloxycarbonyl, methyloxycarbonyl, trichloroethyloxycarbonyl, allyloxycarbonyl (Alloc), benzyloxocarbonyl (Cbz), allyl, phthalimide, benzyl (Bn), fluorenylmethylcarbonyl (Fmoc), formyl, acetyl, chloroacetyl, di chloroacetyl, trichloroacetyl, phenylacetyl, trifluoroacetyl, benzoyl, and the like.

[0254] One of skill in the art will appreciate that various functional groups present in compounds of the invention such as aliphatic groups, alcohols, carboxylic acids, esters, amides, aldehydes, halogens, and nitriles can be interconverted by techniques well known in the art including, but not limited to reduction, oxidation, esterification, hydrolysis, partial oxidation, partial reduction, halogenation, dehydration, partial hydration, and hydration. See, for example, March ’s Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, M. B. Smith, and J. March, 7thEdition, John Wiley & Sons, 2013, Comprehensive Organic Transformations, R. C. Larock, 3rdEdition, John Wiley & Sons, 2018, the entirety of each of which is incorporated herein by reference. Such interconversions may require one or more of the aforementioned techniques, and certain methods for synthesizing compounds of the invention are described below.

[0255] One of skill in the art will appreciate that various functional groups present in compounds of the invention such as aliphatic groups, alcohols, carboxylic acids, esters, amides, aldehydes, halogens, and nitriles can be interconverted by techniques well known in the art including, but not limited to reduction, oxidation, esterification, hydrolysis, partial oxidation, partial reduction, halogenation, dehydration, partial hydration, and hydration. Such groups and transformations are described in detail in March 's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, M. B. Smith and J. March, 7thEdition, John Wiley & Sons, 2013, Comprehensive Organic Transformations, R. C. Larock, 3rdEdition, John Wiley & Sons, 2018, and Protective Groups in Organic Synthesis, P. G. M. Wuts, 5thedition, John Wiley & Sons, 2014, the entirety of each of which is hereby incorporated herein by reference. Such interconversions112335850176 CENC-014 / 01WO 360899-2049may require one or more of the aforementioned techniques, and certain methods for synthesizing compounds of the invention are described below in the Exemplification.EXEMPLIFICATION

[0256] As depicted in the Examples below, exemplary compounds are prepared according to the following general procedures and used in biological assays and other procedures described generally herein. It will be appreciated that, although the general methods depict the synthesis of certain compounds of the present invention, the following general methods, and other methods known to one of ordinary skill in the art, can be applied to all compounds and subclasses and species of each of these compounds, as described herein. Similarly, assays and other analyses can be adapted according to the knowledge of one of ordinary skilled in the art.Example 1: Synthesis of compoundsGeneral Synthetic Schemes

[0257] The compounds of Formula 1 may be prepared by the methods described below, together with synthetic methods known in the art of organic chemistry, or modifications and transformations that are familiar to those of ordinary skill in the art. The starting materials used herein are commercially available or may be prepared by routine methods known in the art, such as those methods disclosed in standard reference books. Preferred methods include, but are not limited to, those described below.

[0258] During any of the following synthetic sequences, it may be necessary and / or desirable to protect sensitive or reactive groups on any of the molecules concerned. This can be achieved by means of conventional protecting groups, such as those described in T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Chemistry, John Wiley & Sons, 1999, which are hereby incorporated by reference.

[0259] Compounds of Formula la, or their pharmaceutically acceptable salts, can be prepared according to the reaction Schemes discussed herein below. Unless otherwise indicated, the substituents in the Schemes are defined as above. Isolation and purification of the products is accomplished by standard procedures, which are known to a chemist of ordinary skill.

[0260] It will be understood by one skilled in the art that the various symbols, superscripts and subscripts used in the schemes, methods and examples are used for the convenience of113335850176 CENC-014 / 01WO 360899-2049representation and / or to reflect the order in which they are introduced in the schemes, and are not intended to necessarily correspond to the symbols, superscripts or subscripts in the appended claims. Additionally, one skilled in the art will recognize that in many cases, these compounds will be mixtures of stereoisomers that may be separated at various stages of the synthetic schemes using conventional techniques, such as, but not limited to, crystallization, normal phase chromatography, reversed phase chromatography and chiral chromatography, to afford single enantiomers. The schemes are representative of methods useful in synthesizing the compounds of the present invention. They are not to constrain the scope of the invention in any way.Scheme 1

[0261] Scheme 1 illustrates a generally applicable approach to the synthesis of various intermediates and compounds of Formula 1. An aldehyde of Formula A, wherein Ri, R2 and R3 are optionally selected substituents, and an N-aryl 4-aminotriazole of Formula B in which the aryl ring of Formula B may contain further substituents indicated by *R4 as desired, are converted to a 3,4,6,7-tetrahydro-5H-[l,2,3]triazolo[4,5-b]pyridin-5-one of Formula C by reaction with 114335850176 CENC-014 / 01WO 360899-2049Meldrum’s acid (2, 2-dimethyl-l,3-dioxane-4, 6-dione) in a reaction compatible solvent, frequently a lower alcohol such as ethanol. Compounds of Formulas A and B are well known in the chemical literature and many such compounds are commercially available.

[0262] The compound of Formula C is further elaborated to a compound of Formula D by alkylation with a suitable alkylating agent, usually in the presence of an alkali. The alkylating agent is most conveniently of the general formula Rs-Br or Rs-I, however the alkylation of pyridines such as this is very well known in the art and many permutations of this transformation are known. The compound of Formula D is transformed into a compound of Formula E by reaction with a suitable strong base and an azide transfer reagent. In practice, the azide transfer reagent selected is commonly 2,4,6-triisopropylbenzenesulfonyl azide, and the base is an amide base such as an alkali metal bis(trimethylsilyl)amide or lithium diisopropylamide. The transformation is well represented in the chemical literature. It will be appreciated that two stereogenic centers are produced in this reaction and that the compound of Formula E so produced will likely contain a mixture of stereoisomers, and that these stereoisomers may be separated at various points in the synthetic sequence.

[0263] The azide compound of Formula E may be reduced to an amine compound of Formula F by numerous means, this being a well-studied and useful transformation in organic synthesis. A particularly suitable method for accomplishing the reduction is by use of the Staudinger reaction, taking advantage of the high functional group compatibility and robust selectivity of the reaction conditions.

[0264] The amine of Formula F may be transformed to a compound of Formula 1 by the formation of an amide with a carboxylic acid of Formula ReCChH, in which the substituent Re may vary widely, as will be seen in the following Examples. Besides carboxylic acids of Formula ReCChH, the corresponding carboxylic acid halides and anhydrides may be employed. The preparation of amides from amines and carboxylic acids is well known in synthetic organic chemistry and an abundance of effective methods are known and exemplified in the Examples that follow.

[0265] One skilled in the art will discern that the stereocenter next to the pyridine carbonyl may be epimerized under appropriate conditions as shown, providing a means for converting compounds of Formula 1 into other compounds of Formula 1 with a change in the stereochemical relationship between the substituents at the 3- and 4- positions of the central 3,4,6,7-tetrahydro-115335850176 CENC-014 / 01WO 360899-20495H-[l,2,3]triazolo[4,5-b]pyridin-5-one core structure. The execution of these steps is detailed in the Preparations and Examples that follow.Experimental Procedures and Working Examples

[0266] The following illustrate the synthesis of various compounds of the present invention. Additional compounds within the scope of this invention may be prepared using the methods illustrated in these Examples, either alone or in combination with techniques generally known in the art.

[0267] It will be understood that the intermediate compounds of the invention depicted above are not limited to the particular enantiomer(s) shown but also include all stereoisomers and mixtures thereof.Experimental Procedures

[0268] Experiments were carried out with continuous stirring under inert atmosphere (nitrogen or argon). Commercial solvents and reagents were generally used without further purification, including anhydrous solvents where appropriate. Unless noted otherwise, all reactants were obtained commercially. All concentrations were conducted under reduced pressure using techniques well known to one skilled in the art. Solvent mixtures used for chromatography are expressed as volume percent ratios. Products were generally dried under vacuum before being carried on to further reactions or submitted for biological testing.

[0269] Mass spectrometry data is reported from either liquid chromatography-mass spectrometry (LCMS), atmospheric pressure chemical ionization (APCI) or gas chromatographymass spectrometry (GCMS) instrumentation. It will be noted that LCMS instruments are generally capable of returning positive ions resulting from the addition of a proton to the analyte, negative ions resulting from the loss of a proton from the analyte, or both. Depending on the chemical structure of the particular analyte, the positive or negative ion may be more abundant. Proton NMR spectra were recorded on Bruker 400 MHz and Varian 400 MHz instruments internally referenced to a tetramethyl silane (TMS) signal. Chemical shifts (5) and coupling constants (J) are expressed in parts per million and hertz, respectively.

[0270] Methods used for LCMS include the following:116335850176 CENC-014 / 01WO 360899-2049

[0271] Method-A: LCMS, X-Select (Formic acid); Column: X-Select CSH C18 3.0*50 mm, 2.5 um; Mobile Phases: A, 0.05 % Formic acid in water: MeCN (95:5); B, 0.05 % Formic acid in MeCN; Inj. Volume: 2.0pL; Column oven temperature: 50 °C; Flow Rate: 1.2 mL / min; Gradient Program (B%):0.0 / 2, 0.3 / 2, 2.0 / 98, 2.8 / 98, 3.0 / 2, 3.7 / 2.

[0272] Method-B: Column: X-Bridge BEH C18, 50mm*3.0mm, 2.5pm; Mobile Phases: A, 2.5mM Ammonium Bicarbonate in Water + 5 % MeCN; Mobile Phase B, 100 % MeCN; Flow rate: 1.0 mL / min; Column temperature: 40 °C; Gradient Program (B%): 0.0 / 2, 0.3 / 2, 2.0 / 98, 2.8 / 98, 3.0 / 2, 3.7 / 2.

[0273] Method-C: Column: X-Select CSH C18 50mm*3.0mm, 2.5pm; Mobile Phases: A, 0.05 % TFA in Water; Mobile Phase B, 0.05 % TFA in MeCN; Flow rate: 1.0 mL / min; Column temperature: 40 °C; Gradient Program (B%): 0.0 / 2, 0.3 / 2, 2.0 / 98, 2.8 / 98, 3.0 / 2, 3.7 / 2.

[0274] Method-F: Column: Poroshell 120 EC-C183*100mm, 2.7pm; Mobile Phases: A, 0.05 % TFA in Water; B, 0.05 % TFA in MeCN, Flow rate: 0.80 mL / min (Gradient); Column Oven Temp: 40 °C; Gradient Program (B%): 0.01 / 2, 0.2 / 2, 3 / 98, 5 / 98, 5.2 / 2, 7 / 2.

[0275] Methods used for analytical HPLC include the following:

[0276] Method-A: Column: X Select CSH C18 150*4.6 mm, 3.5p; Mobile phase A: 0.1 % Formic acid in Water: MeCN (95:05); Mobile phase B: MeCN; Gradient Programme: T / B%: 0.01 / 5, 1 / 5, 8 / 100, 12 / 100, 14 / 5, 18 / 5; Flow rate: 1.2 mL / min.

[0277] Method-B: Column: X-Bridge CSH C18 150*4.6mm, 3.5pm; Mobile Phase-A: 5mM NH4HCO3 in water; Mobile Phase-B: MeCN; Programme / B%: 0.01 / 5, 1.0 / 5, 8.0 / 100, 12.0 / 100, 14.0 / 5, 18.0 / 5; Flow: 1.0 mL / min.

[0278] Method-C: Column: X SELECT CSH C18 150*4.6mm, 3.5p; Mobile Phase A; 0.05 % TFA in water: MeCN (95:05); Mobile Phase B: 0.05 % TFA in water: MeCN (05:95); Programme: T / B%: 0.01 / 10, 12 / 90, 16 / 90; Flow rate: 1.0 mL / min.; Diluent: water: MeCN (80:20).

[0279] Methods used for chiral analytical HPLC include the following:

[0280] Method-A: Column: X Select CSH C18 4.6*150 mm; 3.5p; Mobile phase A: 0.1% formic acid in water - MeCN (95:05), Mobile phase B: MeCN; Gradient: (time / %B): 0.01 / 5,1 / 5, 8 / 100,12 / 100,14 / 5,18 / 5; Flow rate:1.2 mL / min.117335850176 CENC-014 / 01WO 360899-2049

[0281] For syntheses referencing procedures in other Examples or Methods, reaction conditions (length of reaction and temperature) may vary. In general, reactions were followed by thin layer chromatography and / or liquid chromatography-mass spectrometry and subjected to work-up when appropriate. It will be recognized by one skilled in the art that purifications may vary between experiments: in general, sorbents, solvents and the solvent ratios used for eluants / gradients were chosen to provide appropriate Rfs or retention times. It will also be recognized by one skilled in the art that HPLC purifications may be effected in a variety of ways, including the use of normal stationary phases, reverse stationary phases, chiral stationary phases, and supercritical eluants. The appropriate choices of conditions for chromatographic and HPLC purifications will be discerned by one skilled in the art.

[0282] The following Preparations describe the preparation of certain intermediates used in the Methods and Examples that follow. The following Preparations, Methods and Examples are intended to illustrate particular embodiments of the invention and preparations thereto and are not intended to limit the specification, including the claims, in any manner.Abbreviations

[0283] Unless indicated otherwise, the following abbreviations have the indicated meanings:118335850176 CENC-014 / 01WO 360899-2049

[0284] Unless indicated otherwise, the following chemical formulas and acronyms have the indicated meanings:119335850176 CENC-014 / 01WO 360899-2049Preparations

[0285] Preparation 1: Synthesis of 7-(4-fluorophenyl)-3-phenyl-6,7-dihydro-4~{H}-triazolo[4,5-b]pyridin-5-one (1)335850176 CENC-014 / 01WO 360899-2049

[0286] A solution of l-phenyl-lH-l,2,3-triazol-5-amine (CAS 99584-30-2, 420 mg, 2.62 mmol), 4-fluorobenzaldehyde (0.32 g, 2.62 mmol) and Meldrum’s acid (2,2-dimethyl-l,3-dioxane-4, 6-dione, 0.37 g, 2.62 mmol) in EtOH (4 mL) was heated at about 80 °C for about 16 h, then diluted with water and filtered. The precipitate was washed with EtOH and dried to afford the title compound 1 (740 mg, 91% yield).

[0287] 'HNMR (400 MHz, DMSO-de) 6 = 10.98 (s, 1H), 7.64 - 7.54 (m, 5H), 7.33 - 7.30 (m, 2H), 7.20 - 7.16 (m, 2H), 4.56 (t, J= 6.8 Hz, 1H), 3.13 - 3.07 (m, 1H), 2.82 - 2.76 (m, 1H).LC-MS (Method-B): Calculated for C17H13FN4O 308.1; Found: 309.0 [M+H]+.

[0288] Preparation 2: Synthesis of 4-ethyl-7-(4-fluorophenyl)-3-phenyl-6,7-dihydrotriazolo[4,5-b]pyridin-5-one (2)2

[0289] Bromoethane (0.26 g, 2.42 mmol) was added to a mixture of compound 1 (680 mg, 2.20 mmol) and K2CO3 (0.33 g, 2.42 mmol) in DMF (7 mL) and the reaction mixture was stirred for about 16 h about 25 °C before being diluted with water (20 mL) and extracted with EtOAc (2 x 20 mL). The combined EtOAc extracts were dried (Na? SO4), filtered and concentrated. The residue was purified by silica gel column chromatography and eluted at 30-40 % EtOAc in hexane to afford the title compound 2 (440 mg, 59% yield).

[0290] 1H NMR (400 MHz, DMSO-de) d = 7.58 - 7.57 (m, 2H), 7.54 - 7.52 (m, 2H), 7.26 (t, J = 8.4 Hz, 2H), 7.03 (t, J= 8.4 Hz, 3H), 4.51 (t, J= 6.0 Hz, 1H), 3.72 - 3.71 (m, 1H), 3.33 - 3.29 (m, 1H), 3.17 - 3.16 (m, 1H), 3.09 - 3.08 (m, 1H), 0.79 (t, J= 7.2 Hz, 3H).

[0291] LC-MS (Method-B): Calculated for C19H17FN4O 336.1; Found: 337.27 [M+H]+.121335850176 CENC-014 / 01WO 360899-2049

[0292] Preparation 3: Synthesis of (67?,77?)-6-azido-4-ethyl-7-(4-fluorophenyl)-3-phenyl-6,7-dihydrotriazolo[4,5-b]pyridin-5-one (3)3

[0293] A solution of compound 2 (420 mg, 1.24 mmol) in THF (5 mL) was treated with lithium bis(trimethylsilyl)amide solution (1 M in THF, 1.49 mL, 1.49 mmol) at about -78 °C for about 30 min, then a solution of 2,4,6-triisopropylbenzenesulfonyl azide (CAS 36982-84-0, 0.46 g, 1.49 mmol) in THF (2 mL) was added over about 5 min. After about 1 h, the mixture was warmed to about 25 °C and acetic acid (0.31 mL,5.49 mmol) was added, then the mixture was heated at about 60 °C for about 16 h. After cooling, water (20 mL) was added and the mixture was extracted with EtOAc (2 x 25 mL). The combined EtOAc extracts were dried (NazSCL), filtered and concentrated. The residue purified by silica gel column chromatography eluted at 60-70% EtOAc in heptane to afford the title compound 3 (240 mg, 50% yield).

[0294] 'H NMR (400 MHz, DMSO-ds) 6 = 7.61 - 7.57 (m, 3H), 7.55 - 7.53 (m, 2H), 7.30 -7.26 (m, 2H), 7.10 (t, J= 8.8 Hz, 2H), 4.44 (d, J= 9.6 Hz, 1H), 4.34 - 4.31 (m, 1H), 3.69 - 3.62 (m, 1H), 3.50 - 3.44 (m, 1H), 0.90 (t, J= 7.2 Hz, 3H).

[0295] Preparation 4: Synthesis of (6A,7 )-6-amino-4-ethyl-7-(4-fluorophenyl)-3-phenyl-6,7-dihydrotriazolo[4,5-b]pyridin-5-one (4)122335850176 CENC-014 / 01WO 360899-20494

[0296] A solution of compound 3 (220 mg, 0.58 mmol) in EtOH was added to a solution of tri / / -butyl phosphine (0.15 g, 0.75 mmol) in EtOH (3 mL) and water (0.5 mL) at about 0 °C. After stirring at about 25 °C for about 16 h, the mixture was evaporated. Water (1 mL) was added and the mixture was extracted with DCM (2 x 10 mL). The combined DCM extracts were dried (Na2SO4), filtered and concentrated to give the title compound 4 (210 mg), which was used without further purification.

[0297] 'H NMR (400 MHz, DMSO-de) d = 7.78 - 7.58 (m, 3H), 7.40 - 7.28 (m, 3H), 7.21 -7.12 (m, 3H), 5.74 (s, 1H), 5.07 (s, 1H), 4.20 (d, J= 9.2 Hz, 1H), 4.04 - 4.02 (m, 1H), 3.85 - 3.81 (m, 1H), 3.52 - 3.47 (m, 1H), 1.17 (t, J = 7.6 Hz, 3H).

[0298] LC-MS (Method-B): Calculated for CwHisFNsO 351.1; Found: 352.1 [M+H]+.

[0299] Preparation 5: Synthesis of tert-butyl (3-(5-oxo-3-phenyl-4,5,6,7-tetrahydro-3H-[l,2,3]triazolo[4,5-b]pyridin-7-yl)benzyl)carbamate (5)

[0300] A solution of l-phenyl-lH-l,2,3-triazol-5-amine (CAS 99584-30-2, 5.4 g, 32 mmol), tert-butyl (3-formylbenzyl)carbamate (CAS 170853-04-0, 8.0 g, 29 mmol), and Meldrum’s acid (2, 2-dimethyl-l,3-dioxane-4, 6-dione, 4.7 g, 32 mmol) in EtOH was heated at about 80 °C for about 16 h. After cooling, the solvent was evaporated and the residue was purified by silica gel column chromatography, eluting with 50-55% EtOAc in heptane to afford compound 5 (6.0 g, 42% yield).

[0301] 'H NMR (400 MHz, DMSO-de) A 10.96 (s, 1H), 7.62 - 7.54 (m, 5H), 7.37 - 7.27 (m, 2H), 7.16 - 7.09 (s, 3H), 4.51 (t, J= 6.4 Hz, 1H), 4.11 (d,. / - 6.4 Hz, 2H), 3.15 - 3.09 (m, 1H), 2.79 - 2.74 (m, 1H), 1.38 (s, 9H).

[0302] LC-MS (Method-B): Calculated for C23H25N5O3419.0; Found: 418.1 [M-H] ’.123335850176 CENC-014 / 01WO 360899-2049

[0303] Preparation 6: Synthesis of tert-butyl (3-(4-ethyl-5-oxo-3-phenyl-4,5,6,7-tetrahydro-3H-[l,2,3]triazolo[4,5-b]pyridin-7-yl)benzyl)carbamate (6)6

[0304] A mixture of compound 5 (6.0 g, 12.2 mmol), K2CO3 (3.39 g, 24.3 mmol) and bromoethane (1.62 g, 14.6 mmol) in MeCN (140 mb) was stirred at about 25 °C for about 16 h, then diluted with water (50 mL) and extracted with EtOAc (2 x 150 mL). The combined EtOAc extracts were washed with brine, dried (Na2SO4), filtered and concentrated. The residue was purified by silica gel column chromatography, eluting with 35-40% EtOAc in heptanes to afford compound 6 (2.60 g, 39%).

[0305] ' H NMR (400 MHz, DMSO-de) <5: 7.58 - 7.53 (m, 5H), 7.32 - 7.28 (m, 1H), 7.20 - 7.15 (m, 3H), 4.80 (s, 1H), 4.50 (d, J= 6.0 Hz, 1H), 4.29 (d, J= 5.2 Hz, 2H), 3.74 - 3.69 (m, 1H), 3.33 - 3.28 (m, 1H), 3.21 - 3.15 (m, 1H), 3.09 - 3.04 (m, 1H), 1.45 - 1.42 (m, 9H), 0.82 (t, J= 7.2 Hz, 3H).

[0306] LC-MS (Method-A): Calculated for C25H29N5O3447.2; Found: 448.3 [M+H]+.

[0307] Preparation 7. Synthesis of rac-tert-butyl (3-((6R,7R)-6-azido-4-ethyl-5-oxo-3-phenyl- 4,5,6,7-tetrahydro-3H-[l,2,3]triazolo[4,5-b]pyridin-7-yl)benzyl)carbamate (7)124335850176 CENC-014 / 01WO 360899-2049

[0308] A solution of compound 6 (4.59 g, 10 mmol) in THF (60 mL) in a two neck round bottom flask was cooled to about -78 °C and a solution of lithium bis(trimethylsilyl)amide (1 M in toluene, 26 mL g, 26 mmol) was added slowly. After about another 30 min at about -78 °C, a solution of 2,4,6-triisopropylbenzenesulfonyl azide (CAS 36982-84-0, 4.1 g, 13 mmol) in THF (60 mL) was added over about 20 min. The reaction mixture was stirred at about -78 °C for about 30 min further, then treated with acetic acid (2.8 g, 46 mmol) and allowed to warm to about 25 °C. After about 2 h at about 25 °C, the mixture was heated under reflux for about 6 h. The mixture was cooled, diluted with water (50 mL) and extracted with EtOAc (2 x 100 mL). The combined EtOAc extracts were concentrated, and the residue was purified by silica gel column chromatography, eluting with 40-45% EtOAc in heptanes to afford the title compound 7 (2.3 g, 46% yield).

[0309] 'H NMR (400 MHz, CDCh) 3 7.61 - 7.55 (m, 5H), 7.37 (t, J= 7.6 Hz, 1H), 7.28 -7.18 (m, 3H), 4.49 (d, J= 8.4 Hz, 1H), 4.34 - 4.32 (m, 3H), 3.64 - 3.60 (m, 1H), 3.53 - 3.48 (m, 1H), 1.45 (s, 9H), 0.97 - 0.86 (m, 4H).

[0310] LC-MS (Method-A): Calculated for C25H28N8O3488.2; Found: 489.29 [M+H]+.

[0311] Preparation 8: Synthesis of rac-tert-butyl (3-((6R,7R)-6-amino-4-ethyl-5-oxo-3-phenyl-4,5,6,7-tetrahydro-3H-[l,2,3]triazolo[4,5-b]pyridin-7-yl)benzyl)carbamate (8)125335850176 CENC-014 / 01WO 360899-2049

[0312] Tri-n-butyl phosphine (3.5 g, 8.8 mmol) was added to a solution of compound 7 (2.3 g, 4.4 mmol) in EtOH (30 mL) and water (25 mL) at about 25 °C and the mixture was kept for about 16 h. After concentration, the residue was diluted with water (10 mL) and extracted with 5% MeOH in DCM (2 x 50 mL). The combined extracts were dried (Na2SO4), filtered and evaporated. The residue was triturated with pentane and dried to afford the title compound 8 (1.5 g, 47% yield), which was used without further purification.[00313J LC-MS (Method-A): Calculated for C25H30N6O3462.2; Found: 463.3 [M+H]+.

[0314] Preparation 9: Synthesis of rac-tert-butyl (3-((6R,7R)-4-ethyl-5-oxo-3-phenyl-6-(4-(trifluoromethyl)pyrimidine-2-carboxamido)-4,5,6,7-tetrahydro-3H-[l,2,3]triazolo[4,5-b]pyridin-7-yl)benzyl)carbamate (9)9

[0315] A solution of compound 8 (283 mg, 0.61 mmol), 4-(trifluoromethyl)pyrimidine-2-carboxylic acid (CAS 1000931-46-3, 0.10 g, 0.55 mmol), and DIEA (0.24 g, 1.83 mmol) in DMF (10 mL) was cooled to about 0 °C and treated with FIATU (0.36 g, 0.91 mmol). The reaction mixture was then stirred at about 25 °C for about 12 h before being diluted with water (5 mL) and126335850176 CENC-014 / 01WO 360899-2049extracted with EtOAc (2 x 20 mL). The combined EtOAc extracts were washed with brine, dried (Na2SC>4), filtered and concentrated. The residue was purified by silica gel column chromatography, eluting with a gradient of 35-40% EtOAc in heptanes to afford the title compound 9 (220 mg, 58% yield).

[0316] rH NMR (400 MHz, DMSO-de) 5: 9.43 - 9.27 (m, 2H), 8.19 (d, J= 5.0 Hz, 1H), 7.78 - 7.59 (m, 6H), 7.35 - 7.00 (m, 4H), 5.47 - 5.24 (m, 1H), 4.95 - 4.77 (m, 1H), 4.05 - 3.97 (m, 2H), 3.73 - 3.64 (m, 1H), 3.14 -3.05 (m, 1H), 1.39 - 1.25 (m, 9H), 0.78 (t, J= 6.63 Hz, 3H).

[0317] LC-MS (Method-C): Calculated for C31H31F3N8O4636.2; Found: 637.3 [M+H]+.

[0318] Preparation 10: Synthesis of rac-N-((6R,7R)-7-(3-(aminomethyl)phenyl)-4-ethyl-5-oxo-3-phenyl-4,5,6,7-tetrahydro-3H-[l,2,3]triazolo[4,5-b]pyridin-6-yl)-4-(trifluoromethyl)pyrimidine-2-carboxamide (10):10

[0319] A solution of compound 9 (140 mg, 0.17 mmol) in DCM (2 mL) was treated with TFA (0.04 g, 0.34 mmol) and kept at about 25 °C for about 2 h. After concentration, the residue was made alkaline with NaHCCh solution (10 mL) and extracted with DCM (2x 10 mL). The combined DCM extracts were concentrated to give the title compound 10 (90 mg, 80% yield), which was used without further purification.

[0320] 1H NMR (400 MHz, DMSO-de) 3 9.38 (d, J = 92 Hz, 1H), 9.33 (d, J = 4.8 Hz, 1H), 8.22 (d, J= 4.8 Hz, 1H), 7.78 (d, J= 3.2 Hz, 2H), 7.67 (d, J= 3.2 Hz, 3H), 7.34 (s, 1H), 7.24 (s, 3H), 5.37-5.31 (m, 1H), 4.84 (d, J= 12.4 Hz, 1H), 3.73 - 3.68 (m, 3H), 3.16-3.12 (m, 1H), 0.81 (t, J = 7.2 Hz, 3H).

[0321] LC-MS (Method-C): Calculated for C26H23F3N8O2536.2; Found: 537.5 [M+H]+.127335850176 CENC-014 / 01WO 360899-2049

[0322] Preparation 11: Synthesis of rac-tert-butyl (3-((6R,7R)-4-ethyl-5-oxo-3-phenyl-6-(3- (trifluoromethyl)benzamido)-4,5,6,7-tetrahydro-3H-[l,2,3]triazolo[4,5-b]pyridin-7-yl)benzyl)carbamate (11)11

[0323] A solution of compound 8 (600 mg, 1.29 mmol), 3-(trifluoromethyl)benzoic acid (0.14 g, 1.16 mmol) and DIEA (0.33 g, 3.89 mmol) in DMF (10 mL) was cooled to about 0 °C and treated with HATU (0.49 g, 1.94 mmol), after which the reaction mixture was kept at about 25 °C for about 4 h before the addition of water (10 mL). After extraction with EtOAc (2 x 20 mL), the combined EtOAc extracts were washed with brine, dried (Na2SO4), fdtered and concentrated. Th residue was purified by silica gel column chromatography, eluted with 35-40% EtOAc in heptanes to give the title product 11 (450 mg, 54%).

[0324] 'H NMR (400 MHz, DMSO-d6) 3 7.90 (s, 1H), 7.82 (d, J= 6.0 Hz, 1H), 7.73 (d, J = 7.6 Hz, 1H), 7.60 - 7.52 (m, 6H), 7.33 (s, 3H), 7.25 (s, 1H), 6.55 (s, 1H), 5.36 (s, 1H), 5.29 (s, 1H), 4.85 (s, 1H), 4.50 (s, 1H), 4.28 (s, 1H), 3.89 (s, 1H), 3.25 (s, 1H), 1.43 (s, 9H), 0.92 (s, 3H).

[0325] LC-MS (Method-A): Calculated for C33H33F3N6O4634.3; Found: 635.42 [M+H]+.

[0326] Preparation 12: Synthesis of rac-N-((6R,7R)-7-(3-(aminomethyl)phenyl)-4-ethyl-5-oxo-3-phenyl-4,5,6,7-tetrahydro-3H-[l,2,3]triazolo[4,5-b]pyridin-6-yl)-3-(trifluoromethyl)benzamide (12)335850176 CENC-014 / 01WO 360899-204912[00327J Trifluoroacetic acid (0.13 g, 1.14 mmol) was added to a solution of compound 11 (450 mg, 0.57 mmol) in DCM (10 mL) at about 0 °C. The reaction mixture was kept at about 25 °C for about 2 h, then concentrated. The residue was triturated with pentane and the mixture was concentrated to give compound 12 (450 mg), which was used without further purification.

[0328] 'HNMR (400 MHz, DMSO-d6) 3 8.17 (s, 3H), 8.06 (s, 2H), 7.92 (d, J= 6.0 Hz, 1H), 7.76- 7.68 (m, 6H), 7.48 - 7.39 (s, 4H), 5.31 (s, 1H), 4.67 (d, J= 12.0 Hz, 1H), 4.00 (s, 2H), 3.70 (d, = 6.0 Hz, 1H), 3.18 (d, J = 6.4 Hz, 1H), 0.81 (s, 3H).

[0329] Preparation 13: Synthesis of rac-tert-butyl (3-((6R,7R)-4-ethyl-5-oxo-3-phenyl-6-(l- (tri fluoromethyl)- lH-pyrazole-3-carboxamido)-4, 5,6, 7-tetrahydro-3H-[l, 2, 3]triazolo[4, 5-b ] py ri din- 7-y l)b enzy l)carb am ate[00330J A solution of compound 8 (450 mg, 0.61 mmol), l-(trifluoromethyl)-lH-pyrazole-3-carboxylic acid (CAS 2092678-51-6, 0.10 g 0.55 mmol) and DIEA (0.24 g, 1.83 mmol) in DMF (9 mL) was treated with HATU (0.35 g, 0.91 mmol) at about 0 °C, then kept at about 25 °C for about 12 h. The mixture was then diluted with water (10 mL) and extracted with EtOAc (2 x 15 mL). The combined EtOAc extracts were washed with brine (2 x 10 mL), dried (Na2SO4), filtered 129335850176 CENC-014 / 01WO 360899-2049and concentrated. The residue was purified by silica gel column chromatography, eluting with 30-35% EtOAc in heptanes to afford the title compound 13 (280 mg, 41% yield).[0033118.84 (d, J= 9.2 Hz, 1H), 8.58 (d, J= 2.4 Hz, 1H), 7.75(s, 2H), 7.66 (d, J= 3.2 Hz, 3H), 7.32 - 7.24 (m, 3H), 7.14 (d, J= 6.8 Hz, 1H), 6.91 (s, 1H), 5.25 (s, 1H), 4.75 (d, J = 12.8 Hz, 1H), 4.09 (d, J= 5.6 Hz, 2H), 3.73 - 3.77 (m, 1H), 3.17 - 3.11 (m, 1H), 1.37 (s, 9H), 0.80 (t, J= 7.2 Hz, 3H).

[0332] LC-MS (Method-A): Calculated for C30H31F3N8O4 624.2; Found: 625.4 [M+H]+.

[0333] Preparation 14: Synthesis of rac-N-((6R,7R)-7-(3-(aminomethyl)phenyl)-4-ethyl-5-oxo-3 -phenyl-4, 5,6, 7-tetrahydro-3H-[ 1,2, 3]triazolo[4, 5-b]pyridin-6-yl)-l -(tri fluoromethyl)- 1H-pyrazole-3 -carboxamide (14):14

[0334] Trifluoroacetic acid (0.06 g, 0.51 mmol) was added to a solution of compound 13 (159 mg, 0.25 mmol) in DCM (5 mb) with cooling to about 0 °C, after which the reaction mixture was kept at about 25 °C for about 2 h. After concentration, the residue was made alkaline with NaHCCh solution (5 mb) and extracted with 10% MeOH in DCM (2x 10 mb). The combined extracts were concentrated, triturated with pentane, and dried to afford the title compound 14 (150 mg, 92% yield), which was used without further purification.

[0335] LC-MS (Method-A): Calculated for C25H23F3N8O2524.2; Found: 525.3 [M+H]+.

[0336] Synthesis of rac-A-[(6?,77?)-4-ethyl-7-(4-fluorophenyl)-5-oxo-3-phenyl-6,7-dihydrotriazolo[4,5-b]pyridin-6-yl]-3-(trifluoromethyl)benzamide (1-10)130335850176 CENC-014 / 01WO 360899-20491-10

[0337] To a solution of compound 4 (204 mg, 0.58 mmol) and DIEA (0.22 g, 1.74 mmol) in DCM (4 mL) was added 3-(trifluoromethyl)benzoyl chloride (0.14 mL, 0.87 mmol) at about 0 °C. After about 3 h at about 25 °C, cold water (10 mL) was added, and the mixture was extracted with DCM (2 x 20 mL). The combined DCM extracts were dried (Na2SC>4), filtered and concentrated. The residue was purified by silica gel column chromatography eluted at 50-60% EtOAc in heptanes to afford the title product A-[(6A,7 )-4-ethyl-7-(4-fluorophenyl)-5-oxo-3-phenyl-6,7-dihydrotriazolo[4,5-b]pyridin-6-yl]-3-(trifluoromethyl) benzamide 1-10 (35 mg, 11% yield).

[0338] 1H NMR (400 MHz, DMSO-de) d = 9.08 (d, J= 8.8 Hz, 1H), 8.05 - 8.03 (m, 2H), 7.93 - 7.91 (m, 1H), 7.78 - 7.66 (m, 6H), 7.46 - 7.43 (m, 2H), 7.19 - 7.15 (m, 2H), 5.35 - 5.29 (m, 1H), 4.65 (d, J= 12.8 Hz, 1H), 3.74 - 3.69 (m, 1H), 3.15 - 3.10 (m, 1H), 0.81 (t, J = 6.8 Hz, 3H).

[0339] LC-MS (Method-B) Calculated for C27H21F4N5O2523.2; Found: 524.0 [M+H]+.

[0340] LC-MS purity (Method-B): 97.23% at RT 2.29 min.

[0341] HPLC (Method-B): 97.52% at RT 8.48 min.

[0342] Synthesis of rac-A-[(67?,7S)-4-ethyl-7-(4-fluorophenyl)-5-oxo-3-phenyl-6,7-dihydrotriazolo[4,5-b]pyridin-6-yl]-3-(trifluoromethyl)benzamide (1-1)335850176 CENC-014 / 01WO 360899-2049

[0343] A mixture of T-10 (150 mg, 0.286 mmol) and K2CO3 in MeCN (4 mL) was heated at about 80 °C for about 16 h, then cooled and concentrated. The residue was diluted with water (10 mL) and extracted with EtOAc (2 x 20 mL). The combined EtOAc extracts were dried (Na2SO4), filtered and concentrated. The residue was purified by silica gel column chromatography, eluted at 40-50 % EtOAc in heptanes to afford the title product 1-1 rac-N-((6R,7S)-4-ethyl-7-(4-fluorophenyl)-5-oxo-3-phenyl-4,5,6,7-tetrahydro-3H-[l,2,3]triazolo[4,5-b]pyridin-6-yl)-3-(trifluoromethyl)benzamide (43 mg, 28%).

[0344] ' H NMR (400 MHz, CDCI3) d = 8.01 (s, 1H), 7.88 - 7.78 (m, 2H), 7.66 - 7.53 (m, 6H), 7.00 - 6.93 (m, 4H), 6.87 (d, J= 5.4 Hz, 1H), 5.33 (dd, J= 5.9, 7.3 Hz, 1H), 5.19 (d, J= 7.5 Hz, 1H), 4.06 - 3.96 (m, 1H), 3.28 - 3.19 (m, 1H), 1.01 (t, J= 7.1 Hz, 3H).

[0345] LC-MS (Method-F): Calculated for C27H21F4N5O2523.2; Found: 524.2 [M+H]+.

[0346] LC-MS purity (Method-F): 97.76% at RT 6.001 min.

[0347] HPLC purity (Method-B): 97.87% at RT 8.90 min.

[0348] Synthesis of rac-N-((6R,7R)-4-ethyl-7-(3-((2-(morpholinomethyl)-acrylamido)methyl)phenyl)-5-oxo-3-phenyl-4,5,6,7-tetrahydro-3H-[l,2,3]triazolo[4,5-b]pyridin-6-yl)-4-(trifluoromethyl)pyrimidine-2-carboxamide (1-11)1-11

[0349] HATU (0.07 g, 0.18 mmol) was added to a solution of compound 10 (90 mg, 0.12 mmol), 2-(morpholinomethyl)acrylic acid (CAS 4432-44-4, 0.02 g, 0.11 mmol) and DIEA (0.04 g, 0.37 mmol) in DMF (2 mL) at about 0 °C. The reaction was continued at about 25 °C for about 12 h, then diluted with water (5 mL) and extracted with EtOAc (2x 10 mL). The combined EtOAc extracts were washed with brine, dried (Na2SC>4), filtered and evaporated. The residue was purified 132335850176 CENC-014 / 01WO 360899-2049by preparative HPLC (Column: X-Bridge C18 4.6*150) mm, 5 p; Mobile Phase A: water (containing 5 mM NH4HCO3), Mobile Phase B: MeCN, Flow Rate: 1.0 mL / minute, Gradient program: Time (min) / B Cone.: 0.01 / 05, 1.00 / 05, 8.00 / 100, 12.00 / 100, 14.00 / 05, 18.00 / 5) to afford the title product 1-11 (25 mg, 30% yield).

[0350] 'H NMR (400 MHz, DMSO-de) S 9.38 (d, J= 9.6 Hz, 1H), 9.32 (d, J= 4.8 Hz, 1H), 8.97 (t, J= 6.0 Hz, 1H), 8.21 (d, J= 5.2 Hz, 1H), 7.78 - 7.76 (m, 2H), 7.67 -7.65 (m, 3H), 7.30 -7.28 (m, 3H), 7.21 - 7.18 (m, 1H), 5.88 (s, 1H), 5.43 (s, 1H), 5.36 - 5.31 (m, 1H), 4.86 (d, J= 12.8 Hz, 1H), 4.33 (d, J= 6.0 Hz, 2H), 3.73 - 3.68 (m, 1H), 3.43 (t, J= 4.4 Hz, 4H), 3.15 (s, 3H), 2.32 - 2.30 (m, 4H), 0.81 (t, J= 6.8 Hz, 3H).

[0351] LC-MS (Method-C): Calculated for C34H34F3N9O4689.3; Found: 690.8 [M+H]+.

[0352] LC-MS purity (Method-C): 99.67% at RT 4.91 min.

[0353] HPLC purity (Method-A): 99.57% at RT 4.01 min.

[0354] Chiral HPLC purity (Method-A): Peak 1: 50.25 % at RT 7.29 min, Peak 2: 49.75 % at RT 9.87 min.Chiral Separation of 1-11 by preparative chiral HPLC

[0355] A sample of 1-11 (80 mg, 0.11 mmol) was purified by chiral HPLC (Column IK 30 *250 mm, 5p); Mobile phase A: n-hexane, Mobile phase B: EtOH - MeOH (1:1); Eluent A: B: 60-40, Total Flow rate (mL / min) 42 ml / min; Run time 10 min; No. of Injections, 4 (38 mg per injection) to provide rel-N-((6R,7R)-4-ethyl-7-(3-((2-(morpholinomethyl)acrylamido)-methyl)phenyl)-5-oxo-3-phenyl-4,5,6,7-tetrahydro-3H-[l,2,3]triazolo[4,5-b]pyridin-6-yl)-4-(trifluoromethyl)pyrimidine-2-carboxamide 1-6 (25 mg, 31% yield) and rel-N-((6S,7S)-4-ethyl-7- 133335850176 CENC-014 / 01WO 360899-2049(3-((2-(morpholinomethyl)acrylamido)methyl)phenyl)-5-oxo-3-phenyl-4,5,6,7-tetrahydro-3H-[l,2,3]triazolo[4,5-b]pyridin-6-yl)-4-(trifluoromethyl)pyrimidine-2-carboxamide 1-7 (25 mg, 31% yield).Data for 1-6

[0356] ' H NMR (400 MHz, DMSO-de) 3 9.39 (d, J = 8.8 Hz, 1H), 9.32 (d, J = 5.2 Hz, 1H), 8.98 (t, J= 6.0 Hz, 1H), 8.22 (d, J = 52 Hz, 1H), 7.78 - 7.76 (m, 2H), 7.67 - 7.65 (m, 3H), 7.30 -7.28 (m, 3H), 7.19 (s, 1H), 5.87 (s, 1H), 5.42 (s, 1H), 5.37 - 5.31 (m, 1H), 4.86 (d, J= 12.4 Hz, 1H), 4.33 (d, J= 6.0 Hz, 2H), 3.74 - 3.68 (m, 1H), 3.43 (s, 4H), 3.13 (s, 3H), 2.30 (s, 4H), 0.81 (t,.7= 6.8 Hz, 3H).

[0357] LC-MS (Method-C): Calculated for C34H34F3N9O4689.3; Found: 690.2 [M+H]+.

[0358] LC-MS purity (Method-C): 98.21% at RT 4.01 min.

[0359] HPLC purity (Method-B): 99.64% at RT 7.63 min.

[0360] Chiral HPLC (Method-A): 99.28% at RT 7.37 min.Data for 1-7

[0361] ' H NMR (400 MHz, DMSO-d6) <5: 9.39 (d, J = 9.6 Hz, 1H), 9.32 (d, J = 52 Hz, 1H), 8.98 (t, J= 5.6 Hz, 1H), 8.22 (d, J= 52 Hz, 1H), 7.79 - 7.76 (m, 2H), 7.67 - 7.65 (m, 3H), 7.30 -7.28 (m, 3H), 7.20 - 7.19 (m, 1H), 5.87 (s, 1H), 5.42 (s, 1H), 5.37 - 5.31 (m, 1H), 4.86 (d, J= 12.4 Hz, 1H), 4.33 (d,.7= 6.0 Hz, 2H), 3.74 - 3.68 (m, 1H), 3.43 (t,.7= 4.4 Hz, 4H), 3.15 (s, 3H), 2.32 - 2.30 (m, 4H), 0.81 (t, J= 6.8 Hz, 3H).

[0362] LC-MS (Method-C): Calculated for C34H34F3N9O4689.3; Found: 690.2 [M+H]+.

[0363] LC-MS purity (Method-C): 98.80% at RT 4.02 min.

[0364] HPLC purity (Method-B): 97.54% at RT 7.62 min.

[0365] Chiral HPLC purity (Method-A): Peak 1, 6.57 % at RT 7.37 min; Peak 2, 93.42% at RT 9.71 min.

[0366] Synthesis of rac-N-((6R,7R)-4-ethyl-7-(3-((2- (morpholinomethyl)acrylamido)methyl)phenyl)-5-oxo-3-phenyl-4,5,6,7-tetrahydro-3H-[l,2,3]triazolo[4,5-b]pyridin-6-yl)-3-(trifluoromethyl)benzamide (1-8)134335850176 CENC-014 / 01WO 360899-20491-8

[0367] A solution of compound 12 (360 mg, 0.63 mmol) and DIEA (200 mg, 1.54 mmol) in DMF (5 mL) was treated with HATU (350 mg, 0.89 mmol), followed by 2-(morpholinomethyl)acrylic acid (CAS 4432-44-4, 160 mg, 0.88 mmol) at about 25 °C. The reaction mixture was kept at about 25 °C for about 16 h. Water (25 mL) was added, and the mixture was extracted with EtOAc (2 x 30 mL). The combined EtOAc extracts were washed with brine (2 x 30 mL), dried (Na2SC>4), filtered, and concentrated. The residue was purified by preparative HPLC (Column: X-bridge C18 30*250 mm, 5p; Mobile phase A: water (containing 10 mm NH4HCO3), Mobile phase B: MeCN; flow rate 25 mL / min; gradient (min / %B) 0 / 20,3 / 20,10 / 40,20 / 50,30 / 60,40 / 70,50 / 80,60 / 90,70 / 99,80 / 99; Solvent used for injection: MeCN / water) to afford the title product rac-N-((6R,7R)-4-ethyl-7-(3-((2-(morpholinomethyl)acrylamido)methyl)phenyl)-5-oxo-3-phenyl -4,5,6, 7-tetrahy dro-3H-[l,2,3]triazolo[4,5-b]pyridin-6-yl)-3-(trifluoromethyl)benzamide 1-8 (190 mg, 43%).

[0368] 'H NMR (400 MHz, DMSO-d6) A 9.08 (d, J= 92 Hz, 1H), 8.99 (s, 1H), 8.03 (d, J = 8.8 Hz, 2H), 7.91 (d, J= 8.0 Hz, 1H), 7.79 - 7.76 (m, 2H), 7.73 - 7.66 (m, 4H), 7.32 - 7.30 (m, 3H), 7.21 (s, 1H), 5.89 (s, 1H), 5.43 (s, 1H), 5.29 - 5.26 (m, 1H), 4.70 - 4.60 (m, 1H), 4.35 (d, J = 6.0 Hz, 2H), 3.69 - 3.66 (m, 1H), 3.42 (t, J= 8.0 Hz, 4H), 3.14 (s, 3H), 2.28 (s, 4H), 0.80 (t, J = 6.8 Hz, 3H).

[0369] LC-MS (Method-C): Calculated for C36H36F3N7O4687.3; Found: 688.3 [M+H]1.

[0370] LC-MS purity (Method-C): 98.83% at RT 4.52 min.

[0371] HPLC purity (Method-B): 99.89% at RT 8.23 min.

[0372] Chiral HPLC purity (Method-A): Peak 1, 50.03% at RT 7.41 min; Peak 2, 49.96% at RT 10.51 min.135335850176 CENC-014 / 01WO 360899-2049Chiral Separation of 1-8 by preparative chiral HPLC1-9 1-2

[0373] A sample of 1-8 (0.16 g, 0.23 mmol) was purified by chiral HPLC (Column IK 30 *250 mm, 5p); Mobile phase A: n-hexane, Mobile phase B: EtOH - MeOH (1:1); Eluent A: B: 60-40, Total Flow rate (mL / min) 46 ml / min; Run time 10 min; No. of Injections, 4 (38 mg per injection) to provide rel-N-((6R,7R)-4-ethyl-7-(3-((2-(morpholinomethyl)acrylamido)methyl)phenyl)-5-oxo-3-phenyl-4,5,6,7-tetrahydro-3H-[l,2,3]triazolo[4,5-b]pyridin-6-yl)-3-(trifluoromethyl)benzamide 1-9 (55 mg, 34% yield) and rel-N-((6S,7S)-4-ethyl-7-(3-((2-(morpholinomethyl)acrylamido)methyl)phenyl)-5-oxo-3-phenyl -4,5,6, 7-tetrahydro-3H-[l,2,3]triazolo[4,5-b]pyridin-6-yl)-3-(trifluoromethyl)benzamide 1-2 (45 mg, 28% yield).Data for 1-9

[0374] 'H NMR (400 MHz, DMSO-de) 3 9.07 (d, J = 8.8 Hz, 1H), 8.98 (t, J = 5.6 Hz, 1H), 8.04 - 8.02 (m, 2H), 7.91 (d, J= 7.6 Hz, 1H), 7.79 - 7.66 (m, 6H), 7.32 - 7.30 (m, 3H), 7.22 -7.20 (m, 1H), 5.89 (s, 1H), 5.43 (s, 1H), 5.31 - 5.26 (m, 1H), 4.64 (d, J= 12.4 Hz, 1H), 4.35 (d, J = 5.6 Hz, 2H), 3.71 - 3.66 (m, 1H), 3.43 - 3.41 (m, 4H), 3.15 - 3.14 (m, 3H), 2.29 (s, 4H), 0.81 (t, J= 7.2 Hz, 3H).

[0375] LC-MS (Method-A): Calculated for C36H36F3N7O4687.3; Found: 688.56 [M+H]+.

[0376] LC-MS purity (Method-A): 99.74% at RT 1.82 min.

[0377] HPLC purity (Method-C): 98.24% at RT 4.73 min.

[0378] Chiral HPLC purity (Method-A): 100.00% at RT 6.30 min.Data for T-2136335850176 CENC-014 / 01WO 360899-2049

[0379] ' H NMR (400 MHz, DMSO-de) 6 9.07 (d, J = 9.2 Hz, 1H), 8.98 (t, J = 5.6 Hz, 1H), 8.04 - 8.02 (m, 2H), 7.91 (d, J= 7.6 Hz, 1H), 7.78 - 7.66 (m, 6H), 7.31 (d, J= 6.0 Hz, 3H), 7.21 (s, 1H), 5.89 (s, 1H), 5.43 (s, 1H), 5.31 - 5.26 (m, 1H), 4.64 (d, J= 12.4 Hz, 1H), 4.35 (d, J= 5.6 Hz, 2H), 3.71 - 3.66 (m, 1H), 3.42 (s, 4H), 3.19 - 3.14 (m, 3H), 2.29 (s, 4H), 0.81 (t, J= 7.2 Hz, 3H).

[0380] LC-MS (Method-A): Calculated for C36H36F3N7O4687.3; Found: 688.56 [M+H]+.

[0381] LC-MS purity (Method-A): 99.80 % at RT 1.82 min.

[0382] HPLC purity (Method-C): 98.43 % at RT 4.73 min.

[0383] Chiral HPLC purity (Method-A): 99.99 % at RT 8.76 min.

[0384] Synthesis of rac-N-((6R,7R)-4-ethyl-7-(3-((2-(morpholinomethyl)-acrylamido)methyl)phenyl)-5-oxo-3-phenyl -4,5,6, 7-tetrahydro-3H-[ 1,2, 3]triazolo[4, 5-b]pyridin-6 -y 1 )- 1 -(trifluoromethyl)- 1 H-pyrazole-3 -carboxamide (1-5):

[0385] 2-Chloro-l -methylpyridinium iodide (0.12 g, 0.47 mmol) was added to a solution of compound 14 (134 mg, 0.23 mmol) and 2-(morpholinomethyl)acrylic acid (CAS 4432-44-4, 0.03 g, 0.21 mmol) in DMF (4 mL) at about 25 °C, followed by tri-n-butylamine (0.18 g, 0.95 mmol). The reaction mixture was heated at about 70 °C for about 12 h, then cooled, diluted with water (10 mL) and extracted with EtOAc (2 x 10 mL). The combined EtOAc extracts were washed with brine, dried (NaiSO-i, fdtered and concentrated. The residue was purified by preparative HPLC ((Column: X-Bridge C18 4.6*150) mm, 5 p; Mobile Phase A: water (containing 5 mM NH4HCO3), Mobile Phase B: MeCN, Flow Rate: 1.0 mL / minute, Gradient program: Time (min) / 137335850176 CENC-014 / 01WO 360899-2049B Cone.: 0.01 / 05, 1.00 / 05, 8.00 / 100, 12.00 / 100, 14.00 / 05, 18.00 / 5) to provide the title product I-5 (30 mg, 19% yield).[003861 ‘HNMR (400 MHz, DMSO-d6) 3 8.99 (t, J= 5.2 Hz, 1H), 8.84 (d, J= 9.2 Hz, 1H), 8.57 (d, J= 2.8 Hz, 1H), 7.77 - 7.73 (m, 2H), 7.66 - 7.65 (m, 3H), 7.32 - 7.26 (m, 3H), 7.21 - 7.20 (m, 1H), 6.91 (s, 1H), 5.43 (s, 1H), 5.89 (s, 1H), 5.30 - 5.25 (m, 1H), 4.76 (d, J = 12.4 Hz, 1H), 4.35 (d, J = 6.0 Hz, 1H), 3.72 - 3.66 (m, 1H), 3.44 (s, 4H), 3.16 - 3.11 (m, 4H), 2.32 - 2.31 (m, 4H), 0.81 (t, J = 6.8 Hz, 3H).

[0387] LC-MS (Method-B): Calculated for C33H34F3N9O4677.3; Found: 678.2 [M+H]+.

[0388] LC-MS purity (Method-B): 99.52% at RT 2.11 min.

[0389] HPLC purity (Method-A): 99.11% at RT 4.13 min.

[0390] Chiral HPLC purity (Method-A): Peak 1, 49.72% at RT 7.03 min; Peak 2, 50.27% at RT 8.70 min.Chiral Separation of 1-5 by preparative chiral HPLC

[0391] A sample of 1-5 (85 mg, 0.12 mmol) was purified by chiral HPLC (Column IK 30 *250 mm, 5p); Mobile phase A: n-hexane, Mobile phase B: EtOH - MeOH (1:1); Eluent A: B: 60-40, Total Flow rate (mL / min) 42 ml / min; Run time 10 min; No. of Injections, 4 (38 mg per injection) to provide rel-N-((6R,7R)-4-ethyl-7-(3-((2-(morpholinomethyl)acrylamido)-methyl)phenyl)-5-oxo-3 -phenyl-4, 5,6, 7-tetrahydro-3H-[ 1,2, 3]triazolo[4, 5-b]pyridin-6-yl)-l -(tri fluoromethyl)- 1H-pyrazole-3 -carboxamide 1-3 (28 mg, 33% yield) and rel-N-((6S,7S)-4-ethyl-7-(3-((2-(morpholinomethyl)acrylamido)methyl)phenyl)-5-oxo-3-phenyl-4,5,6,7-tetrahydro-3H-138335850176 CENC-014 / 01WO 360899-2049[l,2,3]triazolo[4,5-b]pyridin-6-yl)-l-(trifluoromethyl)-lH-pyrazole-3-carboxamide T-4 (28 mg, 32% yield).Data for 1-3

[0392] 'H NMR (400 MHz, DMSO-de) S 9.00 (t, J= 6.8 Hz, 1H), 8.85 (d, J= 10.8 Hz, 1H), 8.58 (d, J= 2.8 Hz, 1H), 7.77 - 7.75 (m, 2H), 7.66 - 7.65 (m, 3H), 7.33 - 7.26 (m, 3H), 7.22 - 7.20 (m, 1H), 6.92 (d, J=2.4Hz, 1H), 5.90 (s, 1H), 5.44 (s, 1H), 5.31 - 5.25 (m, 1H), 4.73 (d, J= 12.8 Hz, 1H), 4.35 (d, J= 5.6 Hz, 2H), 3.72 - 3.66 (m, 1H), 3.44 (t, J= 4.4, 4H), 3.16 - 3.10 (m, 3H), 2.32 - 2.31 (m, 4H), 0.81 (t, J= 6.8 Hz, 3H).

[0393] LC-MS (Method-C): Calculated for C33H34F3N9O4677.3; Found: 678.2 [M+H]+.

[0394] LC-MS purity (Method-C): 99.10 % at RT 4.28 min.

[0395] HPLC purity (Method-B): 99.46 % at RT 7.86 min.

[0396] Chiral HPLC purity (Method-A): 99.99 % at RT 6.03 min.Data for 1-4

[0397] ’H NMR (400 MHz, DMSO-de) S 9.00 (t, J= 5.6 Hz, 1H), 8.85 (d, J= 10.8 Hz, 1H), 8.58 (d, J= 2.8 Hz, 1H), 7.77 - 7.75 (m, 2H), 7.66 - 7.65 (m, 3H), 7.33 - 7.26 (m, 3H), 7.22 - 7.20 (m, 1H), 6.92 (d, J=2.4Hz, 1H), 5.90 (s, 1H), 5.44 (s, 1H), 5.31 - 5.25 (m, 1H), 4.73 (d, J= 12.8 Hz, 1H), 4.35 (d, J= 5.6 Hz, 2H), 3.72 - 3.66 (m, 1H), 3.44 (t, J= 4.4, 4H), 3.16 - 3.10 (m, 3H), 2.32 - 2.31 (m, 4H), 0.81 (t,.7= 6.8 Hz, 3H).

[0398] LC-MS (Method-C): Calculated for C33H34F3N9O4677.3; Found: 678.2 [M+H]+.

[0399] LC-MS purity (Method-C): 95.65% at RT 4.29 min.

[0400] HPLC purity (Method-B): 97.65% at RT 7.85 min.

[0401] Chiral HPLC purity (Method-A): 97.38% at RT 7.24 min.Example 2: HBG1 Nanostring Assay

[0402] A Nanostring Assay was performed to evaluate the ability of the compounds to induce expression of the fetal hemoglobin gene HBG1 in cells. The data are shown as EC50, with stronger inducers having a lower EC50 value and higher YMax.CD34 culture and sample preparation139335850176 CENC-014 / 01WO 360899-2049

[0403] Mobilized peripheral blood (mPB) derived CD34+ hematopoietic stem and progenitor cells (HSPCs) were thawed and plated at 500,000 cells / ml on day of cell thaw (day -4) in StemSpan (StemCell Tech, 09600) complete media supplemented with 1% StemSpan CC100 (StemCell Tech, 02690), and 0.2% human recombinant thrombopoietin (StemCell Tech, 02822). Forty eight hours later (day -2), the cells were passaged at a density of 200,000 cells / ml (lOOul / well in 96well culture plate) in complete expantion media. The cells were plated at 200,000 cells / ml on day 0 and day3, 400,000 cells / ml on day 5 in phase 1 erythroid differentiation containing StemSpan with 2.5U / mL of EPO (R& D systems, 287-TC-500), 0.5 mg / mL of Holo-Transferrin (Sigma, T0665-500MG), lx Glutamine (Gluta-Max) (Gibco, 35050-061), 5 pL / mL Lipid Mixture (Sigma, L0288-100ML), 50 ng / mL SCF (R& D Systems, 255-SV-050), 10 ng / mL IL-3 (R& D Systems, 203-IL010) and 10 ng / mL Insulin (Sigma, I9278-5ML) all 200pl per well in 96 well culture plate. Cells were then passaged at 500,000 cells / ml and 200pl per well on day 7 in phase 2 Erythroid differentiation (Phase 1 erythroid differentiation removing IL-3) until collection day (Day 10). The culture conditions were used for both control DMSO as well as experimental treatments.

[0404] For all cell pasagings, cells were centrifuged at 300g for 8 minutes at room temperature and cell number were normalized by MANTIS and Integra VIAFLO 384. All the compounds are diluted in DMSO and added to complete media by Formulatrix FAST and mixed starting from day -2. Cells were counted by Luna cell counter with AOPI Staining Solution (Nexcelom Bioscience, CS2-0106-25mL) on day-2. Cells were counted by BD FACSCelesta Flow Cytometer with CountBright™ Plus Absolute Counting Beads (Thermal Fisher Scientific, C36995) and SYTOX AADvanced™ Ready Flow™ Reagent (Invitrogen, R37173) for other passages. Cells were cultured at 37°C and 5% CO2. DMSO concentration was kept at 0.1% to minimize any effects to the cells by the vehicle. Due to the insolubility of positive control, it was freshly made every 6 weeks with stock concentration at 3mM while stock concentration for other compounds are lOmM. Compound plates were kept at room temptureture to protect from light to avoid multiple freeze and thaw cycle.

[0405] On the collection day (Day 10), 100K cells were collected and stored at -80 °C. For direct hybridization for Nanostring, 100K cell pellet was lyzed in 25 pL ofRLT (QIAGEN, 79216) with lx p -Mercaptoethanol (Gibco, 21985-023) and shaked at 300-500 RPM for 5 minutes at room temperature. Cell lysate was stored in -80°C after lysis.140335850176 CENC-014 / 01WO 360899-2049Hybridization and imaging

[0406] All hybridizations were done in a total volume of 15 pL (3 pL of RNA lysate added to master mix of 12 pL probe A / B, capture probe / reporter probes, proteinase K and attenuation oligos suspended in hybridization buffer). Samples were hybridized at 67 °C for 22 hr. Following hybridization, the tripartide complexes were purified, immobilized by nCounter Prep Station and imaged by Digital Analyzer (nCounter MAX / FLEX Analysis System), to generate digital counts of barcodes corresponding to each target in the multiplexed reaction. Labeled barcodes obtained from unamplified extracts were counted at 555 images or field of view (FOV). The barcode counts for each sample were recorded in Reporter Code Count (RCC) files that are imported into nSolver analysis software (provided with CodeSet by NS) for quality control evaluation.Quality control (QC) metrics and data analysis

[0407] The quality control (QC) metric included limit of detection QC by checking for wells with less than 100 total counts for positive controls.

[0408] Hybridization signals were normalized against the ERCC positive controls and CodeSet Content (housekeeping gene). Briefly, this involved first calculating a sample-specific scaling factor by calculating arithmetic mean of geomeans of all ERCC positive controls with counts more than zero in all samples. Then this arithmetic mean was divided by the geometric mean of each lane to generate a lane-specific normalization factor. All negative controls and targetspecific signal values were then normalized by multiplying counts values with their samplespecific scaling factor. The acceptable range for scaling factors is 0.3-3.0. For housekeeping gene(s) normalization, first calculating the arithmetic mean of geometric means of selected housekeeping genes for each lane for all samples. Then this arithmetic mean was divided by the geometric mean of each lane to generate a lane-specific normalization factor followed by multiplying the counts for every gene by its lane-specific normalization factor. The acceptable range for housekeeping genes normalization scaling factors is 0.1-10.

[0409] HBG1 dose-response curves, %Emax and EC50 values were generated by Dotmatic with setting control DMSO as 0% and biology control as 100%. When reporting EC50, Top will be fixed as 100% for compounds with observed Emax>=50%. For compounds with observed Emax<50% is reporting either inactive or max observed Emax.

[0410] The Nanostring Ymax observed data is relative to a control compound, presented in % which is shown in Table 2 below. Compounds with a Nanostring Ymax greater than 0.0 and less141335850176 CENC-014 / 01WO 360899-2049than or equal to 110.0 are designated as Compounds with a Nanostring Ymax greater than 110.0 are designatedTable 2. HBG1 Nanostring AssayExample 3: AlphaLISA Assay

[0411] An AlphaLISA assay was performed to evaluate the ability of the compounds to suppress neddylation, which is downstream from DCN-1 and DCN-2. A stronger inhibition of DCN-1 and DCN-2 is expected to result in a suppression of neddylation as shown by a lower AlphaLISA signal.

[0412] The AlphaLISA assay for detecting Cullin-3 (CUL3) neddylation was performed according to manufacturer instructions (Revvity, Hopkinton, MA). Briefly, TF1 cells (ATCC) were plated in Iscove’s Modified Dulbecco's Medium (IMDM) without supplements in 384-well plates. These cells were treated with 11 concentrations for 3 hours before lysing them with AlphaLISA lysis buffer, 5X (Revvity). To detect the level of CUL3 neddylation, biotinylated anti-NEDD8 antibody, was added followed by AlphaLISA Acceptor beads conjugated with anti-CUL3 antibody. After overnight incubation, Streptavidin-coated Alpha Donor beads were added and incubated for 1 hour. The AlphaLISA signal was then read on a VICTOR Nivo Multimode Microplate Reader (Revvity, Hopkinton, MA). The positive control was 1 pM DL1548, which is reported to reduce CUL3 neddylation (Zhou et al. Nature Comm. 2021). The neddylation signal was normalized such that the percent inhibition is 0% for vehicle control and 100% for positive control. The dose-response curves were fitted with the Hill equation to obtain IC50 values (Graphpad Prism).

[0413] Compounds with an ICso less than or equal to 10.0 nM are designated as “+++”. Compounds with an ICso greater than 10.0 nM and less than or equal to 100.0 nM are designated as Compounds with an IC50 greater than 100.0 nM are designatedThe results are shown in Table 3 below.Table 3. AlphaLISA Assay142335850176 CENC-014 / 01WO 360899-2049Example 4: TR-FRET assay

[0414] A TR-FRET assay was performed to evaluate the ability of the compounds to bind the DCN-1 protein.

[0415] The TR-FRET assay was designed following the Scott et al. protocol (Scott et al., Nat Chem Biol. 2017 August; 13(8): 850-857. Doi:10.1038 / nchembio.2386). The recombinant form of the DCN1 (DCUND1) protein PONY domain was produced using an E.coli expression system at Viva Biotech (China). The DCN1 protein was biotinylated (EZ sulfo-NHS-LC-biotin; Thermofisher) for labeling with streptavidin terbium (Tb) cryptate in the reaction. The probe was changed to a non-covalent DCN1 inhibitor labeled with carboxyfluorescein (FAM; Zhou et al., Nat Commun. 2017; 8: 1150. Doi: 10.1038 / s41467-017-01243-7). Buffer conditions were modified to enhance protein stability by exchanging Tween20 for TritonX and increasing NaCl to 200 mM. The compounds were screened against 5 nM DCN1 and 20 nM FAM-probe or 0.31 nM DCN1 and 900 nM total probe (100 nM FAM-labeled plus 800 nM unlabeled). The TR-FRET ratio between Tb-DCNl and the FAM-labeled probe was measured in a 384-well opti-plate (Perkin Elmer) using a plate reader (BMG) at 1, 5, and 24 hrs after treatment with compound (final DMSO concentration of 0.1%). The ratio was normalized to the high (DCN1 and FAM-probe) and low (DCN1 and no probe) controls for a readout of % activity (= 100* (x - low) / (high - low). The % activity across concentrations is used to determine the IC50.143335850176 CENC-014 / 01WO 360899-2049

[0416] Compounds with an IC50 less than or equal to 200.0 nM are designated as “++++”. Compounds with an IC50 greater than 200.0 nM and less than or equal to 1000.0 nM are designated as “+++”. Compounds with an IC50 greater than 1.0 mM and less than or equal to 4.0 mM are designated asThe results are shown in Table 4 below.Table 4. TR-FRET AssayExample 5: Intact Protein MS Analysis with the RapidFire-TOF system

[0417] An MS assay was performed to evaluate the ability of the compounds to covalently modify DCN-1.

[0418] DCN1 protein, His-TEV-DCNl, were expressed in / / . Coh. The His-tagged protein was first purified with an Ni-NTA column. The His-tag was cleaved using His-tag TEV protease and the His-tags were removed using a second Ni-NTA column. Protein purity was verified with SDS-PAGE and intact MS. DCN1 was dissolved in a buffer containing 25 mM Tris-HCI, 200 mM NaCl, and 1 mM DTT at 400 nM. 11 concentrations of compounds were added to the DCN1 solution and incubated at room temperature for 3 hours, unless otherwise specified. The reaction144335850176 CENC-014 / 01WO 360899-2049plates were quenched by adding 0.2% formic acid. Quenched assay plates were analyzed with an Agilent RapidFire 360 system connected to an Agilent 6545 Q-TOF mass spectrometer equipped with an AJS source. 10 pL of sample volume was loaded onto a custom packed cartridge (4 pL, PLRP-S 30 µm / 1000Å pore; Optimize Technologies) with loading buffer (ddH₂O with 0.09% (vol / vol) formic acid and 0.01% (vol / vol) trifluoroacetic acid; 1.25 ml / min) for 6 seconds before being eluted directly into the mass spectrometer in elution buffer (80% acetonitrile with 0.09% (vol / vol) formic acid and 0.01% (vol / vol) trifluoroacetic acid; 0.5 ml / min) for 7 seconds. The cartridge was re-equilibrated with loading buffer for 1 second before collection of the next sample. The Q-TOF was operated in TOF-only positive ionization mode set to the following parameters: Gas Temp = 350 C, Drying Gas = 71 / min, Nebulizer = 50 psi, Sheath Gas Temp = 400 C, Sheath Gas Flow = 121 / min, Vcap = 4000 V, Nozzle Voltage = 1000 V, Fragmentor = 125 V, Skimmer = 65 V and Oct 1 RF Vpp = 750V. Raw MS data files were deconvoluted and analyzed using the Agilent MassHunter Bioconfirm software package to identify both parent protein and expected compound adduct mass signatures.

[0419] Compounds with an ECso greater than 0.1 nM and less than or equal to 0.5 nM are designated as “+++”. The results are shown in Table 5 below.

[0420] The MS data is presented in % adduct formation which is shown in Table 5 below. Compounds with an MS Emax % adduct formation greater than or equal to 0.0 and less than or equal to 30.0 are designated asCompounds with an MS Emax % adduct formation greater than 30.0 and less than or equal to 80.0 are designatedCompounds with an MS Emax % adduct formation greater than 80.0 and less than or equal to 100.0 are designated as “+++”.Table 5. Intact Protein MS Analysis145335850176 CENC-014 / 01WO 360899-2049

Claims

CLAIMS1. A compound of Formula la:or a pharmaceutically acceptable salt thereof, wherein:Ring A is phenyl, 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, a 4-10 membered saturated or partially unsaturated bicyclic carbocyclic ring, an 8-10 membered bicyclic aromatic carbocyclic ring, a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-10 membered bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur;Ring B is phenyl or a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;Ring C is phenyl or a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;each occurrence of R1is independently an optionally substituted Ci-6 aliphatic, halogen, -CN, - C(O)R, -C(O)OR, -OC(O)R, -C(O)N(R)2, -N(R)C(O)R, -N(R)C(O)N(R)2, -OC(O)N(R)2, - N(R)C(O)OR, -OR, -N(R)2, -NO2, -SR, -S(O)R, -S(O)2R, -S(O)2N(R)2, or -NRS(O)2R; or two instances of R1together form a 4-6 membered optionally substituted heterocyclic ring having 1-4 heteroatoms selected from nitrogen, oxygen, and sulfur, or two instances of R1together form a 4-6 membered optionally substituted carbocyclic ring;146335850176 CENC-014 / 01WO 360899-2049R2is an optionally substituted group selected from Ci-6 aliphatic and a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring;each occurrence of R3is independently an optionally substituted Ci-6 aliphatic, C3-6 cycloalkyl, halogen, -CN, -C(O)R, -C(O)OR, -OC(O)R, -C(O)N(R)2, -N(R)C(O)R, -N(R)C(O)N(R)2, - OC(O)N(R)2, -N(R)C(O)OR, -OR, -N(R)2, -NO2, -SR, -S(O)R, -S(O)2R, -S(O)2N(R)2, or - NRS(O)2R;R4is a substituent comprising a warhead group;each occurrence of R5is independently halogen, -CN, -C(O)R, -C(O)OR, -OC(O)R, -C(O)N(R)2, -N(R)C(O)R, -N(R)C(O)N(R)2, -OC(O)N(R)2, -N(R)C(O)OR, -OR, -N(R)2, -NO2, -SR, - S(O)R, -S(O)2R, -S(O)2N(R)2, -NRS(O)2R, or an optionally substituted group selected from C1-6 aliphatic, phenyl, or a 5-6 membered heteroaromatic ring having 1-3 heteroatoms selected from nitrogen, sulfur, and oxygen;R6is hydrogen or an optionally substituted C1-6 aliphatic group;each occurrence of R is independently hydrogen or an optionally substituted group selected from C1-6 aliphatic, a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic aromatic carbocyclic ring, a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur;m is 0, 1, 2, 3, 4, or 5;n is 0, 1, 2, 3, 4, or 5; andp is 0, 1, 2, 3, 4, or 5.

2. The compound of claim 1, wherein R4is L2-Y, whereinL2is a covalent bond or a bivalent C2-8 straight or branched, hydrocarbon chain wherein one or two methylene units of L2are optionally and independently replaced by — NRC(O) —, — C(O)NR—, — N(R)SO2—, — SO2N(R)—, — S— „ -O-, -NR-, — S(O)—, — SO2—, -C(O)-, — OC(O) —, or — C(O)O —; and additionally one methylene unit of L2is optionally replaced by an optionally substituted ring selected from a 3-8 membered saturated or partially unsaturated147335850176 CENC-014 / 01WO 360899-2049monocyclic carbocyclic ring, a 4-10 membered bicyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic aromatic carbocyclic ring, a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-10 membered bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur; andY is hydrogen, halogen, -COOR, -CN, -CON(R)2, -NRCN, NO2, -N(R)2, optionally substituted Ci- 8 aliphatic, or an optionally substituted ring selected from a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, a 4-10 membered bicyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic aromatic carbocyclic ring, a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-10 membered bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur;wherein -L2-Y comprises an alpha, beta-unsaturated carbonyl moiety, amide, cyano group, halogen, carbonyl, alkynyl group, sulfonyl group, or epoxide.

3. The compound of claim 1 or 2, wherein R4is L2-Y, whereinL2is a covalent bond or a bivalent C2-8 straight or branched, hydrocarbon chain wherein one or two methylene units of L2are optionally and independently replaced by — NRC(O) —, — C(O)NR—, — N(R)SO2—, — SO2N(R)—, — S—, -O-, -NR-, — S(O)—, — SO2—, -C(O)-, — OC(O) —, or — C(O)O —; and additionally one methylene unit of L2is optionally replaced by an optionally substituted ring selected from a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, or a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; andY is hydrogen, halogen, -COORf, -CN, -CONRf2, -NRfCN, NO2, -NR*2, C1-8 aliphatic optionally148335850176 CENC-014 / 01WO 360899-2049substituted with halogen, NO2, or CN, or an optionally substituted ring selected from a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-10 membered bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein -L2-Y comprises an alpha, beta-unsaturated carbonyl moiety, amide, cyano group, halogen, carbonyl, alkynyl group, sulfonyl group, or epoxide; and wherein each occurrence of Rfis independently H, or straight or branched C1-6 alkyl, C2-6 alkenyl, or C2- 6 alkynyl group optionally substituted with 1, 2 or 3 halogen atoms.

4. The compound of any one of claims 1 to 3, wherein R4is L2-Y, whereinL2is a covalent bond or a bivalent C2-8 straight or branched, hydrocarbon chain wherein one or two methylene units of L2are optionally and independently replaced by — NRC(O) —, — C(O)NR—, — N(R)SO2— — SO2N(R)—, — S— — S(O)—, — SO2— -C(O)-, — OC(O)—, or — C(O)O —; and additionally one methylene unit of L2is optionally replaced by a ring selectedNO2, -NRf2, epoxide, C1-8 aliphatic optionally substituted with halogen, NO2, or CN, or a ring149335850176 CENC-014 / 01WO 360899-2049,; wherein -I?-Y comprises an alpha, beta-unsaturated carbonyl moiety, amide, cyano group, halogen, carbonyl, C2-6 alkynyl group, sulfonyl group, or epoxide; wherein each occurrence of Rfis independently H, or straight or branched Ci-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl group optionally substituted with 1, 2 or 3 halogen atoms; and wherein each occurrence of Rgand Rhis independently H, halogen, OH, or straight or branched C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl group optionally substituted with 1, 2 or 3 halogen atoms.

5. The compound of any one of claims 1 to 4, wherein R4is selected from Table 1c, Table Id or Table le. / VW* I^NH 6. The compound of any one of claims 1 to 5, wherein R4is selected from N7. The compound of any one of claims 1 to 6, wherein Ring A is phenyl.150335850176 CENC-014 / 01WO 360899-20498. The compound of any one of claims 1 to 7, wherein Ring B, taken together with R3, is9. The compound of any one of claims 1 to 8, wherein Ring C is phenyl.

10. The compound of any one of claims 1 to 9, wherein R2is Ci-3 alkyl.

11. The compound of any one of claims 1 to 10, wherein R3is a Ci-6 alkyl group optionally substituted with 1, 2, or 3 halogen atoms, -Ci-6 alkylene, -OR, -C2-4 alkenyl, -C2-4 alkynyl, halogen, -OR, -C(O)R, -CN, -C(O)NR2, -NHMe, -NMe2, or -NH2.

12. The compound of any one of claims 1 to 11, wherein R5is C1-6 aliphatic optionally substituted with 1, 2, or 3 halogen atoms, halogen, -CN, -C(O)R, -C(O)OR, -OC(O)R, - C(O)N(R)2, -N(R)C(O)R, -OR, -N(R)2, -SR, -S(O)R, -S(O)2R, or -S(O)2N(R)2.

13. The compound of any one of claims 1 to 12, wherein R5is halogen.

14. The compound of any one of claims 1 to 13, wherein R6is hydrogen.

15. The compound of any one of claims 1 to 6, wherein the compound is of Formula II:151335850176 CENC-014 / 01WO 360899-2049IIor a pharmaceutically acceptable salt thereof.

16. The compound of any one of claims 1 to 6, wherein the compound is of Formula III:or a pharmaceutically acceptable salt thereof.

17. The compound of any one of claims 1 to 6, wherein the compound is of Formula IVa, Formula IVb, Formula IVc or Formula IVd:IVa IVb152335850176 CENC-014 / 01WO 360899-2049or a pharmaceutically acceptable salt thereof.

18. The compound of any one of claims 1 to 6, wherein the compound is of Formula Va, Formula Vb, Formula Vc or Formula Vd:or a pharmaceutically acceptable salt thereof.

19. The compound of any one of claims 1 to 6, wherein the compound is of Formula Va-i, Formula Vb-i, Formula Vc-i or Formula Vd-i:153335850176 CENC-014 / 01WO 360899-2049Vc-i Vd-ior a pharmaceutically acceptable salt thereof.

20. The compound of any one of claims 1 to 6, wherein the compound is of Formula Via, Formula VIb, Formula Vic or Formula Vid:Via VIb154335850176 CENC-014 / 01WO 360899-2049or a pharmaceutically acceptable salt thereof.

21. The compound of any one of claims 1 to 6, wherein the compound is of Formula Vila, Formula Vllb, Formula Vile or Formula Vlld:or a pharmaceutically acceptable salt thereof.

22. The compound of any one of claims 1 to 6, wherein the compound is of Formula Villa, Formula VUIb, Formula VIIIc or Formula VUId:155335850176 CENC-014 / 01WO 360899-2049or a pharmaceutically acceptable salt thereof.

23. The compound of any one of claims 1 to 6, wherein the compound is of Formula IXa, Formula IXb, Formula IXc or Formula IXd:IXa IXb156335850176 CENC-014 / 01WO 360899-2049or a pharmaceutically acceptable salt thereof.

24. The compound of any one of claims 1 to 6, wherein the compound is of Formula Xa,or a pharmaceutically acceptable salt thereof.

25. The compound of any one of claims 1 to 6, wherein the compound is of Formula Xia, Formula Xlb, Formula XIc or Formula Xld:157335850176 CENC-014 / 01WO 360899-2049or a pharmaceutically acceptable salt thereof.

26. The compound of any one of claims 1 to 6, wherein the compound is of Formula Xlla, Formula Xllb, Formula XIIc, or Formula Xlld:Xlla Xllb158335850176 CENC-014 / 01WO 360899-2049XIIc Xlldor a pharmaceutically acceptable salt thereof.

27. The compound of any one of claims 1 to 6, wherein the compound is of Formula XHIa, Formula XHIb, Formula XIIIc or Formula XHId:or a pharmaceutically acceptable salt thereof.

28. A compound selected from one of those shown in Table 1, or a pharmaceutically acceptable salt thereof.159335850176 CENC-014 / 01WO 360899-204929. A pharmaceutical composition comprising the compound of any one of claims 1 to 28, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

30. A method of treating a hemoglobinopathy disorder or disease, comprising administering to a subject in need thereof the compound of any one of claims 1 to 28, or a pharmaceutically acceptable salt thereof.

31. The method of claim 30, wherein the hemoglobinopathy is a sickle cell disorder or disease.

32. The method of claim 30, wherein the hemoglobinopathy is a thalassemia disorder or disease.

33. A method of modulating the activity of DCN-1 and / or DCN-2, comprising the step of contacting DCN-1 and / or DCN-2 with the compound of any one of claims 1 to 28, or a pharmaceutically acceptable salt thereof.160335850176 CENC-014 / 01WO 360899-2049